Inflammation and tumor progression: signaling pathways and targeted intervention

Abstract

Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses tumor progression, potentially displaying opposing effects on therapeutic outcomes. Chronic inflammation facilitates tumor progression and treatment resistance, whereas induction of acute inflammatory reactions often stimulates the maturation of dendritic cells (DCs) and antigen presentation, leading to anti-tumor immune responses. In addition, multiple signaling pathways, such as nuclear factor kappa B (NF-kB), Janus kinase/signal transducers and activators of transcription (JAK-STAT), toll-like receptor (TLR) pathways, cGAS/STING, and mitogen-activated protein kinase (MAPK); inflammatory factors, including cytokines (e.g., interleukin (IL), interferon (IFN), and tumor necrosis factor (TNF)-α), chemokines (e.g., C-C motif chemokine ligands (CCLs) and C-X-C motif chemokine ligands (CXCLs)), growth factors (e.g., vascular endothelial growth factor (VEGF), transforming growth factor (TGF)-β), and inflammasome; as well as inflammatory metabolites including prostaglandins, leukotrienes, thromboxane, and specialized proresolving mediators (SPM), have been identified as pivotal regulators of the initiation and resolution of inflammation. Nowadays, local irradiation, recombinant cytokines, neutralizing antibodies, small-molecule inhibitors, DC vaccines, oncolytic viruses, TLR agonists, and SPM have been developed to specifically modulate inflammation in cancer therapy, with some of these factors already undergoing clinical trials. Herein, we discuss the initiation and resolution of inflammation, the crosstalk between tumor development and inflammatory processes. We also highlight potential targets for harnessing inflammation in the treatment of cancer.

References 906

1. 1.

   Bray F, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2018;68:394-424.

   Not in our library10.3322/caac.21492

2. 2.

   Vasan N, Baselga J, Hyman DM. A view on drug resistance in cancer. Nature. 2019;575:299-309.

   Not in our library10.1038/s41586-019-1730-1

3. 3.
   The mechanisms of sorafenib resistance in hepatocellular carcinoma: theoretical basis and therapeutic aspects · 2020

   No notice
4. 4.

   Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 2010;140:883-899.

   Not in our library10.1016/j.cell.2010.01.025

5. 5.

   Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420:860-867.

   Not in our library10.1038/nature01322

6. 6.

   Crusz SM, Balkwill FR. Inflammation and cancer: advances and new agents. Nat. Rev. Clin. Oncol. 2015;12:584-596.

   Not in our library10.1038/nrclinonc.2015.105

7. 7.

   Shacter E, Weitzman SA. Chronic inflammation and cancer. Oncology. 2002;16:217-226.

   Not in our library

8. 8.

   Schaue D, et al. Radiation and inflammation. Semin Radiat. Oncol. 2015;25:4-10.

   Not in our library10.1016/j.semradonc.2014.07.007

9. 9.

   Guthrie GJ, et al. The systemic inflammation-based neutrophil-lymphocyte ratio: experience in patients with cancer. Crit. Rev. Oncol. Hematol. 2013;88:218-230.

   Not in our library10.1016/j.critrevonc.2013.03.010

10. 10.

    Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet. 2001;357:539-545.

    Not in our library10.1016/s0140-6736(00)04046-0

11. 11.

    Punt S, et al. A beneficial tumor microenvironment in oropharyngeal squamous cell carcinoma is characterized by a high T cell and low IL-17(+) cell frequency. Cancer Immunol. Immunother. 2016;65:393-403.

    Not in our library10.1007/s00262-016-1805-x

12. 12.

    Elinav E, et al. Inflammation-induced cancer: crosstalk between tumours, immune cells and microorganisms. Nat. Rev. Cancer. 2013;13:759-771.

    Not in our library10.1038/nrc3611

13. 13.

    Ma Y, et al. Anticancer chemotherapy-induced intratumoral recruitment and differentiation of antigen-presenting cells. Immunity. 2013;38:729-741.

    Not in our library10.1016/j.immuni.2013.03.003

14. 14.

    Nathan C, Ding A. Nonresolving inflammation. Cell. 2010;140:871-882.

    Not in our library10.1016/j.cell.2010.02.029

15. 15.

    Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008;454:436-444.

    Not in our library10.1038/nature07205

16. 16.

    Ritter B, Greten FR. Modulating inflammation for cancer therapy. J. Exp. Med. 2019;216:1234-1243.

    Not in our library10.1084/jem.20181739

17. 17.

    Diakos CI, Charles KA, McMillan DC, Clarke SJ. Cancer-related inflammation and treatment effectiveness. Lancet Oncol. 2014;15:e493-e503.

    Not in our library10.1016/s1470-2045(14)70263-3

18. 18.

    Cuzick J, et al. Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement. Lancet Oncol. 2009;10:501-507.

    Not in our library10.1016/s1470-2045(09)70035-x

19. 19.

    Rothwell PM, et al. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet. 2011;377:31-41.

    Not in our library10.1016/s0140-6736(10)62110-1

20. 20.

    Cuzick J, et al. Estimates of benefits and harms of prophylactic use of aspirin in the general population. Ann. Oncol. 2015;26:47-57.

    Not in our library10.1093/annonc/mdu225

21. 21.

    Bonovas S, Filioussi K, Tsavaris N, Sitaras NM. Use of statins and breast cancer: a meta-analysis of seven randomized clinical trials and nine observational studies. J. Clin. Oncol. 2005;23:8606-8612.

    Not in our library10.1200/jco.2005.02.7045

22. 22.

    Maisonneuve P, Lowenfels AB. Statins and the risk of colorectal cancer. N. Engl. J. Med. 2005;353:952-954.

    Not in our library10.1056/nejmc051738

23. 23.

    Bonovas S, Nikolopoulos G, Sitaras NM. Statins and reduced risk of hepatocellular carcinoma in patients with hepatitis C virus infection: further evidence is warranted. J. Clin. Oncol. 2013;31:4160.

    Not in our library10.1200/jco.2013.50.9208

24. 24.

    Hao H, et al. Lipoxin A4 and its analog suppress hepatocellular carcinoma via remodeling tumor microenvironment. Cancer Lett. 2011;309:85-94.

    Not in our library10.1016/j.canlet.2011.05.020

25. 25.

    Li Y, et al. Pleiotropic regulation of macrophage polarization and tumorigenesis by formyl peptide receptor-2. Oncogene. 2011;30:3887-3899.

    Not in our library10.1038/onc.2011.112

26. 26.

    Wang Z, et al. Lipid mediator lipoxin A4 inhibits tumor growth by targeting IL-10-producing regulatory B (Breg) cells. Cancer Lett. 2015;364:118-124.

    Not in our library10.1016/j.canlet.2015.04.030

27. 27.

    Mulder WJM, Gnjatic S. Cancer immunotherapy: from local to global. Nat. Nanotechnol. 2017;12:840-841.

    Not in our library10.1038/nnano.2017.196

28. 28.
    Targeting immune cells for cancer therapy · 2019

    No notice
29. 29.

    Davila ML, et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci. Transl. Med. 2014;6:224ra225.

    Not in our library10.1126/scitranslmed.3008226

30. 30.

    Bonifant CL, Jackson HJ, Brentjens RJ, Curran KJ. Toxicity and management in CAR T-cell therapy. Mol. Ther. Oncolytics. 2016;3:16011.

    Not in our library10.1038/mto.2016.11

31. 31.

    Dorward DA, Lucas CD, Rossi AG, Haslett C, Dhaliwal K. Imaging inflammation: molecular strategies to visualize key components of the inflammatory cascade, from initiation to resolution. Pharm. Ther. 2012;135:182-199.

    Not in our library10.1016/j.pharmthera.2012.05.006

32. 32.

    Sun SC. The non-canonical NF-kappaB pathway in immunity and inflammation. Nat. Rev. Immunol. 2017;17:545-558.

    Not in our library10.1038/nri.2017.52

33. 33.

    Medzhitov R. Origin and physiological roles of inflammation. Nature. 2008;454:428-435.

    Not in our library10.1038/nature07201

34. 34.

    Kono H, Rock KL. How dying cells alert the immune system to danger. Nat. Rev. Immunol. 2008;8:279-289.

    Not in our library10.1038/nri2215

35. 35.

    Nathan C. Points of control in inflammation. Nature. 2002;420:846-852.

    Not in our library10.1038/nature01320

36. 36.

    Headland SE, Norling LV. The resolution of inflammation: Principles and challenges. Semin. Immunol. 2015;27:149-160.

    Not in our library10.1016/j.smim.2015.03.014

37. 37.

    Wright HL, Moots RJ, Bucknall RC, Edwards SW. Neutrophil function in inflammation and inflammatory diseases. Rheumatology. 2010;49:1618-1631.

    Not in our library10.1093/rheumatology/keq045

38. 38.

    Savill JS, et al. Macrophage phagocytosis of aging neutrophils in inflammation. Programmed cell death in the neutrophil leads to its recognition by macrophages. J. Clin. Invest. 1989;83:865-875.

    Not in our library10.1172/jci113970

39. 39.

    Rossi AG, et al. Cyclin-dependent kinase inhibitors enhance the resolution of inflammation by promoting inflammatory cell apoptosis. Nat. Med. 2006;12:1056-1064.

    Not in our library10.1038/nm1468

40. 40.

    Gilroy DW, Lawrence T, Perretti M, Rossi AG. Inflammatory resolution: new opportunities for drug discovery. Nat. Rev. Drug Disco. 2004;3:401-416.

    Not in our library10.1038/nrd1383

41. 41.

    Serhan CN. The resolution of inflammation: the devil in the flask and in the details. Faseb J. 2011;25:1441-1448.

    Not in our library10.1096/fj.11-0502ufm

42. 42.

    Xu H, et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J. Clin. Invest. 2003;112:1821-1830.

    Not in our library10.1172/jci200319451

43. 43.

    Kumar R, Clermont G, Vodovotz Y, Chow CC. The dynamics of acute inflammation. J. Theor. Biol. 2004;230:145-155.

    Not in our library10.1016/j.jtbi.2004.04.044

44. 44.

    Serhan CN. Controlling the resolution of acute inflammation: a new genus of dual anti-inflammatory and proresolving mediators. J. Periodontol. 2008;79:1520-1526.

    Not in our library10.1902/jop.2008.080231

45. 45.

    Ploeger HE, Takken T, de Greef MH, Timmons BW. The effects of acute and chronic exercise on inflammatory markers in children and adults with a chronic inflammatory disease: a systematic review. Exerc. Immunol. Rev. 2009;15:6-41.

    Not in our library

46. 46.

    Boyle M, et al. Chronic inflammation and angiogenic signaling axis impairs differentiation of dental-pulp stem cells. PLoS ONE. 2014;9:e113419.

    Not in our library10.1371/journal.pone.0113419

47. 47.

    Feehan KT, Gilroy DW. Is resolution the end of inflammation? Trends Mol. Med. 2019;25:198-214.

    Not in our library10.1016/j.molmed.2019.01.006

48. 48.

    Nasef NA, Mehta S, Ferguson LR. Susceptibility to chronic inflammation: an update. Arch. Toxicol. 2017;91:1131-1141.

    Not in our library10.1007/s00204-016-1914-5

49. 49.

    Snell LM, McGaha TL, Brooks DG. Type I interferon in chronic virus infection and cancer. Trends Immunol. 2017;38:542-557.

    Not in our library10.1016/j.it.2017.05.005

50. 50.
    Silica, Silicosis, and Autoimmunity · 2016

    No notice
51. 51.
    Chronic Inflammation in Obesity and the Metabolic Syndrome · 2010

    No notice
52. 52.

    Rogovskii V. Modulation of inflammation-induced tolerance in cancer. Front. Immunol. 2020;11:1180.

    Not in our library10.3389/fimmu.2020.01180

53. 53.

    DiNicolantonio JJ, O’Keefe J. The importance of maintaining a low omega-6/omega-3 ratio for reducing the risk of inflammatory cytokine storms. Mo. Med. 2020;117:539-542.

    Not in our library

54. 54.

    Kozhieva MK, et al. Gut human microbiota and multiple sclerosis. Zh. Nevrol. Psikhiatr Im. S S Korsakova. 2017;117:11-19.

    Not in our library10.17116/jnevro201711710211-19

55. 55.

    Bozkurt B, Mann DL, Deswal A. Biomarkers of inflammation in heart failure. Heart Fail Rev. 2010;15:331-341.

    Not in our library10.1007/s10741-009-9140-3

56. 56.

    Glass CK, Saijo K, Winner B, Marchetto MC, Gage FH. Mechanisms underlying inflammation in neurodegeneration. Cell. 2010;140:918-934.

    Not in our library10.1016/j.cell.2010.02.016

57. 57.
    Crosstalk between DNA Damage and Inflammation in the Multiple Steps of Carcinogenesis · 2017

    No notice
58. 58.

    Eiro N, Vizoso FJ. Inflammation and cancer. World J. Gastrointest. Surg. 2012;4:62-72.

    Not in our library10.4240/wjgs.v4.i3.62

59. 59.

    Rogovskii VS. The linkage between inflammation and immune tolerance: interfering with inflammation in cancer. Curr. Cancer Drug Targets. 2017;17:325-332.

    Not in our library10.2174/1568009617666170109110816

60. 60.

    Parkin DM, Hammerl L, Ferlay J, Kantelhardt EJ. Cancer in Africa 2018: the role of infections. Int. J. Cancer. 2020;146:2089-2103.

    Not in our library10.1002/ijc.32538

61. 61.

    Hashimoto M, et al. CD8 T cell exhaustion in chronic infection and cancer: opportunities for interventions. Annu. Rev. Med. 2018;69:301-318.

    Not in our library10.1146/annurev-med-012017-043208

62. 62.

    Pober JS, Cotran RS. The role of endothelial cells in inflammation. Transplantation. 1990;50:537-544.

    Not in our library10.1097/00007890-199010000-00001

63. 63.

    Steinke JW, Borish L. 3. Cytokines and chemokines. J. Allergy Clin. Immunol. 2006;117:S441-S445.

    Not in our library10.1016/j.jaci.2005.07.001

64. 64.

    Pober JS, Sessa WC. Evolving functions of endothelial cells in inflammation. Nat. Rev. Immunol. 2007;7:803-815.

    Not in our library10.1038/nri2171

65. 65.

    Butcher EC. Leukocyte-endothelial cell recognition: three (or more) steps to specificity and diversity. Cell. 1991;67:1033-1036.

    Not in our library10.1016/0092-8674(91)90279-8

66. 66.

    Locati M, Murphy PM. Chemokines and chemokine receptors: biology and clinical relevance in inflammation and AIDS. Annu Rev. Med. 1999;50:425-440.

    Not in our library10.1146/annurev.med.50.1.425

67. 67.

    Kobayashi Y. Neutrophil infiltration and chemokines. Crit. Rev. Immunol. 2006;26:307-316.

    Not in our library10.1615/critrevimmunol.v26.i4.20

68. 68.

    Kolaczkowska E, Kubes P. Neutrophil recruitment and function in health and inflammation. Nat. Rev. Immunol. 2013;13:159-175.

    Not in our library10.1038/nri3399

69. 69.

    Williams MR, Azcutia V, Newton G, Alcaide P, Luscinskas FW. Emerging mechanisms of neutrophil recruitment across endothelium. Trends Immunol. 2011;32:461-469.

    Not in our library10.1016/j.it.2011.06.009

70. 70.

    Simpson PJ, et al. Reduction of experimental canine myocardial reperfusion injury by a monoclonal antibody (anti-Mo1, anti-CD11b) that inhibits leukocyte adhesion. J. Clin. Invest. 1988;81:624-629.

    Not in our library10.1172/jci113364

71. 71.

    Woodfin A, et al. The junctional adhesion molecule JAM-C regulates polarized transendothelial migration of neutrophils in vivo. Nat. Immunol. 2011;12:761-769.

    Not in our library10.1038/ni.2062

72. 72.

    Corada M, et al. Junctional adhesion molecule-A-deficient polymorphonuclear cells show reduced diapedesis in peritonitis and heart ischemia-reperfusion injury. Proc. Natl Acad. Sci. USA. 2005;102:10634-10639.

    Not in our library10.1073/pnas.0500147102

73. 73.

    Nathan C. Neutrophils and immunity: challenges and opportunities. Nat. Rev. Immunol. 2006;6:173-182.

    Not in our library10.1038/nri1785

74. 74.
    Neutrophils in tissue injury and repair · 2018

    No notice
75. 75.

    Harty MW, et al. Neutrophil depletion blocks early collagen degradation in repairing cholestatic rat livers. Am. J. Pathol. 2010;176:1271-1281.

    Not in our library10.2353/ajpath.2010.090527

76. 76.

    Kuhl AA, et al. Aggravation of different types of experimental colitis by depletion or adhesion blockade of neutrophils. Gastroenterology. 2007;133:1882-1892.

    Not in our library10.1053/j.gastro.2007.08.073

77. 77.

    Dewald O, et al. CCL2/monocyte chemoattractant protein-1 regulates inflammatory responses critical to healing myocardial infarcts. Circ. Res. 2005;96:881-889.

    Not in our library10.1161/01.res.0000163017.13772.3a

78. 78.

    Frantz S, et al. Monocytes/macrophages prevent healing defects and left ventricular thrombus formation after myocardial infarction. FASEB J. 2013;27:871-881.

    Not in our library10.1096/fj.12-214049

79. 79.

    Zhao Y, Zou W, Du J, Zhao Y. The origins and homeostasis of monocytes and tissue-resident macrophages in physiological situation. J. Cell Physiol. 2018;233:6425-6439.

    Not in our library10.1002/jcp.26461

80. 80.

    Bystrom J, et al. Resolution-phase macrophages possess a unique inflammatory phenotype that is controlled by cAMP. Blood. 2008;112:4117-4127.

    Not in our library10.1182/blood-2007-12-129767

81. 81.

    Stables MJ, et al. Transcriptomic analyses of murine resolution-phase macrophages. Blood. 2011;118:e192-e208.

    Not in our library10.1182/blood-2011-04-345330

82. 82.

    Fredman G, Serhan CN. Specialized proresolving mediator targets for RvE1 and RvD1 in peripheral blood and mechanisms of resolution. Biochem. J. 2011;437:185-197.

    Not in our library10.1042/bj20110327

83. 83.

    Galli SJ, Nakae S, Tsai M. Mast cells in the development of adaptive immune responses. Nat. Immunol. 2005;6:135-142.

    Not in our library10.1038/ni1158

84. 84.

    Yu Y, Blokhuis BR, Garssen J, Redegeld FA. Non-IgE mediated mast cell activation. Eur. J. Pharm. 2016;778:33-43.

    Not in our library10.1016/j.ejphar.2015.07.017

85. 85.

    Costanza M, Colombo MP, Pedotti R. Mast cells in the pathogenesis of multiple sclerosis and experimental autoimmune encephalomyelitis. Int. J. Mol. Sci. 2012;13:15107-15125.

    Not in our library10.3390/ijms131115107

86. 86.

    Bischoff SC. Role of mast cells in allergic and non-allergic immune responses: comparison of human and murine data. Nat. Rev. Immunol. 2007;7:93-104.

    Not in our library10.1038/nri2018

87. 87.

    Dudeck A, et al. Mast cells are key promoters of contact allergy that mediate the adjuvant effects of haptens. Immunity. 2011;34:973-984.

    Not in our library10.1016/j.immuni.2011.03.028

88. 88.

    Cecere TE, Todd SM, Leroith T. Regulatory T cells in arterivirus and coronavirus infections: do they protect against disease or enhance it? Viruses. 2012;4:833-846.

    Not in our library10.3390/v4050833

89. 89.

    Li G, et al. Coronavirus infections and immune responses. J. Med. Virol. 2020;92:424-432.

    Not in our library10.1002/jmv.25685

90. 90.
    COVID-19: The Inflammation Link and the Role of Nutrition in Potential Mitigation · 2020

    No notice
91. 91.

    Kelly B, O’Neill LA. Metabolic reprogramming in macrophages and dendritic cells in innate immunity. Cell Res. 2015;25:771-784.

    Not in our library10.1038/cr.2015.68

92. 92.

    Steinbach EC, Plevy SE. The role of macrophages and dendritic cells in the initiation of inflammation in IBD. Inflamm. Bowel Dis. 2014;20:166-175.

    Not in our library10.1097/mib.0b013e3182a69dca

93. 93.

    Martinek J, Wu TC, Cadena D, Banchereau J, Palucka K. Interplay between dendritic cells and cancer cells. Int. Rev. Cell Mol. Biol. 2019;348:179-215.

    Not in our library10.1016/bs.ircmb.2019.07.008

94. 94.

    Schuster S, Hurrell B, Tacchini-Cottier F. Crosstalk between neutrophils and dendritic cells: a context-dependent process. J. Leukoc. Biol. 2013;94:671-675.

    Not in our library10.1189/jlb.1012540

95. 95.

    Angeli V, Randolph GJ. Inflammation, lymphatic function, and dendritic cell migration. Lymphat Res. Biol. 2006;4:217-228.

    Not in our library10.1089/lrb.2006.4406

96. 96.

    Salminen A, Kaarniranta K, Kauppinen A. The role of myeloid-derived suppressor cells (MDSC) in the inflammaging process. Ageing Res. Rev. 2018;48:1-10.

    Not in our library10.1016/j.arr.2018.09.001

97. 97.

    Goh CC, et al. Hepatitis C virus-induced myeloid-derived suppressor cells suppress NK cell IFN-gamma production by altering cellular metabolism via arginase-1. J. Immunol. 2016;196:2283-2292.

    Not in our library10.4049/jimmunol.1501881

98. 98.

    Huang S, et al. EZH2 inhibitor GSK126 suppresses antitumor immunity by driving production of myeloid-derived suppressor cells. Cancer Res. 2019;79:2009-2020.

    Not in our library10.1158/0008-5472.can-18-2395

99. 99.

    Gleich GJ. The functions of eosinophils. Ann. Inst. Pasteur Immunol. 1986;137D:136-141.

    Not in our library

100. 100.

     Knol EF, Olszewski M. Basophils and mast cells: underdog in immune regulation? Immunol. Lett. 2011;138:28-31.

     Not in our library10.1016/j.imlet.2011.02.012

101. 101.

     Gilmartin L, Tarleton CA, Schuyler M, Wilson BS, Oliver JM. A comparison of inflammatory mediators released by basophils of asthmatic and control subjects in response to high-affinity IgE receptor aggregation. Int. Arch. Allergy Immunol. 2008;145:182-192.

     Not in our library10.1159/000109287

102. 102.

     Silver MR, et al. IL-33 synergizes with IgE-dependent and IgE-independent agents to promote mast cell and basophil activation. Inflamm. Res. 2010;59:207-218.

     Not in our library10.1007/s00011-009-0088-5

103. 103.

     Gleich GJ, Adolphson CR, Leiferman KM. The biology of the eosinophilic leukocyte. Annu. Rev. Med. 1993;44:85-101.

     Not in our library10.1146/annurev.me.44.020193.000505

104. 104.

     Strandmark J, et al. Eosinophils are required to suppress Th2 responses in Peyer’s patches during intestinal infection by nematodes. Mucosal Immunol. 2017;10:661-672.

     Not in our library10.1038/mi.2016.93

105. 105.

     Tosello-Trampont A, Surette FA, Ewald SE, Hahn YS. Immunoregulatory role of NK Cells in tissue inflammation and regeneration. Front. Immunol. 2017;8:301.

     Not in our library10.3389/fimmu.2017.00301

106. 106.

     Nahrendorf M, et al. The healing myocardium sequentially mobilizes two monocyte subsets with divergent and complementary functions. J. Exp. Med. 2007;204:3037-3047.

     Not in our library10.1084/jem.20070885

107. 107.

     Hofmann U, et al. Activation of CD4+ T lymphocytes improves wound healing and survival after experimental myocardial infarction in mice. Circulation. 2012;125:1652-1663.

     Not in our library10.1161/circulationaha.111.044164

108. 108.

     Wu Y, Antony S, Meitzler JL, Doroshow JH. Molecular mechanisms underlying chronic inflammation-associated cancers. Cancer Lett. 2014;345:164-173.

     Not in our library10.1016/j.canlet.2013.08.014

109. 109.

     Back M, Yurdagul A, Tabas I, Oorni K, Kovanen PT. Inflammation and its resolution in atherosclerosis: mediators and therapeutic opportunities. Nat. Rev. Cardiol. 2019;16:389-406.

     Not in our library10.1038/s41569-019-0169-2

110. 110.

     Ding N, et al. Mast cells are important regulator of acupoint sensitization via the secretion of tryptase, 5-hydroxytryptamine, and histamine. PLoS ONE. 2018;13:e0194022.

     Not in our library10.1371/journal.pone.0194022

111. 111.

     Shi GP, Bot I, Kovanen PT. Reply: The complexity of substance P-mediated mast cell activation. Nat. Rev. Cardiol. 2017;14:124.

     Not in our library10.1038/nrcardio.2016.213

112. 112.

     Oschatz C, et al. Mast cells increase vascular permeability by heparin-initiated bradykinin formation in vivo. Immunity. 2011;34:258-268.

     Not in our library10.1016/j.immuni.2011.02.008

113. 113.

     Stoll G, Nieswandt B. Thrombo-inflammation in acute ischaemic stroke - implications for treatment. Nat. Rev. Neurol. 2019;15:473-481.

     Not in our library10.1038/s41582-019-0221-1

114. 114.

     Nissinen L, Kahari VM. Matrix metalloproteinases in inflammation. Biochim. Biophys. Acta. 2014;1840:2571-2580.

     Not in our library10.1016/j.bbagen.2014.03.007

115. 115.

     Courtois G, Gilmore TD. Mutations in the NF-kappaB signaling pathway: implications for human disease. Oncogene. 2006;25:6831-6843.

     Not in our library10.1038/sj.onc.1209939

116. 116.

     Rius J, et al. NF-kappaB links innate immunity to the hypoxic response through transcriptional regulation of HIF-1alpha. Nature. 2008;453:807-811.

     Not in our library10.1038/nature06905

117. 117.

     Karin M. Nuclear factor-kappaB in cancer development and progression. Nature. 2006;441:431-436.

     Not in our library10.1038/nature04870

118. 118.

     Koehne CH, Dubois RN. COX-2 inhibition and colorectal cancer. Semin. Oncol. 2004;31:12-21.

     Not in our library10.1053/j.seminoncol.2004.03.041

119. 119.

     Szlosarek PW, Balkwill FR. Tumour necrosis factor alpha: a potential target for the therapy of solid tumours. Lancet Oncol. 2003;4:565-573.

     Not in our library10.1016/s1470-2045(03)01196-3

120. 120.

     Uceyler N, et al. Tumor necrosis factor-alpha links heat and inflammation with Fabry pain. Mol. Genet. Metab. 2019;127:200-206.

     Not in our library10.1016/j.ymgme.2019.05.009

121. 121.

     Jordan SC, et al. Interleukin-6, a cytokine critical to mediation of inflammation, autoimmunity and allograft rejection: therapeutic implications of IL-6 receptor blockade. Transplantation. 2017;101:32-44.

     Not in our library10.1097/tp.0000000000001452

122. 122.

     Nguyen DP, Li J, Tewari AK. Inflammation and prostate cancer: the role of interleukin 6 (IL-6). BJU Int. 2014;113:986-992.

     Not in our library10.1111/bju.12452

123. 123.

     Lacy P. Editorial: secretion of cytokines and chemokines by innate immune cells. Front. Immunol. 2015;6:190.

     Not in our library10.3389/fimmu.2015.00190

124. 124.

     Rani A, Dasgupta P, Murphy JJ. Prostate cancer: the role of inflammation and chemokines. Am. J. Pathol. 2019;189:2119-2137.

     Not in our library10.1016/j.ajpath.2019.07.007

125. 125.

     Borroni EM, Savino B, Bonecchi R, Locati M. Chemokines sound the alarmin: The role of atypical chemokine in inflammation and cancer. Semin. Immunol. 2018;38:63-71.

     Not in our library10.1016/j.smim.2018.10.005

126. 126.

     Proost P, et al. Chemokine isoforms and processing in inflammation and immunity. J. Autoimmun. 2017;85:45-57.

     Not in our library10.1016/j.jaut.2017.06.009

127. 127.

     Lazennec G, Richmond A. Chemokines and chemokine receptors: new insights into cancer-related inflammation. Trends Mol. Med. 2010;16:133-144.

     Not in our library10.1016/j.molmed.2010.01.003

128. 128.

     Chen K, et al. Chemokines in homeostasis and diseases. Cell Mol. Immunol. 2018;15:324-334.

     Not in our library10.1038/cmi.2017.134

129. 129.

     Yoshimura T. The production of monocyte chemoattractant protein-1 (MCP-1)/CCL2 in tumor microenvironments. Cytokine. 2017;98:71-78.

     Not in our library10.1016/j.cyto.2017.02.001

130. 130.

     Yoshimura T. The chemokine MCP-1 (CCL2) in the host interaction with cancer: a foe or ally? Cell Mol. Immunol. 2018;15:335-345.

     Not in our library10.1038/cmi.2017.135

131. 131.
     Enhancing the Migration Ability of Mesenchymal Stromal Cells by Targeting the SDF-1/CXCR4 Axis · 2013

     No notice
132. 132.

     Daniel SK, Seo YD, Pillarisetty VG. The CXCL12-CXCR4/CXCR7 axis as a mechanism of immune resistance in gastrointestinal malignancies. Semin. Cancer Biol. 2020;65:176-188.

     Not in our library10.1016/j.semcancer.2019.12.007

133. 133.

     Klos A, Wende E, Wareham KJ, Monk PN. International union of basic and clinical pharmacology [corrected]. LXXXVII. complement peptide C5a, C4a, and C3a receptors. Pharm. Rev. 2013;65:500-543.

     Not in our library10.1124/pr.111.005223

134. 134.

     Martin M, Blom AM. Complement in removal of the dead - balancing inflammation. Immunol. Rev. 2016;274:218-232.

     Not in our library10.1111/imr.12462

135. 135.
     Versatility of the complement system in neuroinflammation, neurodegeneration and brain homeostasis · 2014

     No notice
136. 136.

     Koelman DLH, Brouwer MC, van de Beek D. Targeting the complement system in bacterial meningitis. Brain. 2019;142:3325-3337.

     Not in our library10.1093/brain/awz222

137. 137.

     Erdei A, Andrasfalvy M, Peterfy H, Toth G, Pecht I. Regulation of mast cell activation by complement-derived peptides. Immunol. Lett. 2004;92:39-42.

     Not in our library10.1016/j.imlet.2003.11.019

138. 138.

     Gasque P. Complement: a unique innate immune sensor for danger signals. Mol. Immunol. 2004;41:1089-1098.

     Not in our library10.1016/j.molimm.2004.06.011

139. 139.

     Cain SA, Monk PN. The orphan receptor C5L2 has high affinity binding sites for complement fragments C5a and C5a des-Arg(74). J. Biol. Chem. 2002;277:7165-7169.

     Not in our library10.1074/jbc.c100714200

140. 140.

     Janatova J. C3, C5 components and C3a, C4a, and C5a fragments of the complement system. Methods Enzymol. 1988;162:579-625.

     Not in our library10.1016/0076-6879(88)62104-5

141. 141.

     Lopez-Lera A, et al. Complement as a diagnostic tool in immunopathology. Semin Cell Dev. Biol. 2019;85:86-97.

     Not in our library10.1016/j.semcdb.2017.12.017

142. 142.

     Morgan BP, Harris CL. Complement, a target for therapy in inflammatory and degenerative diseases. Nat. Rev. Drug Disco. 2015;14:857-877.

     Not in our library10.1038/nrd4657

143. 143.

     Basil MC, Levy BD. Specialized pro-resolving mediators: endogenous regulators of infection and inflammation. Nat. Rev. Immunol. 2016;16:51-67.

     Not in our library10.1038/nri.2015.4

144. 144.

     Williams KI, Higgs GA. Eicosanoids and inflammation. J. Pathol. 1988;156:101-110.

     Not in our library10.1002/path.1711560204

145. 145.

     Serhan CN, Chiang N, Dalli J. The resolution code of acute inflammation: novel pro-resolving lipid mediators in resolution. Semin. Immunol. 2015;27:200-215.

     Not in our library10.1016/j.smim.2015.03.004

146. 146.

     Serhan CN. Lipoxins and aspirin-triggered 15-epi-lipoxins are the first lipid mediators of endogenous anti-inflammation and resolution. Prostaglandins Leukot. Ess. Fat. Acids. 2005;73:141-162.

     Not in our library10.1016/j.plefa.2005.05.002

147. 147.

     Serhan CN, Chiang N, Dalli J, Levy BD. Lipid mediators in the resolution of inflammation. Cold Spring Harb. Perspect. Biol. 2014;7:a016311.

     Not in our library10.1101/cshperspect.a016311

148. 148.

     Withana NP, et al. Dual-modality activity-based probes as molecular imaging agents for vascular inflammation. J. Nucl. Med. 2016;57:1583-1590.

     Not in our library10.2967/jnumed.115.171553

149. 149.

     Zayani Y, et al. Inflammations mediators and circulating levels of matrix metalloproteinases: biomarkers of diabetes in tunisians metabolic syndrome patients. Cytokine. 2016;86:47-52.

     Not in our library10.1016/j.cyto.2016.07.009

150. 150.

     Alameddine HS, Morgan JE. Matrix metalloproteinases and tissue inhibitor of metalloproteinases in inflammation and fibrosis of skeletal muscles. J. Neuromuscul. Dis. 2016;3:455-473.

     Not in our library10.3233/jnd-160183

151. 151.

     Baranek T, et al. Elastin receptor (spliced galactosidase) occupancy by elastin peptides counteracts proinflammatory cytokine expression in lipopolysaccharide-stimulated human monocytes through NF-kappaB down-regulation. J. Immunol. 2007;179:6184-6192.

     Not in our library10.4049/jimmunol.179.9.6184

152. 152.

     Maeno T, et al. CD8+ T Cells are required for inflammation and destruction in cigarette smoke-induced emphysema in mice. J. Immunol. 2007;178:8090-8096.

     Not in our library10.4049/jimmunol.178.12.8090

153. 153.

     Campden RI, Zhang Y. The role of lysosomal cysteine cathepsins in NLRP3 inflammasome activation. Arch. Biochem. Biophys. 2019;670:32-42.

     Not in our library10.1016/j.abb.2019.02.015

154. 154.

     Stoka V, Turk V, Turk B. Lysosomal cathepsins and their regulation in aging and neurodegeneration. Ageing Res. Rev. 2016;32:22-37.

     Not in our library10.1016/j.arr.2016.04.010

155. 155.

     van Kasteren SI, Overkleeft HS. Endo-lysosomal proteases in antigen presentation. Curr. Opin. Chem. Biol. 2014;23:8-15.

     Not in our library10.1016/j.cbpa.2014.08.011

156. 156.

     Ahmad S, Siddiqi MI. Insights from molecular modeling into the selective inhibition of cathepsin S by its inhibitor. J. Mol. Model. 2017;23:92.

     Not in our library10.1007/s00894-017-3255-6

157. 157.

     Tang Y, et al. Cathepsin B inhibition ameliorates the non-alcoholic steatohepatitis through suppressing caspase-1 activation. J. Physiol. Biochem. 2018;74:503-510.

     Not in our library10.1007/s13105-018-0644-y

158. 158.

     Pan W, et al. Inhibition of Ctsk alleviates periodontitis and comorbid rheumatoid arthritis via downregulation of the TLR9 signalling pathway. J. Clin. Periodontol. 2019;46:286-296.

     Not in our library10.1111/jcpe.13060

159. 159.

     Asagiri M, et al. Cathepsin K-dependent toll-like receptor 9 signaling revealed in experimental arthritis. Science. 2008;319:624-627.

     Not in our library10.1126/science.1150110

160. 160.

     Anderson P. Post-transcriptional regulons coordinate the initiation and resolution of inflammation. Nat. Rev. Immunol. 2010;10:24-35.

     Not in our library10.1038/nri2685

161. 161.

     Anel R, Kumar A. Human endotoxemia and human sepsis: limits to the model. Crit. Care. 2005;9:151-152.

     Not in our library10.1186/cc3501

162. 162.

     Hesse DG, et al. Cytokine appearance in human endotoxemia and primate bacteremia. Surg. Gynecol. Obstet. 1988;166:147-153.

     Not in our library

163. 163.

     Mazumder B, Sampath P, Fox PL. Regulation of macrophage ceruloplasmin gene expression: one paradigm of 3’-UTR-mediated translational control. Mol. Cells. 2005;20:167-172.

     Not in our library10.1016/j.molcel.2005.10.004

164. 164.

     Mazumder B, et al. Regulated release of L13a from the 60S ribosomal subunit as a mechanism of transcript-specific translational control. Cell. 2003;115:187-198.

     Not in our library10.1016/s0092-8674(03)00773-6

165. 165.

     Sampath P, et al. Noncanonical function of glutamyl-prolyl-tRNA synthetase: gene-specific silencing of translation. Cell. 2004;119:195-208.

     Not in our library10.1016/j.cell.2004.09.030

166. 166.

     Muhl H, Pfeilschifter J. Anti-inflammatory properties of pro-inflammatory interferon-gamma. Int. Immunopharmacol. 2003;3:1247-1255.

     Not in our library10.1016/s1567-5769(03)00131-0

167. 167.

     Mazumder B, Mukhopadhyay CK, Prok A, Cathcart MK, Fox PL. Induction of ceruloplasmin synthesis by IFN-gamma in human monocytic cells. J. Immunol. 1997;159:1938-1944.

     Not in our library

168. 168.

     Sampath P, Mazumder B, Seshadri V, Fox PL. Transcript-selective translational silencing by gamma interferon is directed by a novel structural element in the ceruloplasmin mRNA 3’ untranslated region. Mol. Cell Biol. 2003;23:1509-1519.

     Not in our library10.1128/mcb.23.5.1509-1519.2003

169. 169.

     Mukhopadhyay R, Jia J, Arif A, Ray PS, Fox PL. The GAIT system: a gatekeeper of inflammatory gene expression. Trends Biochem Sci. 2009;34:324-331.

     Not in our library10.1016/j.tibs.2009.03.004

170. 170.

     Serhan CN, et al. Novel functional sets of lipid-derived mediators with antiinflammatory actions generated from omega-3 fatty acids via cyclooxygenase 2-nonsteroidal antiinflammatory drugs and transcellular processing. J. Exp. Med. 2000;192:1197-1204.

     Not in our library10.1084/jem.192.8.1197

171. 171.

     Serhan CN, et al. Resolvins: a family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signals. J. Exp. Med. 2002;196:1025-1037.

     Not in our library10.1084/jem.20020760

172. 172.

     Levy BD, Clish CB, Schmidt B, Gronert K, Serhan CN. Lipid mediator class switching during acute inflammation: signals in resolution. Nat. Immunol. 2001;2:612-619.

     Not in our library10.1038/89759

173. 173.

     Serhan CN, Chiang N. Novel endogenous small molecules as the checkpoint controllers in inflammation and resolution: entree for resoleomics. Rheum. Dis. Clin. North Am. 2004;30:69-95.

     Not in our library10.1016/s0889-857x(03)00117-0

174. 174.

     Schwab JM, Chiang N, Arita M, Serhan CN. Resolvin E1 and protectin D1 activate inflammation-resolution programmes. Nature. 2007;447:869-874.

     Not in our library10.1038/nature05877

175. 175.

     O’Meara SJ, Rodgers K, Godson C. Lipoxins: update and impact of endogenous pro-resolution lipid mediators. Rev. Physiol. Biochem. Pharm. 2008;160:47-70.

     Not in our library10.1007/112_2006_0606

176. 176.

     Serhan CN. Lipoxins and aspirin-triggered 15-epi-lipoxin biosynthesis: an update and role in anti-inflammation and pro-resolution. Prostaglandins Other Lipid Mediat. 2002;68-69:433-455.

     Not in our library10.1016/s0090-6980(02)00047-3

177. 177.

     Serhan CN, Hamberg M, Samuelsson B. Lipoxins: novel series of biologically active compounds formed from arachidonic acid in human leukocytes. Proc. Natl Acad. Sci. USA. 1984;81:5335-5339.

     Not in our library10.1073/pnas.81.17.5335

178. 178.

     Serhan CN, Arita M, Hong S, Gotlinger K. Resolvins, docosatrienes, and neuroprotectins, novel omega-3-derived mediators, and their endogenous aspirin-triggered epimers. Lipids. 2004;39:1125-1132.

     Not in our library10.1007/s11745-004-1339-7

179. 179.

     Serhan CN, Gotlinger K, Hong S, Arita M. Resolvins, docosatrienes, and neuroprotectins, novel omega-3-derived mediators, and their aspirin-triggered endogenous epimers: an overview of their protective roles in catabasis. Prostaglandins Other Lipid Mediat. 2004;73:155-172.

     Not in our library10.1016/j.prostaglandins.2004.03.005

180. 180.

     Eickmeier O, et al. Aspirin-triggered resolvin D1 reduces mucosal inflammation and promotes resolution in a murine model of acute lung injury. Mucosal Immunol. 2013;6:256-266.

     Not in our library10.1038/mi.2012.66

181. 181.

     Samson M, et al. ChemR23, a putative chemoattractant receptor, is expressed in monocyte-derived dendritic cells and macrophages and is a coreceptor for SIV and some primary HIV-1 strains. Eur. J. Immunol. 1998;28:1689-1700.

     Not in our library10.1002/(sici)1521-4141(199805)28:05<1689::aid-immu1689>3.0.co;2-i

182. 182.

     Payrits M, et al. Resolvin D1 and D2 inhibit transient receptor potential Vanilloid 1 and Ankyrin 1 ion channel activation on sensory neurons via lipid raft modification. Int. J. Mol. Sci. 2020;21:5019.

     Not in our library10.3390/ijms21145019

183. 183.

     Chiang N, Dalli J, Colas RA, Serhan CN. Identification of resolvin D2 receptor mediating resolution of infections and organ protection. J. Exp. Med. 2015;212:1203-1217.

     Not in our library10.1084/jem.20150225

184. 184.

     Back M, Hansson GK. Omega-3 fatty acids, cardiovascular risk, and the resolution of inflammation. FASEB J. 2019;33:1536-1539.

     Not in our library10.1096/fj.201802445r

185. 185.

     Lopez-Vicario C, et al. Association of a variant in the gene encoding for ERV1/ChemR23 with reduced inflammation in visceral adipose tissue from morbidly obese individuals. Sci. Rep. 2017;7:15724.

     Not in our library10.1038/s41598-017-15951-z

186. 186.

     Laguna-Fernandez A, et al. ERV1/ChemR23 signaling protects against atherosclerosis by modifying oxidized low-density lipoprotein uptake and phagocytosis in macrophages. Circulation. 2018;138:1693-1705.

     Not in our library10.1161/circulationaha.117.032801

187. 187.

     Zhou Y, et al. Fibrinogen-like protein 2 controls sepsis catabasis by interacting with resolvin Dp5. Sci. Adv. 2019;5:eaax0629.

     Not in our library10.1126/sciadv.aax0629

188. 188.

     Marcheselli VL, et al. Neuroprotectin D1/protectin D1 stereoselective and specific binding with human retinal pigment epithelial cells and neutrophils. Prostaglandins Leukot. Ess. Fat. Acids. 2010;82:27-34.

     Not in our library10.1016/j.plefa.2009.10.010

189. 189.

     Kohli P, Levy BD. Resolvins and protectins: mediating solutions to inflammation. Br. J. Pharm. 2009;158:960-971.

     Not in our library10.1111/j.1476-5381.2009.00290.x

190. 190.

     Serhan CN, et al. Anti-inflammatory actions of neuroprotectin D1/protectin D1 and its natural stereoisomers: assignments of dihydroxy-containing docosatrienes. J. Immunol. 2006;176:1848-1859.

     Not in our library10.4049/jimmunol.176.3.1848

191. 191.

     Serhan CN, Dalli J, Colas RA, Winkler JW, Chiang N. Protectins and maresins: new pro-resolving families of mediators in acute inflammation and resolution bioactive metabolome. Biochim. Biophys. Acta. 2015;1851:397-413.

     Not in our library10.1016/j.bbalip.2014.08.006

192. 192.

     Chiurchiu V, et al. Proresolving lipid mediators resolvin D1, resolvin D2, and maresin 1 are critical in modulating T cell responses. Sci. Transl. Med. 2016;8:353ra111.

     Not in our library10.1126/scitranslmed.aaf7483

193. 193.

     Chatterjee A, et al. The pro-resolving lipid mediator maresin 1 (MaR1) attenuates inflammatory signaling pathways in vascular smooth muscle and endothelial cells. PLoS ONE. 2014;9:e113480.

     Not in our library10.1371/journal.pone.0113480

194. 194.

     Hong S, et al. Maresin-like lipid mediators are produced by leukocytes and platelets and rescue reparative function of diabetes-impaired macrophages. Chem. Biol. 2014;21:1318-1329.

     Not in our library10.1016/j.chembiol.2014.06.010

195. 195.

     Dalli J, et al. The novel 13S,14S-epoxy-maresin is converted by human macrophages to maresin 1 (MaR1), inhibits leukotriene A4 hydrolase (LTA4H), and shifts macrophage phenotype. FASEB J. 2013;27:2573-2583.

     Not in our library10.1096/fj.13-227728

196. 196.

     Liening S, Romp E, Werz O, Scriba GKE, Garscha U. Liquid chromatography-coupled mass spectrometry analysis of glutathione conjugates of oxygenated polyunsaturated fatty acids. Prostaglandins Other Lipid Mediat. 2019;144:106350.

     Not in our library10.1016/j.prostaglandins.2019.106350

197. 197.

     Liu YJ, et al. PCTR1 ameliorates lipopolysaccharide-induced acute inflammation and multiple organ damage via regulation of linoleic acid metabolism by promoting FADS1/FASDS2/ELOV2 expression and reducing PLA2 expression. Lab. Invest. 2020;100:904-915.

     Not in our library10.1038/s41374-020-0412-9

198. 198.

     Ramon S, et al. The protectin PCTR1 is produced by human M2 macrophages and enhances resolution of infectious inflammation. Am. J. Pathol. 2016;186:962-973.

     Not in our library10.1016/j.ajpath.2015.12.012

199. 199.

     Zhang Q, Zhu B, Li Y. Resolution of cancer-promoting inflammation: a new approach for anticancer therapy. Front. Immunol. 2017;8:71.

     Not in our library10.3389/fimmu.2017.00071

200. 200.

     Xian W, et al. The pro-resolving lipid mediator maresin 1 protects against cerebral ischemia/reperfusion injury by attenuating the pro-inflammatory response. Biochem. Biophys. Res. Commun. 2016;472:175-181.

     Not in our library10.1016/j.bbrc.2016.02.090

201. 201.

     Hwang SM, Chung G, Kim YH, Park CK. The role of maresins in inflammatory pain: function of macrophages in wound regeneration. Int. J. Mol. Sci. 2019;20:5849.

     Not in our library10.3390/ijms20235849

202. 202.

     Serhan CN, Chiang N, Dalli J. New pro-resolving n-3 mediators bridge resolution of infectious inflammation to tissue regeneration. Mol. Asp. Med. 2018;64:1-17.

     Not in our library10.1016/j.mam.2017.08.002

203. 203.

     Chiang N, et al. New maresin conjugates in tissue regeneration pathway counters leukotriene D4-stimulated vascular responses. FASEB J. 2018;32:4043-4052.

     Not in our library10.1096/fj.201701493r

204. 204.

     de la Rosa X, et al. Identification and complete stereochemical assignments of the new resolvin conjugates in tissue regeneration in human tissues that stimulate proresolving phagocyte functions and tissue regeneration. Am. J. Pathol. 2018;188:950-966.

     Not in our library10.1016/j.ajpath.2018.01.004

205. 205.

     Flesher RP, Herbert C, Kumar RK. Resolvin E1 promotes resolution of inflammation in a mouse model of an acute exacerbation of allergic asthma. Clin. Sci. 2014;126:805-814.

     Not in our library10.1042/cs20130623

206. 206.

     Wang X, et al. Resolution of inflammation is altered in Alzheimer’s disease. Alzheimers Dement. 2015;11:40-50.

     Not in our library10.1016/j.jalz.2013.12.024

207. 207.

     Yang L, et al. Immune characteristics of severe and critical COVID-19 patients. Signal Transduct. Target Ther. 2020;5:179.

     Not in our library10.1038/s41392-020-00296-3

208. 208.

     Xu Z, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir. Med. 2020;8:420-422.

     Not in our library10.1016/s2213-2600(20)30076-x

209. 209.

     Mehta P, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395:1033-1034.

     Not in our library10.1016/s0140-6736(20)30628-0

210. 210.

     Rokni M, Hamblin MR, Rezaei N. Cytokines and COVID-19: friends or foes? Hum. Vaccin Immunother. 2020;16:2363-2365.

     Not in our library10.1080/21645515.2020.1799669

211. 211.

     Otsuka R, Seino KI. Macrophage activation syndrome and COVID-19. Inflamm. Regen. 2020;40:19.

     Not in our library10.1186/s41232-020-00131-w

212. 212.

     Das UN. Can bioactive lipids inactivate coronavirus (COVID-19)? Arch. Med. Res. 2020;51:282-286.

     Not in our library10.1016/j.arcmed.2020.03.004

213. 213.

     Fekete T, et al. Regulatory NLRs control the RLR-mediated Type I interferon and inflammatory responses in human dendritic cells. Front. Immunol. 2018;9:2314.

     Not in our library10.3389/fimmu.2018.02314

214. 214.

     Si Y, et al. Posttranslational modification control of inflammatory signaling. Adv. Exp. Med. Biol. 2017;1024:37-61.

     Not in our library10.1007/978-981-10-5987-2_2

215. 215.

     Istomin AY, Godzik A. Understanding diversity of human innate immunity receptors: analysis of surface features of leucine-rich repeat domains in NLRs and TLRs. BMC Immunol. 2009;10:48.

     Not in our library10.1186/1471-2172-10-48

216. 216.

     Dolasia K, Bisht MK, Pradhan G, Udgata A, Mukhopadhyay S. TLRs/NLRs: shaping the landscape of host immunity. Int. Rev. Immunol. 2018;37:3-19.

     Not in our library10.1080/08830185.2017.1397656

217. 217.

     Broad A, Kirby JA, Jones DE, Applied I, Transplantation Research G. Toll-like receptor interactions: tolerance of MyD88-dependent cytokines but enhancement of MyD88-independent interferon-beta production. Immunology. 2007;120:103-111.

     Not in our library10.1111/j.1365-2567.2006.02485.x

218. 218.

     Wieland CW, et al. The MyD88-dependent, but not the MyD88-independent, pathway of TLR4 signaling is important in clearing nontypeable haemophilus influenzae from the mouse lung. J. Immunol. 2005;175:6042-6049.

     Not in our library10.4049/jimmunol.175.9.6042

219. 219.

     Triantafilou M, et al. Membrane sorting of toll-like receptor (TLR)-2/6 and TLR2/1 heterodimers at the cell surface determines heterotypic associations with CD36 and intracellular targeting. J. Biol. Chem. 2006;281:31002-31011.

     Not in our library10.1074/jbc.m602794200

220. 220.

     Bagchi A, et al. MyD88-dependent and MyD88-independent pathways in synergy, priming, and tolerance between TLR agonists. J. Immunol. 2007;178:1164-1171.

     Not in our library10.4049/jimmunol.178.2.1164

221. 221.

     Tamassia N, et al. The MyD88-independent pathway is not mobilized in human neutrophils stimulated via TLR4. J. Immunol. 2007;178:7344-7356.

     Not in our library10.4049/jimmunol.178.11.7344

222. 222.

     Karnati HK, et al. TLR-4 signalling pathway: MyD88 independent pathway up-regulation in chicken breeds upon LPS treatment. Vet. Res. Commun. 2015;39:73-78.

     Not in our library10.1007/s11259-014-9621-2

223. 223.

     Inohara N, Nunez G. NODs: intracellular proteins involved in inflammation and apoptosis. Nat. Rev. Immunol. 2003;3:371-382.

     Not in our library10.1038/nri1086

224. 224.

     Chamaillard M, Girardin SE, Viala J, Philpott DJ. Nods, Nalps and Naip: intracellular regulators of bacterial-induced inflammation. Cell Microbiol. 2003;5:581-592.

     Not in our library10.1046/j.1462-5822.2003.00304.x

225. 225.

     Ting JP, et al. The NLR gene family: a standard nomenclature. Immunity. 2008;28:285-287.

     Not in our library10.1016/j.immuni.2008.02.005

226. 226.

     Wagner RN, Proell M, Kufer TA, Schwarzenbacher R. Evaluation of Nod-like receptor (NLR) effector domain interactions. PLoS ONE. 2009;4:e4931.

     Not in our library10.1371/journal.pone.0004931

227. 227.

     Zhou R, Tardivel A, Thorens B, Choi I, Tschopp J. Thioredoxin-interacting protein links oxidative stress to inflammasome activation. Nat. Immunol. 2010;11:136-140.

     Not in our library10.1038/ni.1831

228. 228.

     Davis BK, Wen H, Ting JP. The inflammasome NLRs in immunity, inflammation, and associated diseases. Annu. Rev. Immunol. 2011;29:707-735.

     Not in our library10.1146/annurev-immunol-031210-101405

229. 229.

     Schroder K, Tschopp J. The inflammasomes. Cell. 2010;140:821-832.

     Not in our library10.1016/j.cell.2010.01.040

230. 230.

     Man SM, Karki R, Kanneganti TD. Molecular mechanisms and functions of pyroptosis, inflammatory caspases and inflammasomes in infectious diseases. Immunol. Rev. 2017;277:61-75.

     Not in our library10.1111/imr.12534

231. 231.

     Xue Y, Enosi Tuipulotu D, Tan WH, Kay C, Man SM. Emerging activators and regulators of inflammasomes and pyroptosis. Trends Immunol. 2019;40:1035-1052.

     Not in our library10.1016/j.it.2019.09.005

232. 232.

     Feng S, Fox D, Man SM. Mechanisms of gasdermin family members in inflammasome signaling and cell death. J. Mol. Biol. 2018;430:3068-3080.

     Not in our library10.1016/j.jmb.2018.07.002

233. 233.

     Kanneganti A, et al. GSDMD is critical for autoinflammatory pathology in a mouse model of Familial Mediterranean Fever. J. Exp. Med. 2018;215:1519-1529.

     Not in our library10.1084/jem.20172060

234. 234.
     Gasdermin D mediates the pathogenesis of neonatal-onset multisystem inflammatory disease in mice · 2018

     No notice
235. 235.

     Xu B, et al. Gasdermin D plays a key role as a pyroptosis executor of non-alcoholic steatohepatitis in humans and mice. J. Hepatol. 2018;68:773-782.

     Not in our library10.1016/j.jhep.2017.11.040

236. 236.

     McKenzie BA, et al. Caspase-1 inhibition prevents glial inflammasome activation and pyroptosis in models of multiple sclerosis. Proc. Natl Acad. Sci. USA. 2018;115:E6065-E6074.

     Not in our library10.1073/pnas.1722041115

237. 237.

     Hu B, et al. Inflammation-induced tumorigenesis in the colon is regulated by caspase-1 and NLRC4. Proc. Natl Acad. Sci. USA. 2010;107:21635-21640.

     Not in our library10.1073/pnas.1016814108

238. 238.
     The role of NLRP3 inflammasome in 5-fluorouracil resistance of oral squamous cell carcinoma · 2017

     No notice
239. 239.

     Chen L, et al. Blockage of the NLRP3 inflammasome by MCC950 improves anti-tumor immune responses in head and neck squamous cell carcinoma. Cell Mol. Life Sci. 2018;75:2045-2058.

     Not in our library10.1007/s00018-017-2720-9

240. 240.

     Pikarsky E, et al. NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature. 2004;431:461-466.

     Not in our library10.1038/nature02924

241. 241.

     Carbia-Nagashima A, et al. RSUME, a small RWD-containing protein, enhances SUMO conjugation and stabilizes HIF-1alpha during hypoxia. Cell. 2007;131:309-323.

     Not in our library10.1016/j.cell.2007.07.044

242. 242.

     Herrington FD, Carmody RJ, Goodyear CS. Modulation of NF-kappaB signaling as a therapeutic target in autoimmunity. J. Biomol. Screen. 2016;21:223-242.

     Not in our library10.1177/1087057115617456

243. 243.
     The NF-κB Signaling Pathway, the Microbiota, and Gastrointestinal Tumorigenesis: Recent Advances · 2020

     No notice
244. 244.

     Park YR, et al. NF-kappaB signaling is key in the wound healing processes of silk fibroin. Acta Biomater. 2018;67:183-195.

     Not in our library10.1016/j.actbio.2017.12.006

245. 245.

     McDaniel DK, Eden K, Ringel VM, Allen IC. Emerging roles for noncanonical NF-kappaB signaling in the modulation of inflammatory bowel disease pathobiology. Inflamm. Bowel Dis. 2016;22:2265-2279.

     Not in our library10.1097/mib.0000000000000858

246. 246.

     Mizukami Y, et al. Induction of interleukin-8 preserves the angiogenic response in HIF-1alpha-deficient colon cancer cells. Nat. Med. 2005;11:992-997.

     Not in our library10.1038/nm1294

247. 247.

     Taniguchi K, Karin M. NF-kappaB, inflammation, immunity and cancer: coming of age. Nat. Rev. Immunol. 2018;18:309-324.

     Not in our library10.1038/nri.2017.142

248. 248.

     Tanaka T. Introduction for inflammation and cancer. Semin. Immunopathol. 2013;35:121-122.

     Not in our library10.1007/s00281-012-0360-6

249. 249.

     Gajewski TF, Schreiber H, Fu YX. Innate and adaptive immune cells in the tumor microenvironment. Nat. Immunol. 2013;14:1014-1022.

     Not in our library10.1038/ni.2703

250. 250.

     Corrales L, Matson V, Flood B, Spranger S, Gajewski TF. Innate immune signaling and regulation in cancer immunotherapy. Cell Res. 2017;27:96-108.

     Not in our library10.1038/cr.2016.149

251. 251.

     Dawson MA, Kouzarides T. Cancer epigenetics: from mechanism to therapy. Cell. 2012;150:12-27.

     Not in our library10.1016/j.cell.2012.06.013

252. 252.
     Inflammation, a Double-Edge Sword for Cancer and Other Age-Related Diseases · 2018

     No notice
253. 253.

     Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646-674.

     Not in our library10.1016/j.cell.2011.02.013

254. 254.
     Inflammation and cancer · 2018

     No notice
255. 255.

     Zhang D, et al. Metabolic regulation of gene expression by histone lactylation. Nature. 2019;574:575-580.

     Not in our library10.1038/s41586-019-1678-1

256. 256.

     Ell B, Kang Y. Transcriptional control of cancer metastasis. Trends Cell Biol. 2013;23:603-611.

     Not in our library10.1016/j.tcb.2013.06.001

257. 257.

     Easwaran H, Tsai HC, Baylin SB. Cancer epigenetics: tumor heterogeneity, plasticity of stem-like states, and drug resistance. Mol. Cell. 2014;54:716-727.

     Not in our library10.1016/j.molcel.2014.05.015

258. 258.

     Iliopoulos D, Hirsch HA, Struhl K. An epigenetic switch involving NF-kappaB, Lin28, Let-7 MicroRNA, and IL6 links inflammation to cell transformation. Cell. 2009;139:693-706.

     Not in our library10.1016/j.cell.2009.10.014

259. 259.

     Chiarugi P, Cirri P. Metabolic exchanges within tumor microenvironment. Cancer Lett. 2016;380:272-280.

     Not in our library10.1016/j.canlet.2015.10.027

260. 260.

     Fischer K, et al. Inhibitory effect of tumor cell-derived lactic acid on human T cells. Blood. 2007;109:3812-3819.

     Not in our library10.1182/blood-2006-07-035972

261. 261.

     Gottfried E, et al. Tumor-derived lactic acid modulates dendritic cell activation and antigen expression. Blood. 2006;107:2013-2021.

     Not in our library10.1182/blood-2005-05-1795

262. 262.

     Bader JE, Voss K, Rathmell JC. Targeting metabolism to improve the tumor microenvironment for cancer immunotherapy. Mol. Cell. 2020;78:1019-1033.

     Not in our library10.1016/j.molcel.2020.05.034

263. 263.

     Mu X, et al. Tumor-derived lactate induces M2 macrophage polarization via the activation of the ERK/STAT3 signaling pathway in breast cancer. Cell Cycle. 2018;17:428-438.

     Not in our library10.1080/15384101.2018.1444305

264. 264.

     Colegio OR, et al. Functional polarization of tumour-associated macrophages by tumour-derived lactic acid. Nature. 2014;513:559-563.

     Not in our library10.1038/nature13490

265. 265.

     Jess T, et al. Decreasing risk of colorectal cancer in patients with inflammatory bowel disease over 30 years. Gastroenterology. 2012;143:375-381.

     Not in our library10.1053/j.gastro.2012.04.016

266. 266.

     Keller DS, Windsor A, Cohen R, Chand M. Colorectal cancer in inflammatory bowel disease: review of the evidence. Tech. Coloproctol. 2019;23:3-13.

     Not in our library10.1007/s10151-019-1926-2

267. 267.

     Pekow J, et al. IBD-associated colon cancers differ in DNA methylation and gene expression profiles compared with sporadic colon cancers. J. Crohns Colitis. 2019;13:884-893.

     Not in our library10.1093/ecco-jcc/jjz014

268. 268.

     Bian S, et al. Single-cell multiomics sequencing and analyses of human colorectal cancer. Science. 2018;362:1060-1063.

     Not in our library10.1126/science.aao3791

269. 269.

     Gottlieb M, Nakitende D. Comparison of tamsulosin, nifedipine, and placebo for ureteric colic. CJEM. 2017;19:156-158.

     Not in our library10.1017/cem.2015.105

270. 270.

     Loor A, Dumitrascu DL. Helicobacter pylori infection, gastric cancer and gastropanel. Rom. J. Intern. Med. 2016;54:151-156.

     Not in our library10.1515/rjim-2016-0025

271. 271.
     Macrophages in intestinal homeostasis and inflammation · 2014

     No notice
272. 272.

     Yang H, et al. A common antimicrobial additive increases colonic inflammation and colitis-associated colon tumorigenesis in mice. Sci. Transl. Med. 2018;10:eaan4116.

     Not in our library10.1126/scitranslmed.aan4116

273. 273.
     HBV-Induced Immune Imbalance in the Development of HCC · 2019

     No notice
274. 274.

     Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S. Human papillomavirus and cervical cancer. Lancet. 2007;370:890-907.

     Not in our library10.1016/s0140-6736(07)61416-0

275. 275.

     Li R, et al. Gut microbiota-stimulated cathepsin K secretion mediates TLR4-dependent M2 macrophage polarization and promotes tumor metastasis in colorectal cancer. Cell Death Differ. 2019;26:2447-2463.

     Not in our library10.1038/s41418-019-0312-y

276. 276.

     Kalafati L, et al. Innate immune training of granulopoiesis promotes anti-tumor activity. Cell. 2020;183:771-785 e712.

     Not in our library10.1016/j.cell.2020.09.058

277. 277.

     Smith PM, et al. The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis. Science. 2013;341:569-573.

     Not in our library10.1126/science.1241165

278. 278.

     Furusawa Y, et al. Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells. Nature. 2013;504:446-450.

     Not in our library10.1038/nature12721

279. 279.

     Arpaia N, et al. Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generation. Nature. 2013;504:451-455.

     Not in our library10.1038/nature12726

280. 280.

     Routy B, et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science. 2018;359:91-97.

     Not in our library10.1126/science.aan3706

281. 281.

     Ma C, et al. Gut microbiome-mediated bile acid metabolism regulates liver cancer via NKT cells. Science. 2018;360:eaan5931.

     Not in our library10.1126/science.aan5931

282. 282.

     Elkrief A, Derosa L, Zitvogel L, Kroemer G, Routy B. The intimate relationship between gut microbiota and cancer immunotherapy. Gut Microbes. 2019;10:424-428.

     Not in our library10.1080/19490976.2018.1527167

283. 283.

     Jin S, et al. Maresin 1 improves the Treg/Th17 imbalance in rheumatoid arthritis through miR-21. Ann. Rheum. Dis. 2018;77:1644-1652.

     Not in our library10.1136/annrheumdis-2018-213511

284. 284.

     Laird BJ, et al. The systemic inflammatory response and its relationship to pain and other symptoms in advanced cancer. Oncologist. 2013;18:1050-1055.

     Not in our library10.1634/theoncologist.2013-0120

285. 285.

     Avgerinos KI, Spyrou N, Mantzoros CS, Dalamaga M. Obesity and cancer risk: emerging biological mechanisms and perspectives. Metabolism. 2019;92:121-135.

     Not in our library10.1016/j.metabol.2018.11.001

286. 286.

     Reiche EM, Nunes SO, Morimoto HK. Stress, depression, the immune system, and cancer. Lancet Oncol. 2004;5:617-625.

     Not in our library10.1016/s1470-2045(04)01597-9

287. 287.

     Chan DSM, et al. Body mass index and survival in women with breast cancer-systematic literature review and meta-analysis of 82 follow-up studies. Ann. Oncol. 2014;25:1901-1914.

     Not in our library10.1093/annonc/mdu042

288. 288.

     Larsson SC, Wolk A. Obesity and colon and rectal cancer risk: a meta-analysis of prospective studies. Am. J. Clin. Nutr. 2007;86:556-565.

     Not in our library10.1093/ajcn/86.3.556

289. 289.
     Overweight, obesity and risk of liver cancer: a meta-analysis of cohort studies · 2007

     No notice
290. 290.

     Olsen CM, et al. Obesity and the risk of epithelial ovarian cancer: a systematic review and meta-analysis. Eur. J. Cancer. 2007;43:690-709.

     Not in our library10.1016/j.ejca.2006.11.010

291. 291.

     Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N. Engl. J. Med. 2003;348:1625-1638.

     Not in our library10.1056/nejmoa021423

292. 292.

     Saltiel AR, Olefsky JM. Inflammatory mechanisms linking obesity and metabolic disease. J. Clin. Invest. 2017;127:1-4.

     Not in our library10.1172/jci92035

293. 293.

     Correa LH, Heyn GS, Magalhaes KG. The impact of the adipose organ plasticity on inflammation and cancer progression. Cells. 2019;8:662.

     Not in our library10.3390/cells8070662

294. 294.

     Rogers NH, Perfield JW, Strissel KJ, Obin MS, Greenberg AS. Reduced energy expenditure and increased inflammation are early events in the development of ovariectomy-induced obesity. Endocrinology. 2009;150:2161-2168.

     Not in our library10.1210/en.2008-1405

295. 295.

     Howe LR, Subbaramaiah K, Hudis CA, Dannenberg AJ. Molecular pathways: adipose inflammation as a mediator of obesity-associated cancer. Clin. Cancer Res. 2013;19:6074-6083.

     Not in our library10.1158/1078-0432.ccr-12-2603

296. 296.

     Bochet L, et al. Cancer-associated adipocytes promotes breast tumor radioresistance. Biochem. Biophys. Res. Commun. 2011;411:102-106.

     Not in our library10.1016/j.bbrc.2011.06.101

297. 297.

     Lee YH, Jung YS, Choi D. Recent advance in brown adipose physiology and its therapeutic potential. Exp. Mol. Med. 2014;46:e78.

     Not in our library10.1038/emm.2013.163

298. 298.

     Apostoli AJ, et al. Loss of PPARgamma expression in mammary secretory epithelial cells creates a pro-breast tumorigenic environment. Int. J. Cancer. 2014;134:1055-1066.

     Not in our library10.1002/ijc.28432

299. 299.

     Kolb R, Sutterwala FS, Zhang W. Obesity and cancer: inflammation bridges the two. Curr. Opin. Pharm. 2016;29:77-89.

     Not in our library10.1016/j.coph.2016.07.005

300. 300.

     Deng T, Lyon CJ, Bergin S, Caligiuri MA, Hsueh WA. Obesity, inflammation, and cancer. Annu. Rev. Pathol. 2016;11:421-449.

     Not in our library10.1146/annurev-pathol-012615-044359

301. 301.

     Stein M. Stress, depression, and the immune system. J. Clin. Psychiatry. 1989;50:35-40.

     Not in our library

302. 302.

     Chrousos GP. The hypothalamic-pituitary-adrenal axis and immune-mediated inflammation. N. Engl. J. Med. 1995;332:1351-1362.

     Not in our library10.1056/nejm199505183322008

303. 303.

     Miller ES, et al. Chronic stress induces persistent low-grade inflammation. Am. J. Surg. 2019;218:677-683.

     Not in our library10.1016/j.amjsurg.2019.07.006

304. 304.

     Gao X, et al. Chronic stress promotes colitis by disturbing the gut microbiota and triggering immune system response. Proc. Natl Acad. Sci. USA. 2018;115:E2960-E2969.

     Not in our library10.1073/pnas.1720696115

305. 305.

     Curtin NM, Boyle NT, Mills KH, Connor TJ. Psychological stress suppresses innate IFN-gamma production via glucocorticoid receptor activation: reversal by the anxiolytic chlordiazepoxide. Brain Behav. Immun. 2009;23:535-547.

     Not in our library10.1016/j.bbi.2009.02.003

306. 306.

     Yang H, et al. Stress-glucocorticoid-TSC22D3 axis compromises therapy-induced antitumor immunity. Nat. Med. 2019;25:1428-1441.

     Not in our library10.1038/s41591-019-0566-4

307. 307.

     Gonzalez H, Hagerling C, Werb Z. Roles of the immune system in cancer: from tumor initiation to metastatic progression. Genes Dev. 2018;32:1267-1284.

     Not in our library10.1101/gad.314617.118

308. 308.

     Orimo A, et al. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell. 2005;121:335-348.

     Not in our library10.1016/j.cell.2005.02.034

309. 309.

     Bhowmick NA, Neilson EG, Moses HL. Stromal fibroblasts in cancer initiation and progression. Nature. 2004;432:332-337.

     Not in our library10.1038/nature03096

310. 310.

     Ozdemir BC, et al. Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. Cancer Cell. 2014;25:719-734.

     Not in our library10.1016/j.ccr.2014.04.005

311. 311.
     Gene Expression Signature of Fibroblast Serum Response Predicts Human Cancer Progression: Similarities between Tumors and Wounds · 2004

     No notice
312. 312.

     Wong VW, et al. Focal adhesion kinase links mechanical force to skin fibrosis via inflammatory signaling. Nat. Med. 2011;18:148-152.

     Not in our library10.1038/nm.2574

313. 313.

     Ammirante M, Shalapour S, Kang Y, Jamieson CA, Karin M. Tissue injury and hypoxia promote malignant progression of prostate cancer by inducing CXCL13 expression in tumor myofibroblasts. Proc. Natl Acad. Sci. USA. 2014;111:14776-14781.

     Not in our library10.1073/pnas.1416498111

314. 314.

     Shalapour S, et al. Immunosuppressive plasma cells impede T-cell-dependent immunogenic chemotherapy. Nature. 2015;521:94-98.

     Not in our library10.1038/nature14395

315. 315.

     Yang L, Pang Y, Moses HL. TGF-beta and immune cells: an important regulatory axis in the tumor microenvironment and progression. Trends Immunol. 2010;31:220-227.

     Not in our library10.1016/j.it.2010.04.002

316. 316.

     Ammirante M, Luo JL, Grivennikov S, Nedospasov S, Karin M. B-cell-derived lymphotoxin promotes castration-resistant prostate cancer. Nature. 2010;464:302-305.

     Not in our library10.1038/nature08782

317. 317.

     Ksiazkiewicz M, et al. Importance of CCL2-CCR2A/2B signaling for monocyte migration into spheroids of breast cancer-derived fibroblasts. Immunobiology. 2010;215:737-747.

     Not in our library10.1016/j.imbio.2010.05.019

318. 318.

     Kraman M, et al. Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-alpha. Science. 2010;330:827-830.

     Not in our library10.1126/science.1195300

319. 319.

     Galli SJ, et al. Mast cells as “tunable” effector and immunoregulatory cells: recent advances. Annu. Rev. Immunol. 2005;23:749-786.

     Not in our library10.1146/annurev.immunol.21.120601.141025

320. 320.

     Bulfone-Paus S, Nilsson G, Draber P, Blank U, Levi-Schaffer F. Positive and negative signals in mast cell activation. Trends Immunol. 2017;38:657-667.

     Not in our library10.1016/j.it.2017.01.008

321. 321.

     Aller MA, Arias JI, Arias J. Pathological axes of wound repair: gastrulation revisited. Theor. Biol. Med. Model. 2010;7:37.

     Not in our library10.1186/1742-4682-7-37

322. 322.

     Khazaie K, et al. The significant role of mast cells in cancer. Cancer Metastasis Rev. 2011;30:45-60.

     Not in our library10.1007/s10555-011-9286-z

323. 323.

     Kischer CW, Bunce H, Shetlah MR. Mast cell analyses in hypertrophic scars, hypertrophic scars treated with pressure and mature scars. J. Invest. Dermatol. 1978;70:355-357.

     Not in our library10.1111/1523-1747.ep12543553

324. 324.

     Carlini MJ, et al. Mast cell phenotypes and microvessels in non-small cell lung cancer and its prognostic significance. Hum. Pathol. 2010;41:697-705.

     Not in our library10.1016/j.humpath.2009.04.029

325. 325.

     Strouch MJ, et al. Crosstalk between mast cells and pancreatic cancer cells contributes to pancreatic tumor progression. Clin. Cancer Res. 2010;16:2257-2265.

     Not in our library10.1158/1078-0432.ccr-09-1230

326. 326.

     Kuronita T, et al. A role for the lysosomal membrane protein LGP85 in the biogenesis and maintenance of endosomal and lysosomal morphology. J. Cell Sci. 2002;115:4117-4131.

     Not in our library10.1242/jcs.00075

327. 327.

     Gulubova M, Vlaykova T. Prognostic significance of mast cell number and microvascular density for the survival of patients with primary colorectal cancer. J. Gastroenterol. Hepatol. 2009;24:1265-1275.

     Not in our library10.1111/j.1440-1746.2007.05009.x

328. 328.

     Nakae S, et al. Mast cells enhance T cell activation: importance of mast cell costimulatory molecules and secreted TNF. J. Immunol. 2006;176:2238-2248.

     Not in our library10.4049/jimmunol.176.4.2238

329. 329.

     Roche WR. Mast cells and tumour angiogenesis: the tumor-mediated release of an endothelial growth factor from mast cells. Int. J. Cancer. 1985;36:721-728.

     Not in our library10.1002/ijc.2910360617

330. 330.

     Salmaninejad A, et al. Tumor-associated macrophages: role in cancer development and therapeutic implications. Cell Oncol. 2019;42:591-608.

     Not in our library10.1007/s13402-019-00453-z

331. 331.

     Noy R, Pollard JW. Tumor-associated macrophages: from mechanisms to therapy. Immunity. 2014;41:49-61.

     Not in our library10.1016/j.immuni.2014.06.010

332. 332.
     Tumor-Associated Macrophages and Neutrophils in Tumor Microenvironment · 2016

     No notice
333. 333.

     Giese MA, Hind LE, Huttenlocher A. Neutrophil plasticity in the tumor microenvironment. Blood. 2019;133:2159-2167.

     Not in our library10.1182/blood-2018-11-844548

334. 334.

     Hidalgo A, Chilvers ER, Summers C, Koenderman L. The neutrophil life cycle. Trends Immunol. 2019;40:584-597.

     Not in our library10.1016/j.it.2019.04.013

335. 335.

     Fridlender ZG, et al. Polarization of tumor-associated neutrophil phenotype by TGF-beta: “N1” versus “N2” TAN. Cancer Cell. 2009;16:183-194.

     Not in our library10.1016/j.ccr.2009.06.017

336. 336.

     Nicolas-Avila JA, Adrover JM, Hidalgo A. Neutrophils in homeostasis, immunity, and cancer. Immunity. 2017;46:15-28.

     Not in our library10.1016/j.immuni.2016.12.012

337. 337.

     Castanheira FVS, Kubes P. Neutrophils and NETs in modulating acute and chronic inflammation. Blood. 2019;133:2178-2185.

     Not in our library10.1182/blood-2018-11-844530

338. 338.

     Shaul ME, Fridlender ZG. Cancer-related circulating and tumor-associated neutrophils - subtypes, sources and function. FEBS J. 2018;285:4316-4342.

     Not in our library10.1111/febs.14524

339. 339.
     Neutrophils in cancer: prognostic role and therapeutic strategies · 2017

     No notice
340. 340.

     Sastre B, Rodrigo-Munoz JM, Garcia-Sanchez DA, Canas JA. & Del Pozo, V. Eosinophils: old players in a new game. J. Investig. Allergol. Clin. Immunol. 2018;28:289-304.

     Not in our library10.18176/jiaci.0295

341. 341.

     Gatault S, Legrand F, Delbeke M, Loiseau S, Capron M. Involvement of eosinophils in the anti-tumor response. Cancer Immunol. Immunother. 2012;61:1527-1534.

     Not in our library10.1007/s00262-012-1288-3

342. 342.

     Legrand F, et al. Human eosinophils exert TNF-alpha and granzyme A-mediated tumoricidal activity toward colon carcinoma cells. J. Immunol. 2010;185:7443-7451.

     Not in our library10.4049/jimmunol.1000446

343. 343.

     Carretero R, et al. Eosinophils orchestrate cancer rejection by normalizing tumor vessels and enhancing infiltration of CD8(+) T cells. Nat. Immunol. 2015;16:609-617.

     Not in our library10.1038/ni.3159

344. 344.

     Furbert-Harris PM, et al. Activated eosinophils upregulate the metastasis suppressor molecule E-cadherin on prostate tumor cells. Cell Mol. Biol. (Noisy-le.-Gd.). 2003;49:1009-1016.

     Not in our library

345. 345.

     Alaarg A, et al. Applying nanomedicine in maladaptive inflammation and angiogenesis. Adv. Drug Deliv. Rev. 2017;119:143-158.

     Not in our library10.1016/j.addr.2017.05.009

346. 346.

     von Wasielewski R, et al. Tissue eosinophilia correlates strongly with poor prognosis in nodular sclerosing Hodgkin’s disease, allowing for known prognostic factors. Blood. 2000;95:1207-1213.

     Not in our library10.1182/blood.v95.4.1207.004k34_1207_1213

347. 347.

     Reichman H, Karo-Atar D, Munitz A. Emerging roles for eosinophils in the tumor microenvironment. Trends Cancer. 2016;2:664-675.

     Not in our library10.1016/j.trecan.2016.10.002

348. 348.

     Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat. Rev. Immunol. 2009;9:162-174.

     Not in our library10.1038/nri2506

349. 349.

     Kumar V, Patel S, Tcyganov E, Gabrilovich DI. The nature of myeloid-derived suppressor cells in the tumor microenvironment. Trends Immunol. 2016;37:208-220.

     Not in our library10.1016/j.it.2016.01.004

350. 350.

     Wang C, et al. IFN-gamma-mediated downregulation of LXA4 is necessary for the maintenance of nonresolving inflammation and papilloma persistence. Cancer Res. 2013;73:1742-1751.

     Not in our library10.1158/0008-5472.can-12-2801

351. 351.

     Iwasaki A, Medzhitov R. Control of adaptive immunity by the innate immune system. Nat. Immunol. 2015;16:343-353.

     Not in our library10.1038/ni.3123

352. 352.

     Vesely MD, Kershaw MH, Schreiber RD, Smyth MJ. Natural innate and adaptive immunity to cancer. Annu. Rev. Immunol. 2011;29:235-271.

     Not in our library10.1146/annurev-immunol-031210-101324

353. 353.

     Coussens LM, Zitvogel L, Palucka AK. Neutralizing tumor-promoting chronic inflammation: a magic bullet? Science. 2013;339:286-291.

     Not in our library10.1126/science.1232227

354. 354.

     Dong C. Helper T cells and cancer-associated inflammation: a new direction for immunotherapy? J. Interferon Cytokine Res. 2017;37:383-385.

     Not in our library10.1089/jir.2017.0012

355. 355.

     Pedroza-Gonzalez A, et al. Thymic stromal lymphopoietin fosters human breast tumor growth by promoting type 2 inflammation. J. Exp. Med. 2011;208:479-490.

     Not in our library10.1084/jem.20102131

356. 356.
     Profile of Immune Cells in Axillary Lymph Nodes Predicts Disease-Free Survival in Breast Cancer · 2005

     No notice
357. 357.
     Th17 Cell Plasticity and Functions in Cancer Immunity · 2015

     No notice
358. 358.

     Fleming C, Morrissey S, Cai Y, Yan J. gammadelta T cells: unexpected regulators of cancer development and progression. Trends Cancer. 2017;3:561-570.

     Not in our library10.1016/j.trecan.2017.06.003

359. 359.

     Ye J, et al. Tumor-derived gammadelta regulatory T cells suppress innate and adaptive immunity through the induction of immunosenescence. J. Immunol. 2013;190:2403-2414.

     Not in our library10.4049/jimmunol.1202369

360. 360.

     Fleming C, et al. Microbiota-activated CD103(+) DCs stemming from microbiota adaptation specifically drive gammadeltaT17 proliferation and activation. Microbiome. 2017;5:46.

     Not in our library10.1186/s40168-017-0263-9

361. 361.

     Knochelmann HM, et al. When worlds collide: Th17 and Treg cells in cancer and autoimmunity. Cell Mol. Immunol. 2018;15:458-469.

     Not in our library10.1038/s41423-018-0004-4

362. 362.

     Ohue Y, Nishikawa H. Regulatory T (Treg) cells in cancer: can Treg cells be a new therapeutic target? Cancer Sci. 2019;110:2080-2089.

     Not in our library10.1111/cas.14069

363. 363.

     Bromley SK, Mempel TR, Luster AD. Orchestrating the orchestrators: chemokines in control of T cell traffic. Nat. Immunol. 2008;9:970-980.

     Not in our library10.1038/ni.f.213

364. 364.

     van Herk EH, Te Velde AA. Treg subsets in inflammatory bowel disease and colorectal carcinoma: characteristics, role, and therapeutic targets. J. Gastroenterol. Hepatol. 2016;31:1393-1404.

     Not in our library10.1111/jgh.13342

365. 365.

     Alhabbab RY, et al. Regulatory B cells: Development, phenotypes, functions, and role in transplantation. Immunol. Rev. 2019;292:164-179.

     Not in our library10.1111/imr.12800

366. 366.
     B cell regulation of the anti-tumor response and role in carcinogenesis · 2016

     No notice
367. 367.
     The expanding family of regulatory B cells · 2015

     No notice
368. 368.

     Zhang Y, Gallastegui N, Rosenblatt JD. Regulatory B cells in anti-tumor immunity. Int. Immunol. 2015;27:521-530.

     Not in our library10.1093/intimm/dxv034

369. 369.

     Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion. Science. 2011;331:1565-1570.

     Not in our library10.1126/science.1203486

370. 370.

     Schlitzer A, McGovern N, Ginhoux F. Dendritic cells and monocyte-derived cells: Two complementary and integrated functional systems. Semin. Cell Dev. Biol. 2015;41:9-22.

     Not in our library10.1016/j.semcdb.2015.03.011

371. 371.

     Durai V, Murphy KM. Functions of murine dendritic cells. Immunity. 2016;45:719-736.

     Not in our library10.1016/j.immuni.2016.10.010

372. 372.

     Shi M, Chen X, Ye K, Yao Y, Li Y. Application potential of toll-like receptors in cancer immunotherapy: systematic review. Med. 2016;95:e3951.

     Not in our library10.1097/md.0000000000003951

373. 373.

     Chrisikos TT, et al. Molecular regulation of dendritic cell development and function in homeostasis, inflammation, and cancer. Mol. Immunol. 2019;110:24-39.

     Not in our library10.1016/j.molimm.2018.01.014

374. 374.

     Schraml BU, Reis e Sousa C. Defining dendritic cells. Curr. Opin. Immunol. 2015;32:13-20.

     Not in our library10.1016/j.coi.2014.11.001

375. 375.

     Martin JC, et al. Interleukin-22 binding protein (IL-22BP) is constitutively expressed by a subset of conventional dendritic cells and is strongly induced by retinoic acid. Mucosal Immunol. 2014;7:101-113.

     Not in our library10.1038/mi.2013.28

376. 376.

     Van Acker HH, et al. Interleukin-15-cultured dendritic cells enhance anti-tumor gamma delta T cell functions through IL-15 secretion. Front. Immunol. 2018;9:658.

     Not in our library10.3389/fimmu.2018.00658

377. 377.

     Chomarat P, Banchereau J, Davoust J, Palucka AK. IL-6 switches the differentiation of monocytes from dendritic cells to macrophages. Nat. Immunol. 2000;1:510-514.

     Not in our library10.1038/82763

378. 378.

     Chomarat P, Dantin C, Bennett L, Banchereau J, Palucka AK. TNF skews monocyte differentiation from macrophages to dendritic cells. J. Immunol. 2003;171:2262-2269.

     Not in our library10.4049/jimmunol.171.5.2262

379. 379.

     Morvan MG, Lanier LL. NK cells and cancer: you can teach innate cells new tricks. Nat. Rev. Cancer. 2016;16:7-19.

     Not in our library10.1038/nrc.2015.5

380. 380.

     Leon B, Lopez-Bravo M, Ardavin C. Monocyte-derived dendritic cells formed at the infection site control the induction of protective T helper 1 responses against Leishmania. Immunity. 2007;26:519-531.

     Not in our library10.1016/j.immuni.2007.01.017

381. 381.

     Fei M, et al. TNF-alpha from inflammatory dendritic cells (DCs) regulates lung IL-17A/IL-5 levels and neutrophilia versus eosinophilia during persistent fungal infection. Proc. Natl Acad. Sci. USA. 2011;108:5360-5365.

     Not in our library10.1073/pnas.1015476108

382. 382.

     Hammad H, et al. Inflammatory dendritic cells-not basophils-are necessary and sufficient for induction of Th2 immunity to inhaled house dust mite allergen. J. Exp. Med. 2010;207:2097-2111.

     Not in our library10.1084/jem.20101563

383. 383.

     Qian C, Cao X. Dendritic cells in the regulation of immunity and inflammation. Semin. Immunol. 2018;35:3-11.

     Not in our library10.1016/j.smim.2017.12.002

384. 384.

     Wculek SK, et al. Dendritic cells in cancer immunology and immunotherapy. Nat. Rev. Immunol. 2020;20:7-24.

     Not in our library10.1038/s41577-019-0210-z

385. 385.

     Lewis CE, Pollard JW. Distinct role of macrophages in different tumor microenvironments. Cancer Res. 2006;66:605-612.

     Not in our library10.1158/0008-5472.can-05-4005

386. 386.

     Cook J, Hagemann T. Tumour-associated macrophages and cancer. Curr. Opin. Pharm. 2013;13:595-601.

     Not in our library10.1016/j.coph.2013.05.017

387. 387.

     Germano G, et al. Role of macrophage targeting in the antitumor activity of trabectedin. Cancer Cell. 2013;23:249-262.

     Not in our library10.1016/j.ccr.2013.01.008

388. 388.

     Mantovani A, Marchesi F, Malesci A, Laghi L, Allavena P. Tumour-associated macrophages as treatment targets in oncology. Nat. Rev. Clin. Oncol. 2017;14:399-416.

     Not in our library10.1038/nrclinonc.2016.217

389. 389.

     Ino Y, et al. Immune cell infiltration as an indicator of the immune microenvironment of pancreatic cancer. Br. J. Cancer. 2013;108:914-923.

     Not in our library10.1038/bjc.2013.32

390. 390.

     Guiducci C, Vicari AP, Sangaletti S, Trinchieri G, Colombo MP. Redirecting in vivo elicited tumor infiltrating macrophages and dendritic cells towards tumor rejection. Cancer Res. 2005;65:3437-3446.

     Not in our library10.1158/0008-5472.can-04-4262

391. 391.

     Scapini P, et al. Neutrophils produce biologically active macrophage inflammatory protein-3alpha (MIP-3alpha)/CCL20 and MIP-3beta/CCL19. Eur. J. Immunol. 2001;31:1981-1988.

     Not in our library10.1002/1521-4141(200107)31:7<1981::aid-immu1981>3.0.co;2-x

392. 392.

     Eruslanov EB, et al. Tumor-associated neutrophils stimulate T cell responses in early-stage human lung cancer. J. Clin. Invest. 2014;124:5466-5480.

     Not in our library10.1172/jci77053

393. 393.
     Tumor-Associated Neutrophils in Cancer: Going Pro · 2019

     No notice
394. 394.

     Amulic B, Cazalet C, Hayes GL, Metzler KD, Zychlinsky A. Neutrophil function: from mechanisms to disease. Annu. Rev. Immunol. 2012;30:459-489.

     Not in our library10.1146/annurev-immunol-020711-074942

395. 395.

     Chiossone L, Dumas PY, Vienne M, Vivier E. Natural killer cells and other innate lymphoid cells in cancer. Nat. Rev. Immunol. 2018;18:671-688.

     Not in our library10.1038/s41577-018-0061-z

396. 396.

     Artis D, Spits H. The biology of innate lymphoid cells. Nature. 2015;517:293-301.

     Not in our library10.1038/nature14189

397. 397.

     Vacca P, et al. Human natural killer cells and other innate lymphoid cells in cancer: Friends or foes? Immunol. Lett. 2018;201:14-19.

     Not in our library10.1016/j.imlet.2018.11.004

398. 398.

     Smyth MJ, et al. NKG2D function protects the host from tumor initiation. J. Exp. Med. 2005;202:583-588.

     Not in our library10.1084/jem.20050994

399. 399.

     Smyth MJ, et al. Activation of NK cell cytotoxicity. Mol. Immunol. 2005;42:501-510.

     Not in our library10.1016/j.molimm.2004.07.034

400. 400.

     Vivier E, Tomasello E, Baratin M, Walzer T, Ugolini S. Functions of natural killer cells. Nat. Immunol. 2008;9:503-510.

     Not in our library10.1038/ni1582

401. 401.
     The Role of Natural Killer T Cells in Cancer—A Phenotypical and Functional Approach · 2018

     No notice
402. 402.

     Bae EA, Seo H, Kim IK, Jeon I, Kang CY. Roles of NKT cells in cancer immunotherapy. Arch. Pharm. Res. 2019;42:543-548.

     Not in our library10.1007/s12272-019-01139-8

403. 403.

     Rei M, Pennington DJ, Silva-Santos B. The emerging protumor role of gammadelta T lymphocytes: implications for cancer immunotherapy. Cancer Res. 2015;75:798-802.

     Not in our library10.1158/0008-5472.can-14-3228

404. 404.

     Correia DV, Lopes A, Silva-Santos B. Tumor cell recognition by gammadelta T lymphocytes: T-cell receptor vs. NK-cell receptors. Oncoimmunology. 2013;2:e22892.

     Not in our library10.4161/onci.22892

405. 405.

     Silva-Santos B, Serre K, Norell H. gammadelta T cells in cancer. Nat. Rev. Immunol. 2015;15:683-691.

     Not in our library10.1038/nri3904

406. 406.

     Gertner-Dardenne J, et al. Bromohydrin pyrophosphate enhances antibody-dependent cell-mediated cytotoxicity induced by therapeutic antibodies. Blood. 2009;113:4875-4884.

     Not in our library10.1182/blood-2008-08-172296

407. 407.

     Buckley CD, Gilroy DW, Serhan CN. Proresolving lipid mediators and mechanisms in the resolution of acute inflammation. Immunity. 2014;40:315-327.

     Not in our library10.1016/j.immuni.2014.02.009

408. 408.

     Zhang Q, et al. The SP1-12LOX axis promotes chemoresistance and metastasis of ovarian cancer. Mol. Med. 2020;26:39.

     Not in our library10.1186/s10020-020-00174-2

409. 409.

     Hao H, et al. Lipoxin A4 suppresses lipopolysaccharide-induced hela cell proliferation and migration via NF-kappaB pathway. Inflammation. 2015;38:400-408.

     Not in our library10.1007/s10753-014-0044-6

410. 410.

     Lee HJ, Park MK, Lee EJ, Lee CH. Resolvin D1 inhibits TGF-beta1-induced epithelial mesenchymal transition of A549 lung cancer cells via lipoxin A4 receptor/formyl peptide receptor 2 and GPR32. Int. J. Biochem Cell Biol. 2013;45:2801-2807.

     Not in our library10.1016/j.biocel.2013.09.018

411. 411.

     Halder RC, et al. Curcuminoids and omega-3 fatty acids with anti-oxidants potentiate cytotoxicity of natural killer cells against pancreatic ductal adenocarcinoma cells and inhibit interferon gamma production. Front. Physiol. 2015;6:129.

     Not in our library10.3389/fphys.2015.00129

412. 412.

     Gewirtz AT, et al. Lipoxin a4 analogs attenuate induction of intestinal epithelial proinflammatory gene expression and reduce the severity of dextran sodium sulfate-induced colitis. J. Immunol. 2002;168:5260-5267.

     Not in our library10.4049/jimmunol.168.10.5260

413. 413.

     Arita M, et al. Stereochemical assignment, antiinflammatory properties, and receptor for the omega-3 lipid mediator resolvin E1. J. Exp. Med. 2005;201:713-722.

     Not in our library10.1084/jem.20042031

414. 414.

     Marcon R, et al. Maresin 1, a proresolving lipid mediator derived from omega-3 polyunsaturated fatty acids, exerts protective actions in murine models of colitis. J. Immunol. 2013;191:4288-4298.

     Not in our library10.4049/jimmunol.1202743

415. 415.
     The Regulation of Inflammation by Innate and Adaptive Lymphocytes · 2018

     No notice
416. 416.

     Yang Y. Cancer immunotherapy: harnessing the immune system to battle cancer. J. Clin. Invest. 2015;125:3335-3337.

     Not in our library10.1172/jci83871

417. 417.

     Cheng M, Hu S. Lung-resident gammadelta T cells and their roles in lung diseases. Immunology. 2017;151:375-384.

     Not in our library10.1111/imm.12764

418. 418.

     Thommen DS, Schumacher TN. T cell dysfunction in cancer. Cancer Cell. 2018;33:547-562.

     Not in our library10.1016/j.ccell.2018.03.012

419. 419.

     Crespo J, Sun H, Welling TH, Tian Z, Zou W. T cell anergy, exhaustion, senescence, and stemness in the tumor microenvironment. Curr. Opin. Immunol. 2013;25:214-221.

     Not in our library10.1016/j.coi.2012.12.003

420. 420.

     Fruh K, Yang Y. Antigen presentation by MHC class I and its regulation by interferon gamma. Curr. Opin. Immunol. 1999;11:76-81.

     Not in our library10.1016/s0952-7915(99)80014-4

421. 421.

     Hirahara K, et al. Mechanisms underlying helper T-cell plasticity: implications for immune-mediated disease. J. Allergy Clin. Immunol. 2013;131:1276-1287.

     Not in our library10.1016/j.jaci.2013.03.015

422. 422.

     Knutson KL, Disis ML. Tumor antigen-specific T helper cells in cancer immunity and immunotherapy. Cancer Immunol. Immunother. 2005;54:721-728.

     Not in our library10.1007/s00262-004-0653-2

423. 423.

     Topalian SL, et al. Melanoma-specific CD4+ T lymphocytes recognize human melanoma antigens processed and presented by Epstein-Barr virus-transformed B cells. Int. J. Cancer. 1994;58:69-79.

     Not in our library10.1002/ijc.2910580113

424. 424.

     Sarvaria A, Madrigal JA, Saudemont A. B cell regulation in cancer and anti-tumor immunity. Cell Mol. Immunol. 2017;14:662-674.

     Not in our library10.1038/cmi.2017.35

425. 425.

     Dieu-Nosjean MC, Goc J, Giraldo NA, Sautes-Fridman C, Fridman WH. Tertiary lymphoid structures in cancer and beyond. Trends Immunol. 2014;35:571-580.

     Not in our library10.1016/j.it.2014.09.006

426. 426.

     Gottlin EB, et al. The association of intratumoral germinal centers with early-stage non-small cell lung cancer. J. Thorac. Oncol. 2011;6:1687-1690.

     Not in our library10.1097/jto.0b013e3182217bec

427. 427.

     Wang SS, et al. Tumor-infiltrating B cells: their role and application in anti-tumor immunity in lung cancer. Cell Mol. Immunol. 2019;16:6-18.

     Not in our library10.1038/s41423-018-0027-x

428. 428.

     Wouters MCA, Nelson BH. Prognostic significance of tumor-infiltrating B cells and plasma cells in human cancer. Clin. Cancer Res. 2018;24:6125-6135.

     Not in our library10.1158/1078-0432.ccr-18-1481

429. 429.

     Kurebayashi Y, et al. Comprehensive immune profiling of lung adenocarcinomas reveals four immunosubtypes with plasma cell subtype a negative indicator. Cancer Immunol. Res. 2016;4:234-247.

     Not in our library10.1158/2326-6066.cir-15-0214

430. 430.
     Immune and Inflammatory Cell Composition of Human Lung Cancer Stroma. · 2015

     Not checked
431. 431.

     Barker HE, Paget JT, Khan AA, Harrington KJ. The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence. Nat. Rev. Cancer. 2015;15:409-425.

     Not in our library10.1038/nrc3958

432. 432.

     Krysko DV, et al. Immunogenic cell death and DAMPs in cancer therapy. Nat. Rev. Cancer. 2012;12:860-875.

     Not in our library10.1038/nrc3380

433. 433.

     Kroemer G, Galluzzi L, Kepp O, Zitvogel L. Immunogenic cell death in cancer therapy. Annu. Rev. Immunol. 2013;31:51-72.

     Not in our library10.1146/annurev-immunol-032712-100008

434. 434.

     Hirata E, Sahai E. Tumor microenvironment and differential responses to therapy. Cold Spring Harb. Perspect. Med. 2017;7:a026781.

     Not in our library10.1101/cshperspect.a026781

435. 435.

     Li H, Zhou L, Zhou J, Li Q, Ji Q. Underlying mechanisms and drug intervention strategies for the tumour microenvironment. J. Exp. Clin. Cancer Res. 2021;40:97.

     Not in our library10.1186/s13046-021-01893-y

436. 436.

     Rivera G, Wakelee HA. Resistance to therapy. Cancer Treat. Res. 2016;170:183-202.

     Not in our library10.1007/978-3-319-40389-2_9

437. 437.

     Karagiannis GS, Condeelis JS, Oktay MH. Chemotherapy-induced metastasis: molecular mechanisms, clinical manifestations, therapeutic interventions. Cancer Res. 2019;79:4567-4576.

     Not in our library10.1158/0008-5472.can-19-1147

438. 438.

     Yao X, Panichpisal K, Kurtzman N, Nugent K. Cisplatin nephrotoxicity: a review. Am. J. Med. Sci. 2007;334:115-124.

     Not in our library10.1097/maj.0b013e31812dfe1e

439. 439.

     Grabosch S, et al. Cisplatin-induced immune modulation in ovarian cancer mouse models with distinct inflammation profiles. Oncogene. 2019;38:2380-2393.

     Not in our library10.1038/s41388-018-0581-9

440. 440.

     Kashiwagi E, et al. Prostaglandin receptors induce urothelial tumourigenesis as well as bladder cancer progression and cisplatin resistance presumably via modulating PTEN expression. Br. J. Cancer. 2018;118:213-223.

     Not in our library10.1038/bjc.2017.393

441. 441.

     Xu HB, Shen FM, Lv QZ. Celecoxib enhanced the cytotoxic effect of cisplatin in chemo-resistant gastric cancer xenograft mouse models through a cyclooxygenase-2-dependent manner. Eur. J. Pharm. 2016;776:1-8.

     Not in our library10.1016/j.ejphar.2016.02.035

442. 442.

     Robledo-Cadena, D. X. et al. Non-steroidal anti-inflammatory drugs increase cisplatin, paclitaxel, and doxorubicin efficacy against human cervix cancer cells. Pharmaceuticals13, 463 (2020).

     Not in our library10.3390/ph13120463

443. 443.

     Rowinsky EK. The development and clinical utility of the taxane class of antimicrotubule chemotherapy agents. Annu. Rev. Med. 1997;48:353-374.

     Not in our library10.1146/annurev.med.48.1.353

444. 444.

     Volk LD, et al. Nab-paclitaxel efficacy in the orthotopic model of human breast cancer is significantly enhanced by concurrent anti-vascular endothelial growth factor A therapy. Neoplasia. 2008;10:613-623.

     Not in our library10.1593/neo.08302

445. 445.

     Pusztai L, et al. Changes in plasma levels of inflammatory cytokines in response to paclitaxel chemotherapy. Cytokine. 2004;25:94-102.

     Not in our library10.1016/j.cyto.2003.10.004

446. 446.

     Lee LF, Haskill JS, Mukaida N, Matsushima K, Ting JP. Identification of tumor-specific paclitaxel (Taxol)-responsive regulatory elements in the interleukin-8 promoter. Mol. Cell Biol. 1997;17:5097-5105.

     Not in our library10.1128/mcb.17.9.5097

447. 447.

     White CM, Martin BK, Lee LF, Haskill JS, Ting JP. Effects of paclitaxel on cytokine synthesis by unprimed human monocytes, T lymphocytes, and breast cancer cells. Cancer Immunol. Immunother. 1998;46:104-112.

     Not in our library10.1007/s002620050468

448. 448.

     Jaffray DA. Image-guided radiotherapy: from current concept to future perspectives. Nat. Rev. Clin. Oncol. 2012;9:688-699.

     Not in our library10.1038/nrclinonc.2012.194

449. 449.

     Schaue D, Kachikwu EL, McBride WH. Cytokines in radiobiological responses: a review. Radiat. Res. 2012;178:505-523.

     Not in our library10.1667/rr3031.1

450. 450.

     Yang X, et al. Targeting the tumor microenvironment with interferon-beta bridges innate and adaptive immune responses. Cancer Cell. 2014;25:37-48.

     Not in our library10.1016/j.ccr.2013.12.004

451. 451.

     McLaughlin M, et al. Inflammatory microenvironment remodelling by tumour cells after radiotherapy. Nat. Rev. Cancer. 2020;20:203-217.

     Not in our library10.1038/s41568-020-0246-1

452. 452.
     The role of IL-6 in the radiation response of prostate cancer · 2013

     No notice
453. 453.
     IL-6 expression predicts treatment response and outcome in squamous cell carcinoma of the esophagus · 2013

     No notice
454. 454.

     Culig Z, Puhr M. Interleukin-6: a multifunctional targetable cytokine in human prostate cancer. Mol. Cell Endocrinol. 2012;360:52-58.

     Not in our library10.1016/j.mce.2011.05.033

455. 455.

     Hou J, Karin M, Sun B. Targeting cancer-promoting inflammation - have anti-inflammatory therapies come of age? Nat. Rev. Clin. Oncol. 2021;18:261-279.

     Not in our library10.1038/s41571-020-00459-9

456. 456.

     Braaten TJ, et al. Immune checkpoint inhibitor-induced inflammatory arthritis persists after immunotherapy cessation. Ann. Rheum. Dis. 2020;79:332-338.

     Not in our library10.1136/annrheumdis-2019-216109

457. 457.

     Zitvogel L, Galluzzi L, Kepp O, Smyth MJ, Kroemer G. Type I interferons in anticancer immunity. Nat. Rev. Immunol. 2015;15:405-414.

     Not in our library10.1038/nri3845

458. 458.

     Spiotto M, Fu YX, Weichselbaum RR. The intersection of radiotherapy and immunotherapy: mechanisms and clinical implications. Sci. Immunol. 2016;1:eaag1266.

     Not in our library10.1126/sciimmunol.aag1266

459. 459.

     Kuraishy A, Karin M, Grivennikov SI. Tumor promotion via injury- and death-induced inflammation. Immunity. 2011;35:467-477.

     Not in our library10.1016/j.immuni.2011.09.006

460. 460.

     Chen J, et al. IL-17 inhibits CXCL9/10-mediated recruitment of CD8(+) cytotoxic T cells and regulatory T cells to colorectal tumors. J. Immunother. Cancer. 2019;7:324.

     Not in our library10.1186/s40425-019-0757-z

461. 461.
     Intestinal microbiota-derived short-chain fatty acids regulation of immune cell IL-22 production and gut immunity · 2020

     No notice
462. 462.

     Lauko A, Bayik D, Lathia JD. IL-11 drives postsurgical hepatocellular carcinoma recurrence. EBioMedicine. 2019;47:18-19.

     Not in our library10.1016/j.ebiom.2019.08.007

463. 463.

     Schneider C, Pozzi A. Cyclooxygenases and lipoxygenases in cancer. Cancer Metastasis Rev. 2011;30:277-294.

     Not in our library10.1007/s10555-011-9310-3

464. 464.

     Kozlowska R, Bozek A, Jarzab J. Association between cancer and allergies. Allergy Asthma Clin. Immunol. 2016;12:39.

     Not in our library10.1186/s13223-016-0147-8

465. 465.

     Turner MC, Chen Y, Krewski D, Ghadirian P. An overview of the association between allergy and cancer. Int. J. Cancer. 2006;118:3124-3132.

     Not in our library10.1002/ijc.21752

466. 466.

     Chen DS, Mellman I. Elements of cancer immunity and the cancer-immune set point. Nature. 2017;541:321-330.

     Not in our library10.1038/nature21349

467. 467.

     Gajewski TF. The next hurdle in cancer immunotherapy: overcoming the non-T-Cell-inflamed tumor microenvironment. Semin. Oncol. 2015;42:663-671.

     Not in our library10.1053/j.seminoncol.2015.05.011

468. 468.

     Salinas CA, et al. Use of aspirin and other nonsteroidal antiinflammatory medications in relation to prostate cancer risk. Am. J. Epidemiol. 2010;172:578-590.

     Not in our library10.1093/aje/kwq175

469. 469.

     Algra AM, Rothwell PM. Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials. Lancet Oncol. 2012;13:518-527.

     Not in our library10.1016/s1470-2045(12)70112-2

470. 470.

     Rothwell PM, et al. Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. Lancet. 2012;379:1602-1612.

     Not in our library10.1016/s0140-6736(11)61720-0

471. 471.

     Yona, D. & Arber, N. Coxibs and cancer prevention. J. Cardiovasc Pharm. 47(Suppl 1.), S76–S81 (2006).

     Not in our library10.1097/00005344-200605001-00014

472. 472.

     Boudreau DM, Yu O, Johnson J. Statin use and cancer risk: a comprehensive review. Expert Opin. Drug Saf. 2010;9:603-621.

     Not in our library10.1517/14740331003662620

473. 473.

     Dulak J, Jozkowicz A. Anti-angiogenic and anti-inflammatory effects of statins: relevance to anti-cancer therapy. Curr. Cancer Drug Targets. 2005;5:579-594.

     Not in our library10.2174/156800905774932824

474. 474.

     Dinarello CA. Anti-inflammatory agents: present and future. Cell. 2010;140:935-950.

     Not in our library10.1016/j.cell.2010.02.043

475. 475.

     Wang H, Li M, Rinehart JJ, Zhang R. Pretreatment with dexamethasone increases antitumor activity of carboplatin and gemcitabine in mice bearing human cancer xenografts: in vivo activity, pharmacokinetics, and clinical implications for cancer chemotherapy. Clin. Cancer Res. 2004;10:1633-1644.

     Not in our library10.1158/1078-0432.ccr-0829-3

476. 476.

     Chari A, et al. Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma. Blood. 2019;134:421-431.

     Not in our library10.1182/blood.2019000722

477. 477.

     Dimopoulos M, et al. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study. Lancet. 2020;396:186-197.

     Not in our library10.1016/s0140-6736(20)30734-0

478. 478.
     12/15-Lipoxygenase Is Required for the Early Onset of High Fat Diet-Induced Adipose Tissue Inflammation and Insulin Resistance in Mice · 2009

     No notice
479. 479.

     Song M, et al. Effect of supplementation with marine omega-3 fatty acid on risk of colorectal adenomas and serrated polyps in the US general population: a prespecified ancillary study of a randomized clinical trial. JAMA Oncol. 2019;6:108-115.

     Not in our library10.1001/jamaoncol.2019.4587

480. 480.

     Jantan I, et al. Dietary polyphenols suppress chronic inflammation by modulation of multiple inflammation-associated cell signaling pathways. J. Nutr. Biochem. 2021;93:108634.

     Not in our library10.1016/j.jnutbio.2021.108634

481. 481.

     Guo W, Kong E, Meydani M. Dietary polyphenols, inflammation, and cancer. Nutr. Cancer. 2009;61:807-810.

     Not in our library10.1080/01635580903285098

482. 482.

     Banik U, Parasuraman S, Adhikary AK, Othman NH. Curcumin: the spicy modulator of breast carcinogenesis. J. Exp. Clin. Cancer Res. 2017;36:98.

     Not in our library10.1186/s13046-017-0566-5

483. 483.

     Arshad L, Haque MA, Abbas Bukhari SN, Jantan I. An overview of structure-activity relationship studies of curcumin analogs as antioxidant and anti-inflammatory agents. Future Med. Chem. 2017;9:605-626.

     Not in our library10.4155/fmc-2016-0223

484. 484.

     Rauf A, et al. Resveratrol as an anti-cancer agent: a review. Crit. Rev. Food Sci. Nutr. 2018;58:1428-1447.

     Not in our library10.1080/10408398.2016.1263597

485. 485.

     Jiang Z, et al. Resveratrol and cancer treatment: updates. Ann. N. Y Acad. Sci. 2017;1403:59-69.

     Not in our library10.1111/nyas.13466

486. 486.

     Jang GY, et al. Interactions between tumor-derived proteins and Toll-like receptors. Exp. Mol. Med. 2020;52:1926-1935.

     Not in our library10.1038/s12276-020-00540-4

487. 487.

     Johnson DE, O’Keefe RA, Grandis JR. Targeting the IL-6/JAK/STAT3 signalling axis in cancer. Nat. Rev. Clin. Oncol. 2018;15:234-248.

     Not in our library10.1038/nrclinonc.2018.8

488. 488.

     Yoon S, et al. NF-kappaB and STAT3 cooperatively induce IL6 in starved cancer cells. Oncogene. 2012;31:3467-3481.

     Not in our library10.1038/onc.2011.517

489. 489.

     Wolf J, Rose-John S, Garbers C. Interleukin-6 and its receptors: a highly regulated and dynamic system. Cytokine. 2014;70:11-20.

     Not in our library10.1016/j.cyto.2014.05.024

490. 490.

     Patidar A, et al. DAMP-TLR-cytokine axis dictates the fate of tumor. Cytokine. 2018;104:114-123.

     Not in our library10.1016/j.cyto.2017.10.004

491. 491.

     Fang H, et al. TLR4 is essential for dendritic cell activation and anti-tumor T-cell response enhancement by DAMPs released from chemically stressed cancer cells. Cell Mol. Immunol. 2014;11:150-159.

     Not in our library10.1038/cmi.2013.59

492. 492.

     Park HD, et al. Pancreatic adenocarcinoma upregulated factor promotes metastasis by regulating TLR/CXCR4 activation. Oncogene. 2011;30:201-211.

     Not in our library10.1038/onc.2010.401

493. 493.

     Kelly MG, et al. TLR-4 signaling promotes tumor growth and paclitaxel chemoresistance in ovarian cancer. Cancer Res. 2006;66:3859-3868.

     Not in our library10.1158/0008-5472.can-05-3948

494. 494.

     Finke J, et al. MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy. Int. Immunopharmacol. 2011;11:856-861.

     Not in our library10.1016/j.intimp.2011.01.030

495. 495.

     Mantovani A, Sozzani S, Locati M, Allavena P, Sica A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol. 2002;23:549-555.

     Not in our library10.1016/s1471-4906(02)02302-5

496. 496.

     Nishikawa H, Sakaguchi S. Regulatory T cells in tumor immunity. Int. J. Cancer. 2010;127:759-767.

     Not in our library10.1002/ijc.25429

497. 497.

     Medzhitov R, Janeway CA. Innate immune induction of the adaptive immune response. Cold Spring Harb. Symp. Quant. Biol. 1999;64:429-435.

     Not in our library10.1101/sqb.1999.64.429

498. 498.

     Vivier E, et al. Innate lymphoid cells: 10 years on. Cell. 2018;174:1054-1066.

     Not in our library10.1016/j.cell.2018.07.017

499. 499.

     Siebenhaar F, Redegeld FA, Bischoff SC, Gibbs BF, Maurer M. Mast cells as drivers of disease and therapeutic targets. Trends Immunol. 2018;39:151-162.

     Not in our library10.1016/j.it.2017.10.005

500. 500.

     Nonomura N, et al. Decreased number of mast cells infiltrating into needle biopsy specimens leads to a better prognosis of prostate cancer. Br. J. Cancer. 2007;97:952-956.

     Not in our library10.1038/sj.bjc.6603962

501. 501.

     Nielsen HJ, et al. Independent prognostic value of eosinophil and mast cell infiltration in colorectal cancer tissue. J. Pathol. 1999;189:487-495.

     Not in our library10.1002/(sici)1096-9896(199912)189:4<487::aid-path484>3.0.co;2-i

502. 502.

     Welsh TJ, et al. Macrophage and mast-cell invasion of tumor cell islets confers a marked survival advantage in non-small-cell lung cancer. J. Clin. Oncol. 2005;23:8959-8967.

     Not in our library10.1200/jco.2005.01.4910

503. 503.

     Molin D, et al. Mast cell infiltration correlates with poor prognosis in Hodgkin’s lymphoma. Br. J. Haematol. 2002;119:122-124.

     Not in our library10.1046/j.1365-2141.2002.03768.x

504. 504.

     Maurer M, et al. The c-kit ligand, stem cell factor, can enhance innate immunity through effects on mast cells. J. Exp. Med. 1998;188:2343-2348.

     Not in our library10.1084/jem.188.12.2343

505. 505.

     Godot V, et al. H4 histamine receptor mediates optimal migration of mast cell precursors to CXCL12. J. Allergy Clin. Immunol. 2007;120:827-834.

     Not in our library10.1016/j.jaci.2007.05.046

506. 506.

     Dahlin JS, Hallgren J. Mast cell progenitors: origin, development and migration to tissues. Mol. Immunol. 2015;63:9-17.

     Not in our library10.1016/j.molimm.2014.01.018

507. 507.

     Reber LL, Frossard N. Targeting mast cells in inflammatory diseases. Pharm. Ther. 2014;142:416-435.

     Not in our library10.1016/j.pharmthera.2014.01.004

508. 508.

     Kalesnikoff J, Galli SJ. New developments in mast cell biology. Nat. Immunol. 2008;9:1215-1223.

     Not in our library10.1038/ni.f.216

509. 509.

     Zhang T, Finn DF, Barlow JW, Walsh JJ. Mast cell stabilisers. Eur. J. Pharm. 2016;778:158-168.

     Not in our library10.1016/j.ejphar.2015.05.071

510. 510.

     Lv YP, et al. Degranulation of mast cells induced by gastric cancer-derived adrenomedullin prompts gastric cancer progression. Cell Death Dis. 2018;9:1034.

     Not in our library10.1038/s41419-018-1100-1

511. 511.

     Dvorak AM. Ultrastructural studies of human basophils and mast cells. J. Histochem. Cytochem. 2005;53:1043-1070.

     Not in our library10.1369/jhc.5r6647.2005

512. 512.

     Kim MS, Radinger M, Gilfillan AM. The multiple roles of phosphoinositide 3-kinase in mast cell biology. Trends Immunol. 2008;29:493-501.

     Not in our library10.1016/j.it.2008.07.004

513. 513.

     Ching TT, Hsu AL, Johnson AJ, Chen CS. Phosphoinositide 3-kinase facilitates antigen-stimulated Ca(2+) influx in RBL-2H3 mast cells via a phosphatidylinositol 3,4,5-trisphosphate-sensitive Ca(2+) entry mechanism. J. Biol. Chem. 2001;276:14814-14820.

     Not in our library10.1074/jbc.m009851200

514. 514.

     Soucek L, et al. Mast cells are required for angiogenesis and macroscopic expansion of Myc-induced pancreatic islet tumors. Nat. Med. 2007;13:1211-1218.

     Not in our library10.1038/nm1649

515. 515.

     Kennedy Norton S, et al. IL-10 suppresses mast cell IgE receptor expression and signaling in vitro and in vivo. J. Immunol. 2008;180:2848-2854.

     Not in our library10.4049/jimmunol.180.5.2848

516. 516.

     Jones TG, Finkelman FD, Austen KF, Gurish MF. T regulatory cells control antigen-induced recruitment of mast cell progenitors to the lungs of C57BL/6 mice. J. Immunol. 2010;185:1804-1811.

     Not in our library10.4049/jimmunol.1001146

517. 517.

     Soucek L, et al. Modeling pharmacological inhibition of mast cell degranulation as a therapy for insulinoma. Neoplasia. 2011;13:1093-1100.

     Not in our library10.1593/neo.11980

518. 518.

     Ma Y, Hwang RF, Logsdon CD, Ullrich SE. Dynamic mast cell-stromal cell interactions promote growth of pancreatic cancer. Cancer Res. 2013;73:3927-3937.

     Not in our library10.1158/0008-5472.can-12-4479

519. 519.

     Melillo RM, et al. Mast cells have a protumorigenic role in human thyroid cancer. Oncogene. 2010;29:6203-6215.

     Not in our library10.1038/onc.2010.348

520. 520.

     Pittoni P, et al. Mast cell targeting hampers prostate adenocarcinoma development but promotes the occurrence of highly malignant neuroendocrine cancers. Cancer Res. 2011;71:5987-5997.

     Not in our library10.1158/0008-5472.can-11-1637

521. 521.

     Johnson C, et al. Inhibition of mast cell-derived histamine decreases human cholangiocarcinoma growth and differentiation via c-Kit/stem cell factor-dependent signaling. Am. J. Pathol. 2016;186:123-133.

     Not in our library10.1016/j.ajpath.2015.09.016

522. 522.

     Rao Q, et al. Recruited mast cells in the tumor microenvironment enhance bladder cancer metastasis via modulation of ERbeta/CCL2/CCR2 EMT/MMP9 signals. Oncotarget. 2016;7:7842-7855.

     Not in our library10.18632/oncotarget.5467

523. 523.
     Mast Cell Targeted Chimeric Toxin Can Be Developed as an Adjunctive Therapy in Colon Cancer Treatment · 2016

     Not checked
524. 524.

     Yano H, et al. Mast cell infiltration around gastric cancer cells correlates with tumor angiogenesis and metastasis. Gastric Cancer. 1999;2:26-32.

     Not in our library10.1007/s101200050017

525. 525.

     Trabanelli S, et al. PGE2-induced IDO1 inhibits the capacity of fully mature DCs to elicit an in vitro antileukemic immune response. J. Immunol. Res. 2015;2015:253191.

     Not in our library10.1155/2015/253191

526. 526.

     Gardner A, Ruffell B. Dendritic cells and cancer immunity. Trends Immunol. 2016;37:855-865.

     Not in our library10.1016/j.it.2016.09.006

527. 527.

     Zong J, Keskinov AA, Shurin GV, Shurin MR. Tumor-derived factors modulating dendritic cell function. Cancer Immunol. Immunother. 2016;65:821-833.

     Not in our library10.1007/s00262-016-1820-y

528. 528.

     Toi M, Matsumoto T, Bando H. Vascular endothelial growth factor: its prognostic, predictive, and therapeutic implications. Lancet Oncol. 2001;2:667-673.

     Not in our library10.1016/s1470-2045(01)00556-3

529. 529.

     Gabrilovich DI, et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat. Med. 1996;2:1096-1103.

     Not in our library10.1038/nm1096-1096

530. 530.

     Fricke I, et al. Vascular endothelial growth factor-trap overcomes defects in dendritic cell differentiation but does not improve antigen-specific immune responses. Clin. Cancer Res. 2007;13:4840-4848.

     Not in our library10.1158/1078-0432.ccr-07-0409

531. 531.

     Ratta M, et al. Dendritic cells are functionally defective in multiple myeloma: the role of interleukin-6. Blood. 2002;100:230-237.

     Not in our library10.1182/blood.v100.1.230

532. 532.

     Oosterhoff D, et al. Tumor-mediated inhibition of human dendritic cell differentiation and function is consistently counteracted by combined p38 MAPK and STAT3 inhibition. Oncoimmunology. 2012;1:649-658.

     Not in our library10.4161/onci.20365

533. 533.

     Sombroek CC, et al. Prostanoids play a major role in the primary tumor-induced inhibition of dendritic cell differentiation. J. Immunol. 2002;168:4333-4343.

     Not in our library10.4049/jimmunol.168.9.4333

534. 534.

     Bazzoni G, Rasia M. Effects of an amphipathic drug on the rheological properties of the cell membrane. Blood Cells Mol. Dis. 1998;24:552-559.

     Not in our library10.1006/bcmd.1998.0219

535. 535.

     Lo AS, et al. Modulation of dendritic cell differentiation by colony-stimulating factor-1: role of phosphatidylinositol 3’-kinase and delayed caspase activation. J. Leukoc. Biol. 2007;82:1446-1454.

     Not in our library10.1189/jlb.0307142

536. 536.

     Dranoff G, et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc. Natl Acad. Sci. USA. 1993;90:3539-3543.

     Not in our library10.1073/pnas.90.8.3539

537. 537.

     Mach N, et al. Differences in dendritic cells stimulated in vivo by tumors engineered to secrete granulocyte-macrophage colony-stimulating factor or Flt3-ligand. Cancer Res. 2000;60:3239-3246.

     Not in our library

538. 538.

     Sallusto F, Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J. Exp. Med. 1994;179:1109-1118.

     Not in our library10.1084/jem.179.4.1109

539. 539.

     Morales JK, Kmieciak M, Knutson KL, Bear HD, Manjili MH. GM-CSF is one of the main breast tumor-derived soluble factors involved in the differentiation of CD11b-Gr1- bone marrow progenitor cells into myeloid-derived suppressor cells. Breast Cancer Res. Treat. 2010;123:39-49.

     Not in our library10.1007/s10549-009-0622-8

540. 540.

     Parmiani G, et al. Opposite immune functions of GM-CSF administered as vaccine adjuvant in cancer patients. Ann. Oncol. 2007;18:226-232.

     Not in our library10.1093/annonc/mdl158

541. 541.

     Lyman SD, et al. Molecular cloning of a ligand for the flt3/flk-2 tyrosine kinase receptor: a proliferative factor for primitive hematopoietic cells. Cell. 1993;75:1157-1167.

     Not in our library10.1016/0092-8674(93)90325-k

542. 542.

     Naik SH, et al. Cutting edge: generation of splenic CD8+ and CD8- dendritic cell equivalents in Fms-like tyrosine kinase 3 ligand bone marrow cultures. J. Immunol. 2005;174:6592-6597.

     Not in our library10.4049/jimmunol.174.11.6592

543. 543.

     Karsunky H, Merad M, Cozzio A, Weissman IL, Manz MG. Flt3 ligand regulates dendritic cell development from Flt3+ lymphoid and myeloid-committed progenitors to Flt3+ dendritic cells in vivo. J. Exp. Med. 2003;198:305-313.

     Not in our library10.1084/jem.20030323

544. 544.

     McKenna HJ, et al. Mice lacking flt3 ligand have deficient hematopoiesis affecting hematopoietic progenitor cells, dendritic cells, and natural killer cells. Blood. 2000;95:3489-3497.

     Not in our library10.1182/blood.v95.11.3489

545. 545.

     Ginhoux F, et al. The origin and development of nonlymphoid tissue CD103+ DCs. J. Exp. Med. 2009;206:3115-3130.

     Not in our library10.1084/jem.20091756

546. 546.
     Promising Targets for Cancer Immunotherapy: TLRs, RLRs, and STING-Mediated Innate Immune Pathways · 2017

     No notice
547. 547.

     Galluzzi L, et al. Trial Watch: experimental Toll-like receptor agonists for cancer therapy. Oncoimmunology. 2012;1:699-716.

     Not in our library10.4161/onci.20696

548. 548.

     Koizumi S, et al. Extracts of Larix Leptolepis effectively augments the generation of tumor antigen-specific cytotoxic T lymphocytes via activation of dendritic cells in TLR-2 and TLR-4-dependent manner. Cell Immunol. 2012;276:153-161.

     Not in our library10.1016/j.cellimm.2012.05.002

549. 549.

     Jeung HC, et al. Phase III trial of adjuvant 5-fluorouracil and adriamycin versus 5-fluorouracil, adriamycin, and polyadenylic-polyuridylic acid (poly A:U) for locally advanced gastric cancer after curative surgery: final results of 15-year follow-up. Ann. Oncol. 2008;19:520-526.

     Not in our library10.1093/annonc/mdm536

550. 550.

     Dewan MZ, et al. Synergy of topical toll-like receptor 7 agonist with radiation and low-dose cyclophosphamide in a mouse model of cutaneous breast cancer. Clin. Cancer Res. 2012;18:6668-6678.

     Not in our library10.1158/1078-0432.ccr-12-0984

551. 551.

     Tel J, et al. Targeting uptake receptors on human plasmacytoid dendritic cells triggers antigen cross-presentation and robust type I IFN secretion. J. Immunol. 2013;191:5005-5012.

     Not in our library10.4049/jimmunol.1300787

552. 552.

     Scholch S, Rauber C, Weitz J, Koch M, Huber PE. TLR activation and ionizing radiation induce strong immune responses against multiple tumor entities. Oncoimmunology. 2015;4:e1042201.

     Not in our library10.1080/2162402x.2015.1042201

553. 553.

     Van De Voort TJ, Felder MA, Yang RK, Sondel PM, Rakhmilevich AL. Intratumoral delivery of low doses of anti-CD40 mAb combined with monophosphoryl lipid a induces local and systemic antitumor effects in immunocompetent and T cell-deficient mice. J. Immunother. 2013;36:29-40.

     Not in our library10.1097/cji.0b013e3182780f61

554. 554.

     Kubler K, et al. Immunogenic cell death of human ovarian cancer cells induced by cytosolic poly(I:C) leads to myeloid cell maturation and activates NK cells. Eur. J. Immunol. 2011;41:3028-3039.

     Not in our library10.1002/eji.201141555

555. 555.

     Petrasek J, et al. STING-IRF3 pathway links endoplasmic reticulum stress with hepatocyte apoptosis in early alcoholic liver disease. Proc. Natl Acad. Sci. USA. 2013;110:16544-16549.

     Not in our library10.1073/pnas.1308331110

556. 556.

     Sze A, et al. Host restriction factor SAMHD1 limits human T cell leukemia virus type 1 infection of monocytes via STING-mediated apoptosis. Cell Host Microbe. 2013;14:422-434.

     Not in our library10.1016/j.chom.2013.09.009

557. 557.

     Tang CH, et al. Agonist-mediated activation of STING induces apoptosis in malignant B cells. Cancer Res. 2016;76:2137-2152.

     Not in our library10.1158/0008-5472.can-15-1885

558. 558.

     Ablasser, A. & Chen, Z. J. cGAS in action: expanding roles in immunity and inflammation. Science363, eaat8657 (2019).

     Not in our library10.1126/science.aat8657

559. 559.
     Abscopal effect of radiotherapy combined with immune checkpoint inhibitors · 2018

     No notice
560. 560.

     Galluzzi L, Buque A, Kepp O, Zitvogel L, Kroemer G. Immunogenic cell death in cancer and infectious disease. Nat. Rev. Immunol. 2017;17:97-111.

     Not in our library10.1038/nri.2016.107

561. 561.

     Rodriguez-Ruiz ME, et al. Abscopal effects of radiotherapy are enhanced by combined immunostimulatory mAbs and are dependent on CD8 T cells and crosspriming. Cancer Res. 2016;76:5994-6005.

     Not in our library10.1158/0008-5472.can-16-0549

562. 562.

     Deng L, et al. STING-dependent cytosolic DNA sensing promotes radiation-induced type I interferon-dependent antitumor immunity in immunogenic tumors. Immunity. 2014;41:843-852.

     Not in our library10.1016/j.immuni.2014.10.019

563. 563.

     Hou Y, et al. Non-canonical NF-kappaB antagonizes STING sensor-mediated DNA sensing in radiotherapy. Immunity. 2018;49:490-503 e494.

     Not in our library10.1016/j.immuni.2018.07.008

564. 564.

     Gelao L, et al. Dendritic cell-based vaccines: clinical applications in breast cancer. Immunotherapy. 2014;6:349-360.

     Not in our library10.2217/imt.13.169

565. 565.

     Sabado RL, Meseck M, Bhardwaj N. Dendritic cell vaccines. Methods Mol. Biol. 2016;1403:763-777.

     Not in our library10.1007/978-1-4939-3387-7_44

566. 566.

     Cheever MA, Higano CS. PROVENGE (Sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine. Clin. Cancer Res. 2011;17:3520-3526.

     Not in our library10.1158/1078-0432.ccr-10-3126

567. 567.

     Dhodapkar MV, et al. Rapid generation of broad T-cell immunity in humans after a single injection of mature dendritic cells. J. Clin. Invest. 1999;104:173-180.

     Not in our library10.1172/jci6909

568. 568.
     Effective cancer immunotherapy by natural mouse conventional type-1 dendritic cells bearing dead tumor antigen · 2019

     No notice
569. 569.
     Targeting tumor-associated macrophages to synergize tumor immunotherapy · 2021

     No notice
570. 570.

     Haydar D, et al. Azithromycin POlarizes Macrophages to an M2 phenotype via inhibition of the STAT1 and NF-kappaB signaling pathways. J. Immunol. 2019;203:1021-1030.

     Not in our library10.4049/jimmunol.1801228

571. 571.

     Svensson S, et al. CCL2 and CCL5 are novel therapeutic targets for estrogen-dependent breast cancer. Clin. Cancer Res. 2015;21:3794-3805.

     Not in our library10.1158/1078-0432.ccr-15-0204

572. 572.

     Li X, et al. Targeting of tumour-infiltrating macrophages via CCL2/CCR2 signalling as a therapeutic strategy against hepatocellular carcinoma. Gut. 2017;66:157-167.

     Not in our library10.1136/gutjnl-2015-310514

573. 573.

     Nywening TM, et al. Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial. Lancet Oncol. 2016;17:651-662.

     Not in our library10.1016/s1470-2045(16)00078-4

574. 574.

     Zollo M, et al. Targeting monocyte chemotactic protein-1 synthesis with bindarit induces tumor regression in prostate and breast cancer animal models. Clin. Exp. Metastasis. 2012;29:585-601.

     Not in our library10.1007/s10585-012-9473-5

575. 575.

     Gazzaniga S, et al. Targeting tumor-associated macrophages and inhibition of MCP-1 reduce angiogenesis and tumor growth in a human melanoma xenograft. J. Invest. Dermatol. 2007;127:2031-2041.

     Not in our library10.1038/sj.jid.5700827

576. 576.
     The Inflammatory Chemokine CCL5 and Cancer Progression · 2014

     No notice
577. 577.

     Wang HC, et al. Tumor-associated macrophages promote epigenetic silencing of gelsolin through DNA methyltransferase 1 in gastric cancer cells. Cancer Immunol. Res. 2017;5:885-897.

     Not in our library10.1158/2326-6066.cir-16-0295

578. 578.
     Inhibition of the CCL5/CCR5 Axis against the Progression of Gastric Cancer · 2018

     No notice
579. 579.
     CCL5 promotes breast cancer recurrence through macrophage recruitment in residual tumors · 2019

     No notice
580. 580.

     Suarez-Carmona M, et al. CCR5 status and metastatic progression in colorectal cancer. Oncoimmunology. 2019;8:e1626193.

     Not in our library10.1080/2162402x.2019.1626193

581. 581.

     Frankenberger C, et al. Metastasis suppressors regulate the tumor microenvironment by blocking recruitment of prometastatic tumor-associated macrophages. Cancer Res. 2015;75:4063-4073.

     Not in our library10.1158/0008-5472.can-14-3394

582. 582.

     Nie Y, et al. Breast phyllodes tumors recruit and repolarize rumor-associated macrophages via secreting CCL5 to promote malignant progression, which can be inhibited by CCR5 inhibition therapy. Clin. Cancer Res. 2019;25:3873-3886.

     Not in our library10.1158/1078-0432.ccr-18-3421

583. 583.

     Guilliams M, Thierry GR, Bonnardel J, Bajenoff M. Establishment and maintenance of the macrophage niche. Immunity. 2020;52:434-451.

     Not in our library10.1016/j.immuni.2020.02.015

584. 584.

     Chockalingam S, Ghosh SS. Macrophage colony-stimulating factor and cancer: a review. Tumour Biol. 2014;35:10635-10644.

     Not in our library10.1007/s13277-014-2627-0

585. 585.

     Chambers SK. Role of CSF-1 in progression of epithelial ovarian cancer. Future Oncol. 2009;5:1429-1440.

     Not in our library10.2217/fon.09.103

586. 586.

     Okugawa Y, et al. Colony-stimulating factor-1 and colony-stimulating factor-1 receptor co-expression is associated with disease progression in gastric cancer. Int. J. Oncol. 2018;53:737-749.

     Not in our library10.3892/ijo.2018.4406

587. 587.

     Richardsen E, Uglehus RD, Johnsen SH, Busund LT. Macrophage-colony stimulating factor (CSF1) predicts breast cancer progression and mortality. Anticancer Res. 2015;.35:865-874.

     Not in our library

588. 588.

     DeNardo DG, et al. Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Disco. 2011;1:54-67.

     Not in our library10.1158/2159-8274.cd-10-0028

589. 589.

     Escamilla J, et al. CSF1 receptor targeting in prostate cancer reverses macrophage-mediated resistance to androgen blockade therapy. Cancer Res. 2015;75:950-962.

     Not in our library10.1158/0008-5472.can-14-0992

590. 590.
     Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy · 2017

     No notice
591. 591.

     Pyonteck SM, et al. CSF-1R inhibition alters macrophage polarization and blocks glioma progression. Nat. Med. 2013;19:1264-1272.

     Not in our library10.1038/nm.3337

592. 592.

     Ries CH, et al. Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy. Cancer Cell. 2014;25:846-859.

     Not in our library10.1016/j.ccr.2014.05.016

593. 593.

     Weizman N, et al. Macrophages mediate gemcitabine resistance of pancreatic adenocarcinoma by upregulating cytidine deaminase. Oncogene. 2014;33:3812-3819.

     Not in our library10.1038/onc.2013.357

594. 594.

     Mouchemore KA, et al. Specific inhibition of PI3K p110delta inhibits CSF-1-induced macrophage spreading and invasive capacity. FEBS J. 2013;280:5228-5236.

     Not in our library10.1111/febs.12316

595. 595.

     Goldvaser H, Amir E. Role of bisphosphonates in breast cancer therapy. Curr. Treat. Options Oncol. 2019;20:26.

     Not in our library10.1007/s11864-019-0623-8

596. 596.

     Bader JE, et al. Macrophage depletion using clodronate liposomes decreases tumorigenesis and alters gut microbiota in the AOM/DSS mouse model of colon cancer. Am. J. Physiol. Gastrointest. Liver Physiol. 2018;314:G22-G31.

     Not in our library10.1152/ajpgi.00229.2017

597. 597.

     Tang X, et al. Targeted delivery of zoledronic acid through the sialic acid-siglec axis for killing and reversal of M2 phenotypic tumor-associated macrophages—a promising cancer immunotherapy. Int. J. Pharm. 2020;590:119929.

     Not in our library10.1016/j.ijpharm.2020.119929

598. 598.

     Macherey S, et al. Bisphosphonates for advanced prostate cancer. Cochrane Database Syst. Rev. 2017;12:CD006250.

     Not in our library10.1002/14651858.cd006250.pub2

599. 599.

     Cuevas C, Francesch A. Development of Yondelis (trabectedin, ET-743). A semisynthetic process solves the supply problem. Nat. Prod. Rep. 2009;26:322-337.

     Not in our library10.1039/b808331m

600. 600.

     Allavena P, et al. Anti-inflammatory properties of the novel antitumor agent yondelis (trabectedin): inhibition of macrophage differentiation and cytokine production. Cancer Res. 2005;65:2964-2971.

     Not in our library10.1158/0008-5472.can-04-4037

601. 601.

     Liguori M, et al. Functional TRAIL receptors in monocytes and tumor-associated macrophages: a possible targeting pathway in the tumor microenvironment. Oncotarget. 2016;7:41662-41676.

     Not in our library10.18632/oncotarget.9340

602. 602.

     D’Incalci M, Zambelli A. Trabectedin for the treatment of breast cancer. Expert Opin. Investig. Drugs. 2016;25:105-115.

     Not in our library10.1517/13543784.2016.1124086

603. 603.

     D’Incalci M, Badri N, Galmarini CM, Allavena P. Trabectedin, a drug acting on both cancer cells and the tumour microenvironment. Br. J. Cancer. 2014;111:646-650.

     Not in our library10.1038/bjc.2014.149

604. 604.

     Galmbacher K, et al. Shigella mediated depletion of macrophages in a murine breast cancer model is associated with tumor regression. PLoS ONE. 2010;5:e9572.

     Not in our library10.1371/journal.pone.0009572

605. 605.

     Martinez FO, Sica A, Mantovani A, Locati M. Macrophage activation and polarization. Front. Biosci. 2008;13:453-461.

     Not in our library10.2741/2692

606. 606.

     Liebes L, et al. Modulation of monocyte functions by muramyl tripeptide phosphatidylethanolamine in a phase II study in patients with metastatic melanoma. J. Natl Cancer Inst. 1992;84:694-699.

     Not in our library10.1093/jnci/84.9.694

607. 607.

     Bode JG, Ehlting C, Haussinger D. The macrophage response towards LPS and its control through the p38(MAPK)-STAT3 axis. Cell Signal. 2012;24:1185-1194.

     Not in our library10.1016/j.cellsig.2012.01.018

608. 608.

     Hu X, Chakravarty SD, Ivashkiv LB. Regulation of interferon and Toll-like receptor signaling during macrophage activation by opposing feedforward and feedback inhibition mechanisms. Immunol. Rev. 2008;226:41-56.

     Not in our library10.1111/j.1600-065x.2008.00707.x

609. 609.

     Kelsey SM, Hazel D, Murrell C, Newland AC. GM-CSF for peripheral blood stem cell harvest in myeloma. Br. J. Haematol. 1996;92:505.

     Not in our library10.1046/j.1365-2141.1996.d01-1508.x

610. 610.

     Schroder K, Hertzog PJ, Ravasi T, Hume DA. Interferon-gamma: an overview of signals, mechanisms and functions. J. Leukoc. Biol. 2004;75:163-189.

     Not in our library10.1189/jlb.0603252

611. 611.
     Cytokines in Cancer Immunotherapy · 2011

     No notice
612. 612.

     Conlon KC, Miljkovic MD, Waldmann TA. Cytokines in the treatment of cancer. J. Interferon Cytokine Res. 2019;39:6-21.

     Not in our library10.1089/jir.2018.0019

613. 613.

     Sheikh SZ, et al. Cutting edge: IFN-gamma is a negative regulator of IL-23 in murine macrophages and experimental colitis. J. Immunol. 2010;184:4069-4073.

     Not in our library10.4049/jimmunol.0903600

614. 614.

     Pujade-Lauraine E, et al. Intraperitoneal recombinant interferon gamma in ovarian cancer patients with residual disease at second-look laparotomy. J. Clin. Oncol. 1996;14:343-350.

     Not in our library10.1200/jco.1996.14.2.343

615. 615.

     Miller CH, Maher SG, Young HA. Clinical Use of Interferon-gamma. Ann. N. Y Acad. Sci. 2009;1182:69-79.

     Not in our library10.1111/j.1749-6632.2009.05069.x

616. 616.

     Alberts DS, et al. Randomized phase 3 trial of interferon gamma-1b plus standard carboplatin/paclitaxel versus carboplatin/paclitaxel alone for first-line treatment of advanced ovarian and primary peritoneal carcinomas: results from a prospectively designed analysis of progression-free survival. Gynecol. Oncol. 2008;109:174-181.

     Not in our library10.1016/j.ygyno.2008.01.005

617. 617.

     Vonderheide RH. CD40 agonist antibodies in cancer immunotherapy. Annu. Rev. Med. 2020;71:47-58.

     Not in our library10.1146/annurev-med-062518-045435

618. 618.

     Beatty GL, et al. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science. 2011;331:1612-1616.

     Not in our library10.1126/science.1198443

619. 619.

     Beatty GL, et al. A phase I study of an agonist CD40 monoclonal antibody (CP-870,893) in combination with gemcitabine in patients with advanced pancreatic ductal adenocarcinoma. Clin. Cancer Res. 2013;19:6286-6295.

     Not in our library10.1158/1078-0432.ccr-13-1320

620. 620.

     Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat. Rev. Cancer. 2009;9:798-809.

     Not in our library10.1038/nrc2734

621. 621.

     Yin Z, et al. IL-6/STAT3 pathway intermediates M1/M2 macrophage polarization during the development of hepatocellular carcinoma. J. Cell Biochem. 2018;119:9419-9432.

     Not in our library10.1002/jcb.27259

622. 622.

     Sun J, et al. Suppression of TLR4 activation by resveratrol is associated with STAT3 and Akt inhibition in oxidized low-density lipoprotein-activated platelets. Eur. J. Pharm. 2018;836:1-10.

     Not in our library10.1016/j.ejphar.2018.08.014

623. 623.

     Wang H, Feng H, Zhang Y. Resveratrol inhibits hypoxia-induced glioma cell migration and invasion by the p-STAT3/miR-34a axis. Neoplasma. 2016;63:532-539.

     Not in our library10.4149/neo_2016_406

624. 624.

     Vasamsetti SB, et al. Metformin inhibits monocyte-to-macrophage differentiation via AMPK-mediated inhibition of STAT3 activation: potential role in atherosclerosis. Diabetes. 2015;64:2028-2041.

     Not in our library10.2337/db14-1225

625. 625.

     Arredouani MS. Is the scavenger receptor MARCO a new immune checkpoint? Oncoimmunology. 2014;3:e955709.

     Not in our library10.4161/21624011.2014.955709

626. 626.
     Reprogramming Tumor-Associated Macrophages by Antibody Targeting Inhibits Cancer Progression and Metastasis · 2016

     Not checked
627. 627.

     La Fleur L, et al. Expression of scavenger receptor MARCO defines a targetable tumor-associated macrophage subset in non-small cell lung cancer. Int. J. Cancer. 2018;143:1741-1752.

     Not in our library10.1002/ijc.31545

628. 628.

     Mulens-Arias V, et al. Polyethylenimine-coated superparamagnetic iron oxide nanoparticles impair in vitro and in vivo angiogenesis. Nanomedicine. 2019;21:102063.

     Not in our library10.1016/j.nano.2019.102063

629. 629.

     Rolny C, et al. HRG inhibits tumor growth and metastasis by inducing macrophage polarization and vessel normalization through downregulation of PlGF. Cancer Cell. 2011;19:31-44.

     Not in our library10.1016/j.ccr.2010.11.009

630. 630.

     Willingham SB, et al. The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors. Proc. Natl Acad. Sci. USA. 2012;109:6662-6667.

     Not in our library10.1073/pnas.1121623109

631. 631.

     Logtenberg MEW, et al. Glutaminyl cyclase is an enzymatic modifier of the CD47- SIRPalpha axis and a target for cancer immunotherapy. Nat. Med. 2019;25:612-619.

     Not in our library10.1038/s41591-019-0356-z

632. 632.

     Russ A, et al. Blocking “don’t eat me” signal of CD47-SIRPalpha in hematological malignancies, an in-depth review. Blood Rev. 2018;32:480-489.

     Not in our library10.1016/j.blre.2018.04.005

633. 633.

     Schurch CM, et al. The “don’t eat me” signal CD47 is a novel diagnostic biomarker and potential therapeutic target for diffuse malignant mesothelioma. Oncoimmunology. 2017;7:e1373235.

     Not in our library10.1080/2162402x.2017.1373235

634. 634.

     Barkal AA, et al. CD24 signalling through macrophage Siglec-10 is a target for cancer immunotherapy. Nature. 2019;572:392-396.

     Not in our library10.1038/s41586-019-1456-0

635. 635.

     Bradley CA. CD24 - a novel ‘don’t eat me’ signal. Nat. Rev. Cancer. 2019;19:541.

     Not in our library10.1038/s41568-019-0193-x

636. 636.

     Montero AJ, Diaz-Montero CM, Kyriakopoulos CE, Bronte V, Mandruzzato S. Myeloid-derived suppressor cells in cancer patients: a clinical perspective. J. Immunother. 2012;35:107-115.

     Not in our library10.1097/cji.0b013e318242169f

637. 637.

     Limagne E, et al. Accumulation of MDSC and Th17 Cells in patients with etastatic colorectal cancer predicts the efficacy of a FOLFOX-bevacizumab drug treatment regimen. Cancer Res. 2016;76:5241-5252.

     Not in our library10.1158/0008-5472.can-15-3164

638. 638.

     Hansen GL, Gaudernack G, Brunsvig PF, Cvancarova M, Kyte JA. Immunological factors influencing clinical outcome in lung cancer patients after telomerase peptide vaccination. Cancer Immunol. Immunother. 2015;64:1609-1621.

     Not in our library10.1007/s00262-015-1766-5

639. 639.

     Bauer R, et al. Blockade of myeloid-derived suppressor cell expansion with all-trans retinoic acid increases the efficacy of antiangiogenic therapy. Cancer Res. 2018;78:3220-3232.

     Not in our library10.1158/0008-5472.can-17-3415

640. 640.

     Fleet JC, Burcham GN, Calvert RD, Elzey BD, Ratliff TL. 1alpha, 25 Dihydroxyvitamin D (1,25(OH)2D) inhibits the T cell suppressive function of myeloid derived suppressor cells (MDSC). J. Steroid Biochem. Mol. Biol. 2020;198:105557.

     Not in our library10.1016/j.jsbmb.2019.105557

641. 641.

     Roda JM, Parihar R, Carson WE. CpG-containing oligodeoxynucleotides act through TLR9 to enhance the NK cell cytokine response to antibody-coated tumor cells. J. Immunol. 2005;175:1619-1627.

     Not in our library10.4049/jimmunol.175.3.1619

642. 642.

     Kuwata T, et al. Vitamin A deficiency in mice causes a systemic expansion of myeloid cells. Blood. 2000;95:3349-3356.

     Not in our library10.1182/blood.v95.11.3349

643. 643.

     Kulbersh JS, Day TA, Gillespie MB, Young MR. 1alpha,25-Dihydroxyvitamin D(3) to skew intratumoral levels of immune inhibitory CD34(+) progenitor cells into dendritic cells. Otolaryngol. Head. Neck Surg. 2009;140:235-240.

     Not in our library10.1016/j.otohns.2008.11.011

644. 644.

     Young MR, Wright MA, Vellody K, Lathers DM. Skewed differentiation of bone marrow CD34+ cells of tumor bearers from dendritic toward monocytic cells, and the redirection of differentiation toward dendritic cells by 1alpha,25-dihydroxyvitamin D3. Int. J. Immunopharmacol. 1999;21:675-688.

     Not in our library10.1016/s0192-0561(99)00044-2

645. 645.

     Lathers DM, Clark JI, Achille NJ, Young MR. Phase 1B study to improve immune responses in head and neck cancer patients using escalating doses of 25-hydroxyvitamin D3. Cancer Immunol. Immunother. 2004;53:422-430.

     Not in our library10.1007/s00262-003-0459-7

646. 646.

     Mirza N, et al. All-trans-retinoic acid improves differentiation of myeloid cells and immune response in cancer patients. Cancer Res. 2006;66:9299-9307.

     Not in our library10.1158/0008-5472.can-06-1690

647. 647.

     Nefedova Y, et al. Mechanism of all-trans retinoic acid effect on tumor-associated myeloid-derived suppressor cells. Cancer Res. 2007;67:11021-11028.

     Not in our library10.1158/0008-5472.can-07-2593

648. 648.

     Iclozan C, Antonia S, Chiappori A, Chen DT, Gabrilovich D. Therapeutic regulation of myeloid-derived suppressor cells and immune response to cancer vaccine in patients with extensive stage small cell lung cancer. Cancer Immunol. Immunother. 2013;62:909-918.

     Not in our library10.1007/s00262-013-1396-8

649. 649.

     Tobin RP, et al. Targeting myeloid-derived suppressor cells using all-trans retinoic acid in melanoma patients treated with Ipilimumab. Int. Immunopharmacol. 2018;63:282-291.

     Not in our library10.1016/j.intimp.2018.08.007

650. 650.

     Young MR. & Lathers, D.M. Combination docetaxel plus vitamin D(3) as an immune therapy in animals bearing squamous cell carcinomas. Otolaryngol. Head. Neck Surg. 2005;133:611-618.

     Not in our library10.1016/j.otohns.2005.05.658

651. 651.
     Immune changes in patients with advanced breast cancer undergoing chemotherapy with taxanes · 2002

     No notice
652. 652.

     Kodumudi KN, et al. A novel chemoimmunomodulating property of docetaxel: suppression of myeloid-derived suppressor cells in tumor bearers. Clin. Cancer Res. 2010;16:4583-4594.

     Not in our library10.1158/1078-0432.ccr-10-0733

653. 653.

     Michels T, et al. Paclitaxel promotes differentiation of myeloid-derived suppressor cells into dendritic cells in vitro in a TLR4-independent manner. J. Immunotoxicol. 2012;9:292-300.

     Not in our library10.3109/1547691x.2011.642418

654. 654.

     Montero AJ, et al. Phase 2 study of neoadjuvant treatment with NOV-002 in combination with doxorubicin and cyclophosphamide followed by docetaxel in patients with HER-2 negative clinical stage II-IIIc breast cancer. Breast Cancer Res. Treat. 2012;132:215-223.

     Not in our library10.1007/s10549-011-1889-0

655. 655.

     Tian J, et al. beta-Glucan enhances antitumor immune responses by regulating differentiation and function of monocytic myeloid-derived suppressor cells. Eur. J. Immunol. 2013;43:1220-1230.

     Not in our library10.1002/eji.201242841

656. 656.
     The effects of β-glucan on human immune and cancer cells · 2009

     No notice
657. 657.

     Xiang X, et al. Induction of myeloid-derived suppressor cells by tumor exosomes. Int. J. Cancer. 2009;124:2621-2633.

     Not in our library10.1002/ijc.24249

658. 658.

     Chalmin F, et al. Membrane-associated Hsp72 from tumor-derived exosomes mediates STAT3-dependent immunosuppressive function of mouse and human myeloid-derived suppressor cells. J. Clin. Invest. 2010;120:457-471.

     Not in our library10.1172/jci40483

659. 659.

     Fernandez A, et al. Inhibition of tumor-induced myeloid-derived suppressor cell function by a nanoparticulated adjuvant. J. Immunol. 2011;186:264-274.

     Not in our library10.4049/jimmunol.1001465

660. 660.

     Liu Y, et al. Targeting myeloid-derived suppressor cells for cancer immunotherapy. Cancer Immunol. Immunother. 2018;67:1181-1195.

     Not in our library10.1007/s00262-018-2175-3

661. 661.

     Tu SP, et al. Curcumin induces the differentiation of myeloid-derived suppressor cells and inhibits their interaction with cancer cells and related tumor growth. Cancer Prev. Res. 2012;5:205-215.

     Not in our library10.1158/1940-6207.capr-11-0247

662. 662.

     Deguchi A. Curcumin targets in inflammation and cancer. Endocr. Metab. Immune Disord. Drug Targets. 2015;15:88-96.

     Not in our library10.2174/1871530315666150316120458

663. 663.

     Hossain DM, et al. TLR9-targeted STAT3 silencing abrogates immunosuppressive activity of myeloid-derived suppressor cells from prostate cancer patients. Clin. Cancer Res. 2015;21:3771-3782.

     Not in our library10.1158/1078-0432.ccr-14-3145

664. 664.

     Kortylewski M, Moreira D. Myeloid cells as a target for oligonucleotide therapeutics: turning obstacles into opportunities. Cancer Immunol. Immunother. 2017;66:979-988.

     Not in our library10.1007/s00262-017-1966-2

665. 665.

     Kusmartsev S, et al. Oxidative stress regulates expression of VEGFR1 in myeloid cells: link to tumor-induced immune suppression in renal cell carcinoma. J. Immunol. 2008;181:346-353.

     Not in our library10.4049/jimmunol.181.1.346

666. 666.

     Koinis F, et al. Effect of first-line treatment on myeloid-derived suppressor cells’ subpopulations in the peripheral blood of patients with non-small cell lung cancer. J. Thorac. Oncol. 2016;11:1263-1272.

     Not in our library10.1016/j.jtho.2016.04.026

667. 667.

     Limagne E, et al. Accumulation of MDSC and Th17 cells in patients with metastatic colorectal cancer predicts the efficacy of a FOLFOX-bevacizumab drug treatment regimen. Cancer Res. 2016;76:5241-5252.

     Not in our library10.1158/0008-5472.can-15-3164

668. 668.

     Albeituni SH, Ding C, Yan J. Hampering immune suppressors: therapeutic targeting of myeloid-derived suppressor cells in cancer. Cancer J. 2013;19:490-501.

     Not in our library10.1097/ppo.0000000000000006

669. 669.

     Pan PY, et al. Reversion of immune tolerance in advanced malignancy: modulation of myeloid-derived suppressor cell development by blockade of stem-cell factor function. Blood. 2008;111:219-228.

     Not in our library10.1182/blood-2007-04-086835

670. 670.

     Ko JS, et al. Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. Clin. Cancer Res. 2009;15:2148-2157.

     Not in our library10.1158/1078-0432.ccr-08-1332

671. 671.

     Panka DJ, Liu Q, Geissler AK, Mier JW. Effects of HDM2 antagonism on sunitinib resistance, p53 activation, SDF-1 induction, and tumor infiltration by CD11b+/Gr-1+ myeloid derived suppressor cells. Mol. Cancer. 2013;12:17.

     Not in our library10.1186/1476-4598-12-17

672. 672.

     Evans EE, et al. Antibody blockade of semaphorin 4D promotes immune infiltration into tumor and enhances response to other immunomodulatory therapies. Cancer Immunol. Res. 2015;3:689-701.

     Not in our library10.1158/2326-6066.cir-14-0171

673. 673.

     Patnaik A, et al. Safety, pharmacokinetics, and pharmacodynamics of a humanized anti-semaphorin 4D antibody, in a first-in-human study of patients with advanced solid tumors. Clin. Cancer Res. 2016;22:827-836.

     Not in our library10.1158/1078-0432.ccr-15-0431

674. 674.

     Highfill SL, et al. Disruption of CXCR2-mediated MDSC tumor trafficking enhances anti-PD1 efficacy. Sci. Transl. Med. 2014;6:237ra267.

     Not in our library10.1126/scitranslmed.3007974

675. 675.

     Flores-Toro JA, et al. CCR2 inhibition reduces tumor myeloid cells and unmasks a checkpoint inhibitor effect to slow progression of resistant murine gliomas. Proc. Natl Acad. Sci. USA. 2020;117:1129-1138.

     Not in our library10.1073/pnas.1910856117

676. 676.

     Wang T, et al. Galectin-3 contributes to cisplatin-induced myeloid derived suppressor cells (MDSCs) recruitment in Lewis lung cancer-bearing mice. Mol. Biol. Rep. 2014;41:4069-4076.

     Not in our library10.1007/s11033-014-3276-5

677. 677.

     Obermajer N, Muthuswamy R, Lesnock J, Edwards RP, Kalinski P. Positive feedback between PGE2 and COX2 redirects the differentiation of human dendritic cells toward stable myeloid-derived suppressor cells. Blood. 2011;118:5498-5505.

     Not in our library10.1182/blood-2011-07-365825

678. 678.

     Rong Y, et al. Doxorubicin resistant cancer cells activate myeloid-derived suppressor cells by releasing PGE2. Sci. Rep. 2016;6:23824.

     Not in our library10.1038/srep23824

679. 679.

     Takahashi R, et al. Microsomal prostaglandin E synthase-1 promotes lung metastasis via SDF-1/CXCR4-mediated recruitment of CD11b(+)Gr1(+)MDSCs from bone marrow. Biomed. Pharmacother. 2020;121:109581.

     Not in our library10.1016/j.biopha.2019.109581

680. 680.

     Yan G, et al. A RIPK3-PGE2 circuit mediates myeloid-derived suppressor cell-potentiated colorectal carcinogenesis. Cancer Res. 2018;78:5586-5599.

     Not in our library10.1158/0008-5472.can-17-3962

681. 681.
     COX-2 inhibition improves immunotherapy and is associated with decreased numbers of myeloid-derived suppressor cells in mesothelioma. Celecoxib influences MDSC function · 2010

     No notice
682. 682.

     Hong DS, et al. First-in-human phase I study of immunomodulatory E7046, an antagonist of PGE2-receptor E-type 4 (EP4), in patients with advanced cancers. J. Immunother. Cancer. 2020;8:e000222.

     Not in our library10.1136/jitc-2019-000222

683. 683.

     Albu DI, et al. EP4 antagonism by E7046 diminishes myeloid immunosuppression and synergizes with Treg-reducing IL-2-diphtheria toxin fusion protein in restoring anti-tumor immunity. Oncoimmunology. 2017;6:e1338239.

     Not in our library10.1080/2162402x.2017.1338239

684. 684.
     Cyclooxygenase-Dependent Tumor Growth through Evasion of Immunity · 2015

     No notice
685. 685.

     Prima V, Kaliberova LN, Kaliberov S, Curiel DT, Kusmartsev S. COX2/mPGES1/PGE2 pathway regulates PD-L1 expression in tumor-associated macrophages and myeloid-derived suppressor cells. Proc. Natl Acad. Sci. USA. 2017;114:1117-1122.

     Not in our library10.1073/pnas.1612920114

686. 686.

     Gabrilovich DI, Ostrand-Rosenberg S, Bronte V. Coordinated regulation of myeloid cells by tumours. Nat. Rev. Immunol. 2012;12:253-268.

     Not in our library10.1038/nri3175

687. 687.

     De Santo C, et al. Nitroaspirin corrects immune dysfunction in tumor-bearing hosts and promotes tumor eradication by cancer vaccination. Proc. Natl Acad. Sci. USA. 2005;102:4185-4190.

     Not in our library10.1073/pnas.0409783102

688. 688.

     Serafini P, et al. Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function. J. Exp. Med. 2006;203:2691-2702.

     Not in our library10.1084/jem.20061104

689. 689.

     Hassel JC, et al. Tadalafil has biologic activity in human melanoma. Results of a pilot trial with Tadalafil in patients with metastatic melanoma (TaMe). Oncoimmunology. 2017;6:e1326440.

     Not in our library10.1080/2162402x.2017.1326440

690. 690.
     CD39/CD73 upregulation on myeloid-derived suppressor cells via TGF-β-mTOR-HIF-1 signaling in patients with non-small cell lung cancer · 2017

     Not checked
691. 691.

     Li L, et al. Metformin-induced reduction of CD39 and CD73 blocks myeloid-derived suppressor cell activity in patients with ovarian cancer. Cancer Res. 2018;78:1779-1791.

     Not in our library10.1158/0008-5472.can-17-2460

692. 692.

     De Henau O, et al. Overcoming resistance to checkpoint blockade therapy by targeting PI3Kgamma in myeloid cells. Nature. 2016;539:443-447.

     Not in our library10.1038/nature20554

693. 693.

     Zhang X, Shen L, Liu Q, Hou L, Huang L. Inhibiting PI3 kinase-gamma in both myeloid and plasma cells remodels the suppressive tumor microenvironment in desmoplastic tumors. J. Control Release. 2019;309:173-180.

     Not in our library10.1016/j.jconrel.2019.07.039

694. 694.

     Patel K, Danilov AV, Pagel JM. Duvelisib for CLL/SLL and follicular non-Hodgkin lymphoma. Blood. 2019;134:1573-1577.

     Not in our library10.1182/blood.2019001795

695. 695.

     Suzuki E, Kapoor V, Jassar AS, Kaiser LR, Albelda SM. Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin. Cancer Res. 2005;11:6713-6721.

     Not in our library10.1158/1078-0432.ccr-05-0883

696. 696.

     Vincent J, et al. 5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. Cancer Res. 2010;70:3052-3061.

     Not in our library10.1158/0008-5472.can-09-3690

697. 697.

     Hurez V, et al. Mitigating age-related immune dysfunction heightens the efficacy of tumor immunotherapy in aged mice. Cancer Res. 2012;72:2089-2099.

     Not in our library10.1158/0008-5472.can-11-3019

698. 698.

     Dominguez GA, et al. Selective targeting of myeloid-derived suppressor cells in cancer patients using DS-8273a, an agonistic TRAIL-R2 antibody. Clin. Cancer Res. 2017;23:2942-2950.

     Not in our library10.1158/1078-0432.ccr-16-1784

699. 699.

     Qin H, et al. Generation of a new therapeutic peptide that depletes myeloid-derived suppressor cells in tumor-bearing mice. Nat. Med. 2014;20:676-681.

     Not in our library10.1038/nm.3560

700. 700.
     Tumor-Associated Neutrophils as a New Prognostic Factor in Cancer: A Systematic Review and Meta-Analysis · 2014

     No notice
701. 701.

     Granot Z. Neutrophils as a therapeutic target in cancer. Front Immunol. 2019;10:1710.

     Not in our library10.3389/fimmu.2019.01710

702. 702.
     Targeting and exploitation of tumor-associated neutrophils to enhance immunotherapy and drug delivery for cancer treatment · 2020

     Not checked
703. 703.

     Shaul ME, Fridlender ZG. Tumour-associated neutrophils in patients with cancer. Nat. Rev. Clin. Oncol. 2019;16:601-620.

     Not in our library10.1038/s41571-019-0222-4

704. 704.

     Haider C, et al. Transforming growth factor-beta and axl induce CXCL5 and neutrophil recruitment in hepatocellular carcinoma. Hepatology. 2019;69:222-236.

     Not in our library10.1002/hep.30166

705. 705.

     Tauriello DVF, et al. TGFbeta drives immune evasion in genetically reconstituted colon cancer metastasis. Nature. 2018;554:538-543.

     Not in our library10.1038/nature25492

706. 706.

     Mariathasan S, et al. TGFbeta attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature. 2018;554:544-548.

     Not in our library10.1038/nature25501

707. 707.

     Stevenson JP, et al. Immunological effects of the TGFbeta-blocking antibody GC1008 in malignant pleural mesothelioma patients. Oncoimmunology. 2013;2:e26218.

     Not in our library10.4161/onci.26218

708. 708.
     Phase I Study of GC1008 (Fresolimumab): A Human Anti-Transforming Growth Factor-Beta (TGFβ) Monoclonal Antibody in Patients with Advanced Malignant Melanoma or Renal Cell Carcinoma · 2014

     No notice
709. 709.

     Formenti SC, et al. Focal irradiation and systemic TGFbeta blockade in metastatic breast cancer. Clin. Cancer Res. 2018;24:2493-2504.

     Not in our library10.1158/1078-0432.ccr-17-3322

710. 710.

     Kelley RK, et al. A phase 2 study of galunisertib (TGF-beta1 receptor type I inhibitor) and sorafenib in patients with advanced hepatocellular carcinoma. Clin. Transl. Gastroenterol. 2019;10:e00056.

     Not in our library10.14309/ctg.0000000000000056

711. 711.
     Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer · 2018

     No notice
712. 712.
     Targeting the TGFβ pathway with galunisertib, a TGFβRI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint blockade · 2018

     No notice
713. 713.

     Glennon-Alty L, Moots RJ, Edwards SW, Wright HL. Type I interferon regulates cytokine-delayed neutrophil apoptosis, reactive oxygen species production and chemokine expression. Clin. Exp. Immunol. 2021;203:151-159.

     Not in our library10.1111/cei.13525

714. 714.

     Wu CF, et al. The lack of type I interferon induces neutrophil-mediated pre-metastatic niche formation in the mouse lung. Int. J. Cancer. 2015;137:837-847.

     Not in our library10.1002/ijc.29444

715. 715.

     Andzinski L, et al. Type I IFNs induce anti-tumor polarization of tumor associated neutrophils in mice and human. Int. J. Cancer. 2016;138:1982-1993.

     Not in our library10.1002/ijc.29945

716. 716.

     Nauseef WM. How human neutrophils kill and degrade microbes: an integrated view. Immunol. Rev. 2007;219:88-102.

     Not in our library10.1111/j.1600-065x.2007.00550.x

717. 717.

     Semerad CL, Liu F, Gregory AD, Stumpf K, Link DC. G-CSF is an essential regulator of neutrophil trafficking from the bone marrow to the blood. Immunity. 2002;17:413-423.

     Not in our library10.1016/s1074-7613(02)00424-7

718. 718.

     Cheng Y, Ma XL, Wei YQ, Wei XW. Potential roles and targeted therapy of the CXCLs/CXCR2 axis in cancer and inflammatory diseases. Biochim. Biophys. Acta Rev. Cancer. 2019;1871:289-312.

     Not in our library10.1016/j.bbcan.2019.01.005

719. 719.

     Liao W, et al. KRAS-IRF2 axis drives immune suppression and immune therapy resistance in colorectal cancer. Cancer Cell. 2019;35:559-572 e557.

     Not in our library10.1016/j.ccell.2019.02.008

720. 720.

     Jung K, et al. Targeting CXCR4-dependent immunosuppressive Ly6C(low) monocytes improves antiangiogenic therapy in colorectal cancer. Proc. Natl Acad. Sci. USA. 2017;114:10455-10460.

     Not in our library10.1073/pnas.1710754114

721. 721.

     Zeng Y, et al. Dual blockade of CXCL12-CXCR4 and PD-1-PD-L1 pathways prolongs survival of ovarian tumor-bearing mice by prevention of immunosuppression in the tumor microenvironment. FASEB J. 2019;33:6596-6608.

     Not in our library10.1096/fj.201802067rr

722. 722.

     Xue LJ, Mao XB, Ren LL, Chu XY. Inhibition of CXCL12/CXCR4 axis as a potential targeted therapy of advanced gastric carcinoma. Cancer Med. 2017;6:1424-1436.

     Not in our library10.1002/cam4.1085

723. 723.

     Righi E, et al. CXCL12/CXCR4 blockade induces multimodal antitumor effects that prolong survival in an immunocompetent mouse model of ovarian cancer. Cancer Res. 2011;71:5522-5534.

     Not in our library10.1158/0008-5472.can-10-3143

724. 724.

     Gil M, et al. CXCL12/CXCR4 blockade by oncolytic virotherapy inhibits ovarian cancer growth by decreasing immunosuppression and targeting cancer-initiating cells. J. Immunol. 2014;193:5327-5337.

     Not in our library10.4049/jimmunol.1400201

725. 725.

     Glodde N, et al. Reactive neutrophil responses dependent on the receptor tyrosine kinase c-MET limit cancer immunotherapy. Immunity. 2017;47:789-802 e789.

     Not in our library10.1016/j.immuni.2017.09.012

726. 726.

     Kurzrock R, et al. Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. J. Clin. Oncol. 2011;29:2660-2666.

     Not in our library10.1200/jco.2010.32.4145

727. 727.
     Dual effects of a targeted small-molecule inhibitor (cabozantinib) on immune-mediated killing of tumor cells and immune tumor microenvironment permissiveness when combined with a cancer vaccine · 2014

     No notice
728. 728.

     Patnaik A, et al. Cabozantinib eradicates advanced murine prostate cancer by activating antitumor innate immunity. Cancer Disco. 2017;7:750-765.

     Not in our library10.1158/2159-8290.cd-16-0778

729. 729.

     Imai K, Matsuyama S, Miyake S, Suga K, Nakachi K. Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: an 11-year follow-up study of a general population. Lancet. 2000;356:1795-1799.

     Not in our library10.1016/s0140-6736(00)03231-1

730. 730.

     Vitale M, Cantoni C, Pietra G, Mingari MC, Moretta L. Effect of tumor cells and tumor microenvironment on NK-cell function. Eur. J. Immunol. 2014;44:1582-1592.

     Not in our library10.1002/eji.201344272

731. 731.

     Rusakiewicz S, et al. Immune infiltrates are prognostic factors in localized gastrointestinal stromal tumors. Cancer Res. 2013;73:3499-3510.

     Not in our library10.1158/0008-5472.can-13-0371

732. 732.

     Veeramani S, et al. Rituximab infusion induces NK activation in lymphoma patients with the high-affinity CD16 polymorphism. Blood. 2011;118:3347-3349.

     Not in our library10.1182/blood-2011-05-351411

733. 733.

     Shimasaki N, Jain A, Campana D. NK cells for cancer immunotherapy. Nat. Rev. Drug Disco. 2020;19:200-218.

     Not in our library10.1038/s41573-019-0052-1

734. 734.

     Huntington ND. The unconventional expression of IL-15 and its role in NK cell homeostasis. Immunol. Cell Biol. 2014;92:210-213.

     Not in our library10.1038/icb.2014.1

735. 735.

     Porrata LF, et al. Interleukin-15 affects patient survival through natural killer cell recovery after autologous hematopoietic stem cell transplantation for non-Hodgkin lymphomas. Clin. Dev. Immunol. 2010;2010:914945.

     Not in our library10.1155/2010/914945

736. 736.

     Conlon KC, et al. Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer. J. Clin. Oncol. 2015;33:74-82.

     Not in our library10.1200/jco.2014.57.3329

737. 737.

     Perez-Martinez A, et al. A phase I/II trial of interleukin-15-stimulated natural killer cell infusion after haplo-identical stem cell transplantation for pediatric refractory solid tumors. Cytotherapy. 2015;17:1594-1603.

     Not in our library10.1016/j.jcyt.2015.07.011

738. 738.

     Gluck WL, et al. Phase I studies of interleukin (IL)-2 and rituximab in B-cell non-hodgkin’s lymphoma: IL-2 mediated natural killer cell expansion correlations with clinical response. Clin. Cancer Res. 2004;10:2253-2264.

     Not in our library10.1158/1078-0432.ccr-1087-3

739. 739.

     Marcus A, et al. Tumor-derived cGAMP triggers a STING-mediated interferon response in non-tumor cells to activate the NK cell response. Immunity. 2018;49:754-763 e754.

     Not in our library10.1016/j.immuni.2018.09.016

740. 740.

     Breitbach CJ, et al. Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans. Nature. 2011;477:99-102.

     Not in our library10.1038/nature10358

741. 741.

     Alvarez-Breckenridge CA, et al. NK cells impede glioblastoma virotherapy through NKp30 and NKp46 natural cytotoxicity receptors. Nat. Med. 2012;18:1827-1834.

     Not in our library10.1038/nm.3013

742. 742.

     Zamarin D, et al. Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy. Sci. Transl. Med. 2014;6:226ra232.

     Not in our library10.1126/scitranslmed.3008095

743. 743.

     Hsu J, et al. Contribution of NK cells to immunotherapy mediated by PD-1/PD-L1 blockade. J. Clin. Invest. 2018;128:4654-4668.

     Not in our library10.1172/jci99317

744. 744.

     Ohs I, et al. Restoration of natural killer cell antimetastatic activity by IL12 and checkpoint blockade. Cancer Res. 2017;77:7059-7071.

     Not in our library10.1158/0008-5472.can-17-1032

745. 745.

     Concha-Benavente F, et al. PD-L1 mediates dysfunction in activated PD-1(+) NK Cells in head and neck cancer patients. Cancer Immunol. Res. 2018;6:1548-1560.

     Not in our library10.1158/2326-6066.cir-18-0062

746. 746.

     Kohrt HE, et al. Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies. Blood. 2014;123:678-686.

     Not in our library10.1182/blood-2013-08-519199

747. 747.

     Paolino M, et al. The E3 ligase Cbl-b and TAM receptors regulate cancer metastasis via natural killer cells. Nature. 2014;507:508-512.

     Not in our library10.1038/nature12998

748. 748.

     Chan CJ, et al. The receptors CD96 and CD226 oppose each other in the regulation of natural killer cell functions. Nat. Immunol. 2014;15:431-438.

     Not in our library10.1038/ni.2850

749. 749.

     Kohrt HE, et al. Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer. J. Clin. Invest. 2012;122:1066-1075.

     Not in our library10.1172/jci61226

750. 750.

     Kohrt HE, et al. CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies. Blood. 2011;117:2423-2432.

     Not in our library10.1182/blood-2010-08-301945

751. 751.

     Andre P, et al. Anti-NKG2A mAb is a checkpoint inhibitor that promotes anti-tumor immunity by unleashing both T and NK cells. Cell. 2018;175:1731-1743 e1713.

     Not in our library10.1016/j.cell.2018.10.014

752. 752.

     Elliott JM, Yokoyama WM. Unifying concepts of MHC-dependent natural killer cell education. Trends Immunol. 2011;32:364-372.

     Not in our library10.1016/j.it.2011.06.001

753. 753.

     Chang YH, et al. A chimeric receptor with NKG2D specificity enhances natural killer cell activation and killing of tumor cells. Cancer Res. 2013;73:1777-1786.

     Not in our library10.1158/0008-5472.can-12-3558

754. 754.

     Imai C, Iwamoto S, Campana D. Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells. Blood. 2005;106:376-383.

     Not in our library10.1182/blood-2004-12-4797

755. 755.

     Huland E, Huland H. Tumor-associated eosinophilia in interleukin-2-treated patients: evidence of toxic eosinophil degranulation on bladder cancer cells. J. Cancer Res. Clin. Oncol. 1992;118:463-467.

     Not in our library10.1007/bf01629431

756. 756.

     Tepper RI, Coffman RL, Leder P. An eosinophil-dependent mechanism for the antitumor effect of interleukin-4. Science. 1992;257:548-551.

     Not in our library10.1126/science.1636093

757. 757.

     Schaefer JT, et al. Dynamic changes in cellular infiltrates with repeated cutaneous vaccination: a histologic and immunophenotypic analysis. J. Transl. Med. 2010;8:79.

     Not in our library10.1186/1479-5876-8-79

758. 758.

     Gebhardt C, et al. Myeloid cells and related chronic inflammatory factors as novel predictive markers in melanoma treatment with Ipilimumab. Clin. Cancer Res. 2015;21:5453-5459.

     Not in our library10.1158/1078-0432.ccr-15-0676

759. 759.

     Weide B, et al. Baseline biomarkers for outcome of melanoma patients treated with Pembrolizumab. Clin. Cancer Res. 2016;22:5487-5496.

     Not in our library10.1158/1078-0432.ccr-16-0127

760. 760.

     Davis BP, Rothenberg ME. Eosinophils and cancer. Cancer Immunol. Res. 2014;2:1-8.

     Not in our library10.1158/2326-6066.cir-13-0196

761. 761.

     Kataoka S, Konishi Y, Nishio Y, Fujikawa-Adachi K, Tominaga A. Antitumor activity of eosinophils activated by IL-5 and eotaxin against hepatocellular carcinoma. DNA Cell Biol. 2004;23:549-560.

     Not in our library10.1089/dna.2004.23.549

762. 762.

     Rothenberg ME, Hogan SP. The eosinophil. Annu. Rev. Immunol. 2006;24:147-174.

     Not in our library10.1146/annurev.immunol.24.021605.090720

763. 763.

     Rosenberg HF, Dyer KD, Foster PS. Eosinophils: changing perspectives in health and disease. Nat. Rev. Immunol. 2013;13:9-22.

     Not in our library10.1038/nri3341

764. 764.

     Caruso RA, et al. Ultrastructural descriptions of heterotypic aggregation between eosinophils and tumor cells in human gastric carcinomas. Ultrastruct. Pathol. 2011;35:145-149.

     Not in our library10.3109/01913123.2011.578233

765. 765.

     Simon HU, et al. Interleukin-2 primes eosinophil degranulation in hypereosinophilia and Wells’ syndrome. Eur. J. Immunol. 2003;33:834-839.

     Not in our library10.1002/eji.200323727

766. 766.

     Rivoltini L, et al. In vitro anti-tumor activity of eosinophils from cancer patients treated with subcutaneous administration of interleukin 2. Role of interleukin 5. Int. J. Cancer. 1993;54:8-15.

     Not in our library10.1002/ijc.2910540103

767. 767.

     Sosman JA, et al. Evidence for eosinophil activation in cancer patients receiving recombinant interleukin-4: effects of interleukin-4 alone and following interleukin-2 administration. Clin. Cancer Res. 1995;1:805-812.

     Not in our library

768. 768.

     Benatar T, et al. IL-17E, a proinflammatory cytokine, has antitumor efficacy against several tumor types in vivo. Cancer Immunol. Immunother. 2010;59:805-817.

     Not in our library10.1007/s00262-009-0802-8

769. 769.

     Steinman RM. Decisions about dendritic cells: past, present, and future. Annu. Rev. Immunol. 2012;30:1-22.

     Not in our library10.1146/annurev-immunol-100311-102839

770. 770.

     Monney L, et al. Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease. Nature. 2002;415:536-541.

     Not in our library10.1038/415536a

771. 771.

     Carroll MC, Isenman DE. Regulation of humoral immunity by complement. Immunity. 2012;37:199-207.

     Not in our library10.1016/j.immuni.2012.08.002

772. 772.

     Wernersson S, Pejler G. Mast cell secretory granules: armed for battle. Nat. Rev. Immunol. 2014;14:478-494.

     Not in our library10.1038/nri3690

773. 773.

     Chaudhry A, Rudensky AY. Control of inflammation by integration of environmental cues by regulatory T cells. J. Clin. Invest. 2013;123:939-944.

     Not in our library10.1172/jci57175

774. 774.

     Cai X, Zhang L, Wei W. Regulatory B cells in inflammatory diseases and tumor. Int. Immunopharmacol. 2019;67:281-286.

     Not in our library10.1016/j.intimp.2018.12.007

775. 775.

     Volaric I, Vicic M, Prpic-Massari L. The role of CD8+ T-cells and their cytokines in the pathogenesis of psoriasis. Acta Dermatovenerol. Croat. 2019;27:159-162.

     Not in our library

776. 776.

     Fernandez-Poma SM, et al. Expansion of tumor-infiltrating CD8(+) T cells expressing PD-1 improves the efficacy of adoptive T-cell therapy. Cancer Res. 2017;77:3672-3684.

     Not in our library10.1158/0008-5472.can-17-0236

777. 777.

     Woo SR, Corrales L, Gajewski TF. The STING pathway and the T cell-inflamed tumor microenvironment. Trends Immunol. 2015;36:250-256.

     Not in our library10.1016/j.it.2015.02.003

778. 778.

     Weiss JM, et al. The STING agonist DMXAA triggers a cooperation between T lymphocytes and myeloid cells that leads to tumor regression. Oncoimmunology. 2017;6:e1346765.

     Not in our library10.1080/2162402x.2017.1346765

779. 779.

     Ara A, Ahmed KA, Xiang J. Multiple effects of CD40-CD40L axis in immunity against infection and cancer. Immunotargets Ther. 2018;7:55-61.

     Not in our library10.2147/itt.s163614

780. 780.

     Martin S, Pahari S, Sudan R, Saha B. CD40 signaling in CD8+CD40+ T cells turns on contra-T regulatory cell functions. J. Immunol. 2010;184:5510-5518.

     Not in our library10.4049/jimmunol.0902762

781. 781.

     Esensten JH, Helou YA, Chopra G, Weiss A, Bluestone JA. CD28 costimulation: from mechanism to therapy. Immunity. 2016;44:973-988.

     Not in our library10.1016/j.immuni.2016.04.020

782. 782.

     Frauwirth KA, et al. The CD28 signaling pathway regulates glucose metabolism. Immunity. 2002;16:769-777.

     Not in our library10.1016/s1074-7613(02)00323-0

783. 783.

     Jeong S, Park SH. Co-stimulatory receptors in cancers and their implications for cancer immunotherapy. Immune Netw. 2020;20:e3.

     Not in our library10.4110/in.2020.20.e3

784. 784.

     Wei SC, Duffy CR, Allison JP. Fundamental mechanisms of immune checkpoint blockade therapy. Cancer Disco. 2018;8:1069-1086.

     Not in our library10.1158/2159-8290.cd-18-0367

785. 785.

     Wieder T, Eigentler T, Brenner E, Rocken M. Immune checkpoint blockade therapy. J. Allergy Clin. Immunol. 2018;142:1403-1414.

     Not in our library10.1016/j.jaci.2018.02.042

786. 786.

     Jiang T, Zhou C, Ren S. Role of IL-2 in cancer immunotherapy. Oncoimmunology. 2016;5:e1163462.

     Not in our library10.1080/2162402x.2016.1163462

787. 787.

     West EE, et al. PD-L1 blockade synergizes with IL-2 therapy in reinvigorating exhausted T cells. J. Clin. Invest. 2013;123:2604-2615.

     Not in our library10.1172/jci67008

788. 788.

     Moynihan KD, et al. Eradication of large established tumors in mice by combination immunotherapy that engages innate and adaptive immune responses. Nat. Med. 2016;22:1402-1410.

     Not in our library10.1038/nm.4200

789. 789.

     Brooks DG, et al. IL-10 and PD-L1 operate through distinct pathways to suppress T-cell activity during persistent viral infection. Proc. Natl Acad. Sci. USA. 2008;105:20428-20433.

     Not in our library10.1073/pnas.0811139106

790. 790.

     Labanieh L, Majzner RG, Mackall CL. Programming CAR-T cells to kill cancer. Nat. Biomed. Eng. 2018;2:377-391.

     Not in our library10.1038/s41551-018-0235-9

791. 791.

     Cruz-Ramos M, Garcia-Foncillas J. CAR-T cell and personalized medicine. Adv. Exp. Med. Biol. 2019;1168:131-145.

     Not in our library10.1007/978-3-030-24100-1_9

792. 792.

     Heng G, et al. Sustained therapeutic efficacy of humanized anti-CD19 chimeric antigen receptor T Cells in relapsed/refractory acute lymphoblastic leukemia. Clin. Cancer Res. 2020;26:1606-1615.

     Not in our library10.1158/1078-0432.ccr-19-1339

793. 793.

     Maude SL, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N. Engl. J. Med. 2014;371:1507-1517.

     Not in our library10.1056/nejmoa1407222

794. 794.

     Park JH, et al. Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N. Engl. J. Med. 2018;378:449-459.

     Not in our library10.1056/nejmoa1709919

795. 795.

     Mardiana S, Solomon BJ, Darcy PK, Beavis PA. Supercharging adoptive T cell therapy to overcome solid tumor-induced immunosuppression. Sci. Transl. Med. 2019;11:eaaw2293.

     Not in our library10.1126/scitranslmed.aaw2293

796. 796.

     Liu Y, et al. Gasdermin E-mediated target cell pyroptosis by CAR T cells triggers cytokine release syndrome. Sci. Immunol. 2020;5:eaax7969.

     Not in our library10.1126/sciimmunol.aax7969

797. 797.

     Sharabi A, et al. Regulatory T cells in the treatment of disease. Nat. Rev. Drug Disco. 2018;17:823-844.

     Not in our library10.1038/nrd.2018.148

798. 798.
     Prognostic value of tumor-infiltrating FoxP3+ regulatory T cells in cancers: a systematic review and meta-analysis · 2015

     No notice
799. 799.

     Ribas A, et al. Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J. Clin. Oncol. 2013;31:616-622.

     Not in our library10.1200/jco.2012.44.6112

800. 800.

     Quirk SK, Shure AK, Agrawal DK. Immune-mediated adverse events of anticytotoxic T lymphocyte-associated antigen 4 antibody therapy in metastatic melanoma. Transl. Res. 2015;166:412-424.

     Not in our library10.1016/j.trsl.2015.06.005

801. 801.
     The impact of CTLA-4 blockade and interferon-α on clonality of T-cell repertoire in the tumor microenvironment and peripheral blood of metastatic melanoma patients · 2019

     Not checked
802. 802.

     Menjak, I. B., Elias, E. S., Jain, S., Lawrie, D. & Petrella, T. M. Evaluation of a multidisciplinary immunotherapy toxicity monitoring program for patients receiving Ipilimumab for metastatic melanoma. JCO Oncol. Pract. 10.1200/OP.20.00845 (2021).

     Not in our library10.1200/op.20.00845

803. 803.

     Dimitriou F, Long GV, Menzies AM. Novel adjuvant options for cutaneous melanoma. Ann. Oncol. 2021;32:854-865.

     Not in our library10.1016/j.annonc.2021.03.198

804. 804.

     Slingluff CL, et al. A phase 1 study of NY-ESO-1 vaccine + anti-CTLA4 antibody Ipilimumab (IPI) in patients with unresectable or metastatic melanoma. Oncoimmunology. 2021;10:1898105.

     Not in our library10.1080/2162402x.2021.1898105

805. 805.

     Kanikarla Marie P, et al. Pilot clinical trial of perioperative durvalumab and tremelimumab in the treatment of resectable colorectal cancer liver metastases. Clin. Cancer Res. 2021;27:3039-3049.

     Not in our library10.1158/1078-0432.ccr-21-0163

806. 806.
     CTLA-4 in Regulatory T Cells for Cancer Immunotherapy · 2021

     No notice
807. 807.

     Zappasodi R, et al. CTLA-4 blockade drives loss of Treg stability in glycolysis-low tumours. Nature. 2021;591:652-658.

     Not in our library10.1038/s41586-021-03326-4

808. 808.
     Association of Survival and Immune-Related Adverse Events With Anti-PD-1/PD-L1 and Anti-CTLA-4 Inhibitors, Alone or Their Combination for the Treatment of Cancer: A Systematic Review and Meta-Analysis of 13 Clinical Trials · 2021

     Not checked
809. 809.

     Patel, S. P. et al. A phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) SWOG S1609: high-grade neuroendocrine neoplasm cohort. Cancer10.1002/cncr.33591 (2021).

     Not in our library10.1002/cncr.33591

810. 810.

     Wong, S. K., Beckermann, K. E., Johnson, D. B. & Das, S. Combining anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) and -programmed cell death protein 1 (PD-1) agents for cancer immunotherapy. Expert. Opin. Biol. Ther. 10.1080/14712598.2021.1921140 (2021).

     Not in our library10.1080/14712598.2021.1921140

811. 811.

     Solinas C, De Silva P, Bron D, Willard-Gallo K, Sangiolo D. Significance of TIM3 expression in cancer: from biology to the clinic. Semin Oncol. 2019;46:372-379.

     Not in our library10.1053/j.seminoncol.2019.08.005

812. 812.

     Qi Y, et al. Research progress concerning dual blockade of lymphocyte-activation gene 3 and programmed death-1/programmed death-1 ligand-1 blockade in cancer immunotherapy: preclinical and clinical evidence of this potentially more effective immunotherapy strategy. Front. Immunol. 2020;11:563258.

     Not in our library10.3389/fimmu.2020.563258

813. 813.

     Chauvin JM, Zarour HM. TIGIT in cancer immunotherapy. J. Immunother. Cancer. 2020;8:e000957.

     Not in our library10.1136/jitc-2020-000957

814. 814.

     Sakuishi K, et al. TIM3(+)FOXP3(+) regulatory T cells are tissue-specific promoters of T-cell dysfunction in cancer. Oncoimmunology. 2013;2:e23849.

     Not in our library10.4161/onci.23849

815. 815.

     Anderson AC. Tim-3: an emerging target in the cancer immunotherapy landscape. Cancer Immunol. Res. 2014;2:393-398.

     Not in our library10.1158/2326-6066.cir-14-0039

816. 816.

     Ngiow SF, et al. Anti-TIM3 antibody promotes T cell IFN-gamma-mediated antitumor immunity and suppresses established tumors. Cancer Res. 2011;71:3540-3551.

     Not in our library10.1158/0008-5472.can-11-0096

817. 817.

     Sabatos CA, et al. Interaction of Tim-3 and Tim-3 ligand regulates T helper type 1 responses and induction of peripheral tolerance. Nat. Immunol. 2003;4:1102-1110.

     Not in our library10.1038/ni988

818. 818.

     Schaer DA, Murphy JT, Wolchok JD. Modulation of GITR for cancer immunotherapy. Curr. Opin. Immunol. 2012;24:217-224.

     Not in our library10.1016/j.coi.2011.12.011

819. 819.
     Combined PD-1 blockade and GITR triggering induce a potent antitumor immunity in murine cancer models and synergizes with chemotherapeutic drugs · 2014

     No notice
820. 820.

     Ko K, et al. Treatment of advanced tumors with agonistic anti-GITR mAb and its effects on tumor-infiltrating Foxp3+CD25+CD4+ regulatory T cells. J. Exp. Med. 2005;202:885-891.

     Not in our library10.1084/jem.20050940

821. 821.

     Wang B, et al. Combination cancer immunotherapy targeting PD-1 and GITR can rescue CD8(+) T cell dysfunction and maintain memory phenotype. Sci. Immunol. 2018;3:eaat7061.

     Not in our library10.1126/sciimmunol.aat7061

822. 822.

     Shimizu J, Yamazaki S, Takahashi T, Ishida Y, Sakaguchi S. Stimulation of CD25(+)CD4(+) regulatory T cells through GITR breaks immunological self-tolerance. Nat. Immunol. 2002;3:135-142.

     Not in our library10.1038/ni759

823. 823.

     Curti BD, et al. OX40 is a potent immune-stimulating target in late-stage cancer patients. Cancer Res. 2013;73:7189-7198.

     Not in our library10.1158/0008-5472.can-12-4174

824. 824.

     Lutsiak ME, et al. Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood. 2005;105:2862-2868.

     Not in our library10.1182/blood-2004-06-2410

825. 825.

     Whiteside TL. The role of regulatory T cells in cancer immunology. Immunotargets Ther. 2015;4:159-171.

     Not in our library10.2147/itt.s55415

826. 826.

     Desar IM, et al. Sorafenib reduces the percentage of tumour infiltrating regulatory T cells in renal cell carcinoma patients. Int. J. Cancer. 2011;129:507-512.

     Not in our library10.1002/ijc.25674

827. 827.

     Adotevi O, et al. A decrease of regulatory T cells correlates with overall survival after sunitinib-based antiangiogenic therapy in metastatic renal cancer patients. J. Immunother. 2010;33:991-998.

     Not in our library10.1097/cji.0b013e3181f4c208

828. 828.

     Dannull J, et al. Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J. Clin. Invest. 2005;115:3623-3633.

     Not in our library10.1172/jci25947

829. 829.

     Maury S, et al. Lymphodepletion followed by infusion of suicide gene-transduced donor lymphocytes to safely enhance their antitumor effect: a phase I/II study. Leukemia. 2014;28:2406-2410.

     Not in our library10.1038/leu.2014.237

830. 830.

     Fallarino F, et al. Modulation of tryptophan catabolism by regulatory T cells. Nat. Immunol. 2003;4:1206-1212.

     Not in our library10.1038/ni1003

831. 831.

     Sharma MD, et al. Indoleamine 2,3-dioxygenase controls conversion of Foxp3+ Tregs to TH17-like cells in tumor-draining lymph nodes. Blood. 2009;113:6102-6111.

     Not in our library10.1182/blood-2008-12-195354

832. 832.

     Sugiyama D, et al. Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+ regulatory T cells, evoking antitumor immune responses in humans. Proc. Natl Acad. Sci. USA. 2013;110:17945-17950.

     Not in our library10.1073/pnas.1316796110

833. 833.

     Faget J, et al. Early detection of tumor cells by innate immune cells leads to T(reg) recruitment through CCL22 production by tumor cells. Cancer Res. 2011;71:6143-6152.

     Not in our library10.1158/0008-5472.can-11-0573

834. 834.

     Curiel TJ, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med. 2004;10:942-949.

     Not in our library10.1038/nm1093

835. 835.

     Ogura M, et al. Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-cc chemokine receptor 4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma. J. Clin. Oncol. 2014;32:1157-1163.

     Not in our library10.1200/jco.2013.52.0924

836. 836.

     Facciabene A, et al. Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and T(reg) cells. Nature. 2011;475:226-230.

     Not in our library10.1038/nature10169

837. 837.

     Okubo Y, Mera T, Wang L, Faustman DL. Homogeneous expansion of human T-regulatory cells via tumor necrosis factor receptor 2. Sci. Rep. 2013;3:3153.

     Not in our library10.1038/srep03153

838. 838.

     Soares KC, et al. TGF-beta blockade depletes T regulatory cells from metastatic pancreatic tumors in a vaccine dependent manner. Oncotarget. 2015;6:43005-43015.

     Not in our library10.18632/oncotarget.5656

839. 839.

     Turnis ME, et al. Interleukin-35 limits anti-tumor immunity. Immunity. 2016;44:316-329.

     Not in our library10.1016/j.immuni.2016.01.013

840. 840.

     Pellegrini P, et al. Disregulation in TH1 and TH2 subsets of CD4+ T cells in peripheral blood of colorectal cancer patients and involvement in cancer establishment and progression. Cancer Immunol. Immunother. 1996;42:1-8.

     Not in our library10.1007/s002620050244

841. 841.

     Fridman WH, et al. The immune microenvironment of human tumors: general significance and clinical impact. Cancer Microenviron. 2013;6:117-122.

     Not in our library10.1007/s12307-012-0124-9

842. 842.

     Zhang Z, et al. Infiltration of dendritic cells and T lymphocytes predicts favorable outcome in epithelial ovarian cancer. Cancer Gene Ther. 2015;22:198-206.

     Not in our library10.1038/cgt.2015.7

843. 843.

     Haabeth OA, et al. Inflammation driven by tumour-specific Th1 cells protects against B-cell cancer. Nat. Commun. 2011;2:240.

     Not in our library10.1038/ncomms1239

844. 844.

     Brunsvig PF, et al. Telomerase peptide vaccination: a phase I/II study in patients with non-small cell lung cancer. Cancer Immunol. Immunother. 2006;55:1553-1564.

     Not in our library10.1007/s00262-006-0145-7

845. 845.

     Kyte JA. Cancer vaccination with telomerase peptide GV1001. Expert Opin. Investig. Drugs. 2009;18:687-694.

     Not in our library10.1517/13543780902897631

846. 846.

     Godet Y, et al. Analysis of spontaneous tumor-specific CD4 T-cell immunity in lung cancer using promiscuous HLA-DR telomerase-derived epitopes: potential synergistic effect with chemotherapy response. Clin. Cancer Res. 2012;18:2943-2953.

     Not in our library10.1158/1078-0432.ccr-11-3185

847. 847.

     Hokey DA, Larregina AT, Erdos G, Watkins SC, Falo LD. Tumor cell loaded type-1 polarized dendritic cells induce Th1-mediated tumor immunity. Cancer Res. 2005;65:10059-10067.

     Not in our library10.1158/0008-5472.can-05-1692

848. 848.

     Xu HM. Th1 cytokine-based immunotherapy for cancer. Hepatobiliary Pancreat. Dis. Int. 2014;13:482-494.

     Not in our library10.1016/s1499-3872(14)60305-2

849. 849.

     Coughlin CM, et al. Interleukin-12 and interleukin-18 synergistically induce murine tumor regression which involves inhibition of angiogenesis. J. Clin. Invest. 1998;101:1441-1452.

     Not in our library10.1172/jci1555

850. 850.

     Carreno BM, et al. IL-12p70-producing patient DC vaccine elicits Tc1-polarized immunity. J. Clin. Invest. 2013;123:3383-3394.

     Not in our library10.1172/jci68395

851. 851.

     Kaisar MMM, et al. Dectin-1/2-induced autocrine PGE2 signaling licenses dendritic cells to prime Th2 responses. PLoS Biol. 2018;16:e2005504.

     Not in our library10.1371/journal.pbio.2005504

852. 852.

     Kapsenberg ML, Hilkens CM, Wierenga EA, Kalinski P. The paradigm of type 1 and type 2 antigen-presenting cells. Implic. Atopic Allergy Clin. Exp. Allergy. 1999;29:33-36.

     Not in our library10.1046/j.1365-2222.1999.00006.x-i2

853. 853.

     Padol IT, Hunt RH. Association of myocardial infarctions with COX-2 inhibition may be related to immunomodulation towards a Th1 response resulting in atheromatous plaque instability: an evidence-based interpretation. Rheumatology. 2010;49:837-843.

     Not in our library10.1093/rheumatology/kep225

854. 854.

     Qian Y, Zhang M. The functional roles of IL-33/ST2 axis in ocular diseases. Mediators Inflamm. 2020;2020:5230716.

     Not in our library10.1155/2020/5230716

855. 855.

     Gao X, et al. Tumoral expression of IL-33 inhibits tumor growth and modifies the tumor microenvironment through CD8+ T and NK cells. J. Immunol. 2015;194:438-445.

     Not in our library10.4049/jimmunol.1401344

856. 856.

     Jiang Z, et al. IL-25 blockade inhibits metastasis in breast cancer. Protein Cell. 2017;8:191-201.

     Not in our library10.1007/s13238-016-0345-7

857. 857.

     Kryczek I, et al. Cutting edge: opposite effects of IL-1 and IL-2 on the regulation of IL-17+ T cell pool IL-1 subverts IL-2-mediated suppression. J. Immunol. 2007;179:1423-1426.

     Not in our library10.4049/jimmunol.179.3.1423

858. 858.

     Haghshenas MR, Khademi B, Faghih Z, Ghaderi A, Erfani N. Immune regulatory cells and IL17-producing lymphocytes in patients with benign and malignant salivary gland tumors. Immunol. Lett. 2015;164:109-116.

     Not in our library10.1016/j.imlet.2015.02.008

859. 859.

     Kryczek I, et al. Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments. Blood. 2009;114:1141-1149.

     Not in our library10.1182/blood-2009-03-208249

860. 860.

     Lai Y, Dong C. Therapeutic antibodies that target inflammatory cytokines in autoimmune diseases. Int. Immunol. 2016;28:181-188.

     Not in our library10.1093/intimm/dxv063

861. 861.

     Chang SH, et al. T helper 17 cells play a critical pathogenic role in lung cancer. Proc. Natl Acad. Sci. USA. 2014;111:5664-5669.

     Not in our library10.1073/pnas.1319051111

862. 862.

     Feng S, Chen XM, Wang JF, Xu XQ. Th17 cells associated cytokines and cancer. Eur. Rev. Med. Pharm. Sci. 2016;20:4032-4040.

     Not in our library

863. 863.

     Gorczynski RM. IL-17 signaling in the tumor microenvironment. Adv. Exp. Med. Biol. 2020;1240:47-58.

     Not in our library10.1007/978-3-030-38315-2_4

864. 864.

     Langowski JL, et al. IL-23 promotes tumour incidence and growth. Nature. 2006;442:461-465.

     Not in our library10.1038/nature04808

865. 865.

     van Duijneveldt G, Griffin MDW, Putoczki TL. Emerging roles for the IL-6 family of cytokines in pancreatic cancer. Clin. Sci. 2020;134:2091-2115.

     Not in our library10.1042/cs20191211

866. 866.

     Feurino LW, et al. IL-6 stimulates Th2 type cytokine secretion and upregulates VEGF and NRP-1 expression in pancreatic cancer cells. Cancer Biol. Ther. 2007;6:1096-1100.

     Not in our library10.4161/cbt.6.7.4328

867. 867.

     Tsou P, Katayama H, Ostrin EJ, Hanash SM. The emerging role of B cells in tumor immunity. Cancer Res. 2016;76:5597-5601.

     Not in our library10.1158/0008-5472.can-16-0431

868. 868.

     Burger JA, Wiestner A. Targeting B cell receptor signalling in cancer: preclinical and clinical advances. Nat. Rev. Cancer. 2018;18:148-167.

     Not in our library10.1038/nrc.2017.121

869. 869.
     The B-Side of Cancer Immunity: The Underrated Tune · 2019

     No notice
870. 870.

     Yuen GJ, Demissie E, Pillai S. B lymphocytes and cancer: a love-hate relationship. Trends Cancer. 2016;2:747-757.

     Not in our library10.1016/j.trecan.2016.10.010

871. 871.

     Sorenmo KU, et al. CD40-activated B cell cancer vaccine improves second clinical remission and survival in privately owned dogs with non-Hodgkin’s lymphoma. PLoS ONE. 2011;6:e24167.

     Not in our library10.1371/journal.pone.0024167

872. 872.

     Wennhold K, et al. CD40-activated B cells induce anti-tumor immunity in vivo. Oncotarget. 2017;8:27740-27753.

     Not in our library10.18632/oncotarget.7720

873. 873.

     Shimabukuro-Vornhagen A, et al. The immunosuppressive factors IL-10, TGF-beta, and VEGF do not affect the antigen-presenting function of CD40-activated B cells. J. Exp. Clin. Cancer Res. 2012;31:47.

     Not in our library10.1186/1756-9966-31-47

874. 874.

     Gonzalez NK, et al. In vitro and in vivo imaging of initial B-T-cell interactions in the setting of B-cell based cancer immunotherapy. Oncoimmunology. 2015;4:e1038684.

     Not in our library10.1080/2162402x.2015.1038684

875. 875.

     Rossetti RAM, et al. B lymphocytes can be activated to act as antigen presenting cells to promote anti-tumor responses. PLoS ONE. 2018;13:e0199034.

     Not in our library10.1371/journal.pone.0199034

876. 876.

     Li Q, et al. Adoptive transfer of tumor reactive B cells confers host T-cell immunity and tumor regression. Clin. Cancer Res. 2011;17:4987-4995.

     Not in our library10.1158/1078-0432.ccr-11-0207

877. 877.

     Sorrentino R, et al. B cells contribute to the antitumor activity of CpG-oligodeoxynucleotide in a mouse model of metastatic lung carcinoma. Am. J. Respir. Crit. Care Med. 2011;183:1369-1379.

     Not in our library10.1164/rccm.201010-1738oc

878. 878.

     Deng J, et al. Engineered fusokine GIFT4 licenses the ability of B cells to trigger a tumoricidal T-cell response. Cancer Res. 2014;74:4133-4144.

     Not in our library10.1158/0008-5472.can-14-0708

879. 879.
     Tumor-derived autophagosomes (DRibbles) induce B cell activation in a TLR2-MyD88 dependent manner. · 2013

     Not checked
880. 880.

     Ren H, et al. Therapeutic antitumor efficacy of B cells loaded with tumor-derived autophagasomes vaccine (DRibbles). J. Immunother. 2014;37:383-393.

     Not in our library10.1097/cji.0000000000000051

881. 881.

     Rosser EC, Blair PA, Mauri C. Cellular targets of regulatory B cell-mediated suppression. Mol. Immunol. 2014;62:296-304.

     Not in our library10.1016/j.molimm.2014.01.014

882. 882.

     Lundy SK, Klinker MW. Characterization and activity of Fas ligand producing CD5(+) B cells. Methods Mol. Biol. 2014;1190:81-102.

     Not in our library10.1007/978-1-4939-1161-5_7

883. 883.

     Olkhanud PB, et al. Tumor-evoked regulatory B cells promote breast cancer metastasis by converting resting CD4(+) T cells to T-regulatory cells. Cancer Res. 2011;71:3505-3515.

     Not in our library10.1158/0008-5472.can-10-4316

884. 884.

     Lindner S, et al. Interleukin 21-induced granzyme B-expressing B cells infiltrate tumors and regulate T cells. Cancer Res. 2013;73:2468-2479.

     Not in our library10.1158/0008-5472.can-12-3450

885. 885.

     Lampropoulou V, et al. TLR-activated B cells suppress T cell-mediated autoimmunity. J. Immunol. 2008;180:4763-4773.

     Not in our library10.4049/jimmunol.180.7.4763

886. 886.

     Serhan CN, Chiang N, Van Dyke TE. Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators. Nat. Rev. Immunol. 2008;8:349-361.

     Not in our library10.1038/nri2294

887. 887.

     Zhang Y, et al. Mammary-tumor-educated B cells acquire LAP/TGF-beta and PD-L1 expression and suppress anti-tumor immune responses. Int. Immunol. 2016;28:423-433.

     Not in our library10.1093/intimm/dxw007

888. 888.

     Song SS, et al. Protective effects of total glucosides of paeony on N-nitrosodiethylamine-induced hepatocellular carcinoma in rats via down-regulation of regulatory B cells. Immunol. Invest. 2015;44:521-535.

     Not in our library10.3109/08820139.2015.1043668

889. 889.

     Kondo K, et al. Ibrutinib modulates the immunosuppressive CLL microenvironment through STAT3-mediated suppression of regulatory B-cell function and inhibition of the PD-1/PD-L1 pathway. Leukemia. 2018;32:960-970.

     Not in our library10.1038/leu.2017.304

890. 890.

     Mohamed E, et al. The unfolded protein response mediator PERK governs myeloid cell-driven immunosuppression in tumors through inhibition of STING signaling. Immunity. 2020;52:668-682 e667.

     Not in our library10.1016/j.immuni.2020.03.004

891. 891.

     Malhi H, Camilleri M. Modulating bile acid pathways and TGR5 receptors for treating liver and GI diseases. Curr. Opin. Pharm. 2017;37:80-86.

     Not in our library10.1016/j.coph.2017.09.008

892. 892.

     Schroeder BO, Backhed F. Signals from the gut microbiota to distant organs in physiology and disease. Nat. Med. 2016;22:1079-1089.

     Not in our library10.1038/nm.4185

893. 893.

     Wargo JA. Modulating gut microbes. Science. 2020;369:1302-1303.

     Not in our library10.1126/science.abc3965

894. 894.

     Shalapour S, Karin M. Immunity, inflammation, and cancer: an eternal fight between good and evil. J. Clin. Invest. 2015;125:3347-3355.

     Not in our library10.1172/jci80007

895. 895.

     Liu L. Antibody glycosylation and its impact on the pharmacokinetics and pharmacodynamics of monoclonal antibodies and Fc-fusion proteins. J. Pharm. Sci. 2015;104:1866-1884.

     Not in our library10.1002/jps.24444

896. 896.

     Dillard T, Yedinak CG, Alumkal J, Fleseriu M. Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis: serious immune related adverse events across a spectrum of cancer subtypes. Pituitary. 2010;13:29-38.

     Not in our library10.1007/s11102-009-0193-z

897. 897.

     Boutros C, et al. Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination. Nat. Rev. Clin. Oncol. 2016;13:473-486.

     Not in our library10.1038/nrclinonc.2016.58

898. 898.

     Osorio JC, et al. Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer. Ann. Oncol. 2017;28:583-589.

     Not in our library10.1093/annonc/mdw640

899. 899.

     Gauci ML, et al. Autoimmune diabetes induced by PD-1 inhibitor-retrospective analysis and pathogenesis: a case report and literature review. Cancer Immunol. Immunother. 2017;66:1399-1410.

     Not in our library10.1007/s00262-017-2033-8

900. 900.

     Shah NN, Fry TJ. Mechanisms of resistance to CAR T cell therapy. Nat. Rev. Clin. Oncol. 2019;16:372-385.

     Not in our library10.1038/s41571-019-0184-6

901. 901.

     Schonthal AH, Chen TC, Hofman FM, Louie SG, Petasis NA. Celecoxib analogs that lack COX-2 inhibitory function: preclinical development of novel anticancer drugs. Expert Opin. Investig. Drugs. 2008;17:197-208.

     Not in our library10.1517/13543784.17.2.197

902. 902.

     Kashfi K, et al. Nitric oxide-donating nonsteroidal anti-inflammatory drugs inhibit the growth of various cultured human cancer cells: evidence of a tissue type-independent effect. J. Pharm. Exp. Ther. 2002;303:1273-1282.

     Not in our library10.1124/jpet.102.042754

903. 903.

     Rigas B, Williams JL. NO-donating NSAIDs and cancer: an overview with a note on whether NO is required for their action. Nitric Oxide. 2008;19:199-204.

     Not in our library10.1016/j.niox.2008.04.022

904. 904.

     Zheng L, Lv W, Zhou Y, Lin X, Yao J. Progress on the mechanism for aspirin’s anti-tumor effects. Curr. Drug Targets. 2021;22:105-111.

     Not in our library10.2174/1389450121999201013152931

905. 905.

     Ding XZ, Iversen P, Cluck MW, Knezetic JA, Adrian TE. Lipoxygenase inhibitors abolish proliferation of human pancreatic cancer cells. Biochem. Biophys. Res. Commun. 1999;261:218-223.

     Not in our library10.1006/bbrc.1999.1012

906. 906.

     Katz MS. Therapy insight: potential of statins for cancer chemoprevention and therapy. Nat. Clin. Pr. Oncol. 2005;2:82-89.

     Not in our library10.1038/ncponc0097

Cited by papers we hold 25

• Microbiota dysbiosis impact on the metabolism of T3 and T4 hormones and its association with thyroid cancer · 2025
  Not checked
• Immunomodulatory potential of exopolysaccharides from Lactiplantibacillus plantarum YY-112 · 2025
  Not checked
• Efficacy prediction of neoadjuvant cadonilimab plus FLOT therapy for advanced gastric cancer: a study based on body composition changes · 2025
  Not checked
• Free radicals and their impact on health and antioxidant defenses: a review · 2025
  No notice
• The Role of Inflammation in Cancer: Mechanisms of Tumor Initiation, Progression, and Metastasis · 2025
  No notice
• Oxidative stress and inflammation in the pathogenesis of neurological disorders: Mechanisms and implications · 2025
  No notice
• Tumor biomarkers for diagnosis, prognosis and targeted therapy · 2024
  No notice
• Tumor initiation and early tumorigenesis: molecular mechanisms and interventional targets · 2024
  No notice
• Intratumoural microbiota: a new frontier in cancer development and therapy · 2024
  No notice
• Mechanisms of immune checkpoint inhibitors: insights into the regulation of circular RNAS involved in cancer hallmarks · 2024
  No notice
• Protein neddylation and its role in health and diseases · 2024
  No notice
• The JAK-STAT pathway: from structural biology to cytokine engineering · 2024
  Corrected
• Cross-talk of inflammation and cellular senescence: a new insight into the occurrence and progression of osteoarthritis · 2024
  No notice
• Theranostic Fluorescent Probes · 2024
  No notice
• Emerging viral infections in immunocompromised patients: A great challenge to better define the role of immune response · 2023
  Not checked
• γδ T cells: origin and fate, subsets, diseases and immunotherapy · 2023
  No notice
• The roles of E3 ubiquitin ligases in cancer progression and targeted therapy · 2023
  No notice
• Macrophages in immunoregulation and therapeutics · 2023
  No notice
• Intratumoral microbiota: roles in cancer initiation, development and therapeutic efficacy · 2023
  No notice
• Anti-inflammatory activity of Sabicea brevipes Wernharm (Rubiaceae) · 2022
  Not checked

and 5 more

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.